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ABSTRACT
Current scientific literature has shown that: 1) NO is a pro-ovulatory agent 
and inhibition of its production inhibits ovulation, and 2) NO has strong anti- 
steroidogenic activity, especially on estradiol (E2) production by granulosa cells. 
The experiments described in this dissertation were designed to answer the 
following questions involving effects of NO on ovarian physiology: 1) is the 
inhibitory effect of nitric oxide synthase (NOS) inhibitors on ovulation irreversible 
(follicular atresia) or temporary (delayed ovulation)? and 2) what is the 
relationship between NO and hCG-induced preovulatory luteinization?
Accordingly, cycling mares were subjected to treatment with NOS 
inhibitors (L-NAME or aminoguanidine) during estrus. Results showed that 
administration of NOS inhibitors temporarily inhibited hCG-induced ovulation for 
up to 5 d. Using a similar experimental approach, Holstein cows treated with 
L-NAME had delayed ovulation and an attenuated post-ovulation rise in plasma 
progesterone (P4) concentration. In a subsequent experiment, analyses of 
follicular fluid from mares in estrus showed that NO concentrations were 
increased after hCG administration. Furthermore, equine and bovine granulosa 
cell cultures treated with NOS inhibitors showed that inhibition of NOS activity in 
vitro luteinization as evidenced by decreased P4.E2 ratios. Pharmacokinetic and 
hemodynamic parameters associated with L-NAME administration in horses 
demonstrated that L-NAME has a short half life (3.6 min) as opposed to its major 
metabolite L-NNA (19.5 h).
The results of these experiments demonstrated that: 1) administration of 
NOS inhibitors delayed ovulation in mares and cows; 2) intrafollicular production 
of NO was up-regulated following hCG administration; 3) inhibition of NO 
prevented preovulatory follicular luteinization and in vitro luteinization of 
granulosa cells; 4) both nonspecific and iNOS-specific inhibitors caused 
significant effects both in vivo and in vitro and 5) L-NAME has a short half life in 
horses and L-NNA is a major metabolite with a relatively long half life. Finally, 
these results will contribute to designing pharmacological therapies for 
manipulating ovarian function for experimental or therapeutic purposes. Future
vii
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studies investigating the involvement of NO with preovulatory luteinization will 
likely contribute to the understanding of ovarian dysfunction, such as cystic 
ovarian syndrome or unruptured luteinized follicles. These conditions affect both 
animals and humans.
viii




The name Alfred Nobel likely sounds familiar to many people worldwide, 
but few probably would remember or know who Ascanio Sobrero (1812-1888) 
was. Sobrero, an Italian chemist, was born in Casale Monferrato and initiated his 
studies in medicine but changed to chemistry. He worked as a chemistry teacher 
at the University of Turin and at the Application School for Engineers. In 1846 
Sobrero discovered a powerful chemical obtained from the addition of glycerin 
into a cooled mixture of nitric and sulfuric acids. The chemical was the nitric acid 
triester of glycerol called glyceryl trinitrate; however, it is commonly referred to as 
nitroglycerin. The liquid was as powerful as it was unstable and the slightest 
motion would trigger its explosion. Sobrero, after being indirectly responsible for 
several explosion-induced injuries (some that were fatal) to the people working in 
his laboratory, including himself, deemed nitroglycerin too dangerous to be safely 
handled and abandoned any further research on that chemical (Sohlman and 
Schuck, 1929). Curiously, he found that a small amount of nitroglycerin in contact 
with oral mucosa would cause headaches that would last for hours.
Alfred Bernhard Nobel (1833-1896) was born in Stockholm, Sweden but 
obtained his education in St. Petersburg, Russia. After his return to Sweden, he 
became interested in researching ways to stabilize and handle nitroglycerin. The 
work was done in his father’s nitroglycerin factory and it was not until after many 
incidents (explosions) that Nobel, serendipitously, found a way to handle, 
transport and use nitroglycerin. One day, a small amount of nitroglycerin dropped 
from the bench where Nobel and his workers were working and, to their surprise, 
nothing happened. Astonishingly, Nobel noticed that the highly volatile explosive 
fell into a box containing a fine porous powder called kieselguhr (Sohlman and 
Schuck, 1929). Kieselguhr is an unconsolidated form of diatomite or silica- 
composed shells of microscopic unicellular aquatic plants (algae). Kieselguhr is 
heat resistant and has been used as an insulator. Because it has abrasive
1
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properties, kieselguhr is used as a component in toothpaste and in metal 
polishes. In the chemical industry, it is also used as a filter to clarify syrups and 
sugar and as a filling material in paper, paints, ceramics, soap and detergents. 
The mixture of nitroglycerin and silica was pasty and malleable. Nobel called his 
discovery dynamite for which he received a patent in 1867. This discovery was 
the landmark of a successful career as an entrepreneur and the foundation of his 
wealth (Sohlman and Schuck, 1929; Fant, 1991).
Alfred Nobel, a pacifist by nature, naively did not predict that his invention 
would do more than be used in road constructions. Disappointed for the potential 
use of dynamite in wars, Nobel left in his will a 9 million dollar funding to award 
outstanding developments and discoveries that would benefit humanity and 
foster peace around the world. Thus was created the Nobel Prize, the most 
honored award in the world in the areas of Physics, Chemistry, Physiology and 
Medicine, Literature, and Peace (Fant, 1991).
Alfred Nobel constantly had health problems during his entire life and late 
in his life he suffered from angina pectoris, a heart condition marked by 
paroxysms of intense chest pains. In 1867, a British physician named Brunton 
found that organic nitrates could be used to ameliorate the painful signs of 
angina pectoris. Later in 1879, William Murrel started to use nitroglycerin for 
angina pectoris. Alfred Nobel was surprised when in 1890 his physician 
prescribed nitroglycerin to treat his heart problem. Nobel refused to be treated 
with such a chemical and confided to a friend:
“...isn't the irony of fate that I have been prescribed nitroglycerin, to be 
taken internally! They call it Trinitrin, so as not to scare the chemist and 
the public...” Alfred Nobel, 1892.
Despite his initial reluctance, Nobel finally agreed to follow his doctor’s 
recommendations before his death in 1896.
One hundred years later, in 1977, a pharmacologist at the University of 
Texas at Houston, Ferid Murad noted that nitroglycerin had the ability to cause 
the release of nitric oxide (NO) in the body (Katsuki et al., 1977). A year later, it 
was reported that biosynthesis of nitrite and nitrate occur in humans, regardless
2
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of whether nitrate ingestion was low or high (Tannenbaum et al., 1978; Green et 
a/., 1981). Later, in 1980, another researcher at the State University of New York, 
Robert Furchgott, reported that endothelial cells played an important role in the 
vasodilatation and relaxation of arteries induced by acetylcholine and other 
muscarinic agents (Furchgott and Zawadzki, 1980). The vascular relaxation was 
shown to be mediated by a highly labile and diffusible agent derived from the 
endothelium that, being unidentified at that time, was called endothelium-derived 
relaxing factor (EDRF).
Finally, in 1987, Louis Ignarro, a pharmacologist at the University of 
California, identified NO as being the long-sought EDRF produced and released 
by arteries and veins (Ignarro etal., 1987). It then became easily understood how 
the NO-releasing nitrate (nitroglycerin) invented by Ascanio Sobrero would bring 
relief to people suffering from angina pectoris. Nitroglycerin causes relaxation of 
smooth muscle, therefore causing systemic vasodilatation of both venous and 
arterial vascular beds (Dinerman et al., 1993). In the venous vascular system, 
nytroglycerin dilates post-capillary vessels and large caliber vessels that promote 
peripheral pooling of blood (Palmer et al., 1987; Palmer et al., 1988). The net 
result is a decreased venous return to the heart, causing a net reduction of the 
end-diastolic pressure in the left ventricle (preload) that contributes to lowering 
systemic blood pressure. Dilatation of peripheral arteries induced by 
nitroglycerin-derived NO reduces systemic vascular resistance and arterial 
pressure (afterioad) that leads to lower systemic blood pressure. Both 
nitroglycerin-derived NO effects on venous and arterial vessels result in 
decreased myocardial oxygen consumption. Because of all these effects, 
nitroglycerin is able to reduce systolic, diastolic and mean arterial blood 
pressures.
The discovery that NO was the EDRF (Ignarro et al., 1987; Palmer et al., 
1987) was received enthusiastically by the scientific community and triggered a 
great deal of research worldwide to unravel the myriad of physiological and 
pathological processes that NO could possibly be involved in. As a result, NO 
has been implicated as a major cell-signaling molecule involved in processes
3
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such as vascular tone (Palmer et al., 1988), neurotransmission and immune 
responses associated with viral (Evans et al., 1994), bacterial (Stuehr et al., 
1985) and parasitic aggression (Evans et al., 1993a; Garcia et al., 1999). As a 
result, it was discovered that NO not only activates guanylate cyclase but also 
has a role in regulating the function of enzymes of the cytochrome P450 
(CYP450).
Accordingly, NO was implicated in several biological processes in virtually 
any tissue in the body and is probably the most versatile known mediator of 
biological processes in the body. Nitric oxide was found to participate in major 
physiological and pathophysiological processes such as vascular dilatation, 
control of basal systemic blood pressure, immune responses to infectious agents 
and parasites (Burgner et al., 1999). Memory and learning centers in the central 
nervous system are also thought to be modulated by NO. Nitric oxide was 
acclaimed in 1992 the “Molecule of the Year” by D. E. Koshland Jr., Editor for the 
scientific journal Science, in recognition of thousands of articles that had been 
published on the biology and biochemistry of NO (Koshland, 1992). The 
recognition of the importance of NO research culminated when, finally, Murad, 
Furchgott and Ignarro were rewarded in 1998 and received the Nobel Prize for 
their independent work showing that NO was, in fact, EORF. Ascanio Sobrero 
would probably be gladdened to know that his invention after all is being used to 
treat medical conditions and more importantly, to know that nitroglycerin was 
pivotal in inciting the work that resulted in identifying NO as one of the most 
versatile cell-signaling molecule.
Along with scientists working in vascular and neuroendocrinology areas, 
reproductive biologists also launched intensive research investigating possible 
NO-mediated phenomena in the male and female reproductive system. The 
outcome of this intensive investigation by several laboratories was that NO was 
found to participate in several processes regulating male and female 
reproductive physiology through mechanisms involving the hypothalamic- 
hypophyseal-gonadal axes (McCann and Rettori, 1996b) and other sex organs, 
such as the penis (Burnett, 1992; Penson et al., 1997), accessory sex glands
4
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(Farnsworth, 1999; Grozdanovic and Goessi, 1999), uterus (Rosselli et al., 
1998), uterine tubes (Rosselli et al., 1994b; Rosselli et al., 1996), cervix 
(Buhimschi etal., 1996; Tschugguel etal., 1999) and vagina (Al-Hijji etal., 2000).
NITRIC OXIDE BIOSYNTHESIS
Nitric oxide (nitrogen monoxide) is a simple gas molecule, lipophilic, highly 
diffusible and with an ultra-short half life when in an aerobic environment. The 
NO molecule is composed of one atom of nitrogen and one atom of oxygen 
bound by a double bond. The oxygen and the nitrogen atoms have two pair and 
one pair of non-bonding electrons, respectively. The NO molecule does not have 
a net charge despite its odd number of electrons, which results in it having an 
atomic number only different from O2. It has, however, a molecular polarity 
represented by a negative charge on the oxygen atom and a positive charge on 
the nitrogen atom.
The presence of an extra electron in the outer shell of the nitrogen atom 
makes this molecule a free radical. A free radical is a single, unpaired electron 
that is found in the valence or outer shell of an atom. Free radical molecules are 
highly reactive because they always seek to find another electron to complete the 
space in the outer shell. These molecules dynamically respond to changes in the 
surrounding magnetic field, and thus, are named paramagnetic (molecules that 
contain unpaired electrons). Accordingly, the NO molecule simply and constantly 
seeks to fulfill the octet rule to become a lower energy species. The seemingly 
ubiquitous involvement of NO in most biological actions in diverse tissues is due 
greatly to its paramagnetism (Stamler et al., 1992). Paramagnetism is not an 
exclusive characteristic of molecules with an odd number of electrons like NO. 
Diamagnetic molecules (with an even number of electrons) can also have 
paramagnetic properties as they may have two orbitals with unpaired electrons. 
For example, the dioxygen molecule (0 2) has two unpaired electrons in two 
different orbitals. Paramagnetism makes NO inherently unstable because 
paramagnetic molecules tend to react with surrounding molecules to become 
stable. NO is, therefore, a free radical.
5
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There are two primary ways that NO molecules become stable: 1) reacting 
with oxygen species and 2) reacting with transition metal ions. Reaction with O2 
in aqueous solutions produces relatively unreactive and stable products, such as 
nitrate (NO3) and nitrite (NO2) ions. Conversely, a very reactive and toxic 
product is generated from the reaction of NO with superoxide (O2 ), the 
peroxynitrite (ONOO), which in turn rapidly generates additional highly reactive 
and seemingly toxic intermediates (Beckman et al., 1990; Beckman and Crow, 
1993). Peroxynitrite is not a free radical but is highly reactive and participates in 
several reactions, including oxidation of sulfhydryls and lipids, and nitration of 
tyrosine groups in proteins. Peroxynitrite also rapidly reacts with carbon dioxide 
to produce the highly reactive nitrosoperoxycarbonate anion adduct, which has 
been implicated as a critical mediator of oxidative injury derived from the reaction 
of NO and O2*.
For most metal ions in biological systems the orbitals are only partially 
occupied and therefore available for pairing with elements having an unpaired 
electron. NO reacts also with transition metal ions to become stable. Iron is a 
suitable candidate for binding with NO because it is the most ubiquitous metal ion 
in mammalian cells and participates in important biological processes involving 
oxidation-reduction reactions. Iron has been shown to be essential for cell 
survival for virtually any organism (Aisen et al., 2001) The amount of energy that 
separates the five orbitals that contain the five (Fe+3) or six (Fe+2) electrons on 
the iron atom is relatively small. These characteristics make iron an important 
target for binding to and reacting with NO. The two main forms of iron in cells are 
heme and non-heme iron, which bind to NO. Heme-containing proteins such as 
hemoglobin, myoglobin and CYP450 enzymes are 0 2 -binding substrates. The 
NO molecule is very similar structurally to O2 and therefore is also highly reactive 
in the presence of these proteins. Iron is also found in non-heme proteins, such 
as the iron-sulfur protein clusters that are essential for the transfer of electrons in 
the mitochondrial electron transfer chain.
6
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NITRIC OXIDE SYNTHASE ENZYMOLOGY
NO is formed from the amino acid substrate L-arginine in the presence of 
O2 and NADPH. The reaction is governed by a group of enzymes known 
collectively as nitric oxide synthases (NOS). Nitric oxide synthases catalyze the 
5-electron oxidation of the terminal guanidine nitrogen of the amino acid 
L-arginine into NO and citrulline in the presence of 0 2 and NADPH-derived 
electrons. It has not been reported whether the citrulline molecule formed is in 
l- or d /l- form (Alderton et al., 2001). The regulation and biological activation of 
NOS have been shown to be either calcium (Ca2*)/calmodulin (CaM)-dependent 
or independent (Moncada et al., 1991). The Ca2+- and CaM-dependent isoforms 
are constitutively expressed; whereas, the expression of the calcium- 
independent isoform is induced. This complexity of NOS regulation accounts for 
the multitude of biological actions of NO, which include, in addition to the control 
of vascular tone, acute and inflammatory reactions. Two constitutive isoforms 
were originally identified in the brain and endothelial cells and were designated 
neuronal (nNOS) and endothelial (eNOS) isoforms, respectively; the inducible 
isoform (iNOS) was associated mainly with macrophages (Abu-Soud et al., 
1995).
Three genes encoding for the two constitutive (Bredt et al., 1991) and one 
inducible NO isoforms have been cloned (Charles etal., 1993; Baek etal., 1993). 
There is a high degree of homology among the NOS isoforms (50-60%) and an 
even higher degree of genetic conservation for the same isoform when examined 
in different species (85% for iNOS and 95% for nNOS and eNOS; Geller et al.,
1993). A numerical nomenclature for the NOS isoforms has been proposed: 
NOS-1, NOS-2 and NOS-3 for nNOS, eNOS and iNOS, respectively. The 
numerical sequence of this classification refers to the order the genes for each 
isoform were cloned. The numerical nomenclature has several advantages 
because all three isoforms have been found to be expressed in tissues other 
than those originally described (Forstermann etal., 1994).
Moreover, both constitutive isoforms can be induced in some tissues and, 
similarly, the inducible isoform can be constitutively expressed in others
7
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(Forstermann et al., 1998; Aiderton et al., 2001). For example, the constitutive 
nNOS isoform expression can be induced by heat, electrical stimulation, light 
exposure and formalin (Forstermann et al., 1998). The expression of the other, 
constitutive isoform, eNOS, can be up-regulated by shear stress, exercise 
training, hypoxia, growth factors and down-regulated by hypertension, 
lipopolysaccharide and increases in cyclic AMP (Forstermann etal., 1998).
However, in this dissertation I will use the terminology suggested by the 
International Union of Pharmacology Committee on Receptor Nomenclature and 
Drug Classification, which recommends: nNOS for the isoform originally found in 
neuronal tissue; eNOS for the isoform originally found in endothelial cells; and 
iNOS for the isoform originally found in macrophages after being induced by 
stimuli such as endotoxin, liposaccharides, cytokines and microbes (Moncada et 
al., 1997).
The complex and diverse action of NO as a cell-signaling molecule 
derives from the similarly complex molecular regulation of the NOS isoforms 
(Bredt et al., 1992). This regulation is critical to controlling the production and 
release of NO in mechanisms involving homeostasis and response to 
immunopathological stimuli. In general small amounts (picomoles) of NO are 
associated with expression of constitutive isoforms, whereas, relatively large 
amounts (nanomoles) of NO are released following the expression of iNOS. 
Prosthetic groups for NOS isoforms include flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and heme, whereas the co-factor is 
tetrahydrobiopterin (BH4). Tetrahydrobiopterin is an essential cofactor for the 
NOS isoforms ability to bind L-arginine (Gross and Levi, 1992). In the absence of 
BH4, NOS isoforms transfer electrons to oxygen to produce the toxic free radical 
0 2‘ (Pou etal., 1992).
In addition to the substrate L-arginine, the reduced form of nicotine 
adenine dinucleotide phosphate (NADPH) and 0 2 also serve as substrates for 
NOS catalytic activity and subsequent NO production (Griffith and Stuehr, 1995). 
The activity of NOS is significantly enhanced in the presence of reduced thiols, 
such as P-mercaptoethanol or glutathione. The complex Ca2+/CaM reversibly
8
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activates the constitutive isoforms nNOS and eNOS; whereas, the iNOS binds 
tightly and irreversibly to CaM and, therefore, its activation is Ca2+-independent. 
However, CaM binding is required for activity of all NOS isoforms (Su et al.,
1995). Once activated, NOS isoforms use NADPH to catalyze the 5-electron 
oxidation of L-arginine to form citrulline and NO in the presence of O2. The 
electrons required for this two-step reaction flow from NADPH to the FAD, then to 
the FMN, and lastly to the heme iron atom. The binding of CaM to NOS regulates 
the flow of electrons from the FMN to the heme iron atom, making this region a 
site for the Ca2+-dependent regulation of the constitutive NOS isoforms.
Three well-defined domains are necessary for the catalytic activity of NOS 
isoforms. Arranged from the COOH-terminus to the NH2-terminus are a 
flavoprotein reductase domain, a CaM recognition sequence binding domain and 
an oxygenase domain. The reductase domain contains the FAD and FMN 
moieties and shares extensive genetic homology with enzymes of the CYP450 
reductase group. This domain transfers electrons from NADPH to the oxygenase 
domain. The oxygenase domain is highly conserved between isoforms and 
across species (amino acid homology sequence ranging from 56% to 87%). This 
domain is the one that actually catalyzes the conversion of L-arginine into 
citrulline and NO. It is also the oxygenase domain that contains the binding sites 
for the heme, tetrahydrobiopterin and arginine. All NOS isoforms contain a CaM 
recognition sequence between the oxygenase and the reductase domains. This 
sequence is also highly conserved among species (100%, 94% and 91% 
homology for nNOS, eNOS and iNOS, respectively) but less conserved among 
isoforms (32 to 60% homology reported for humans; Cho et al., 1992).
The characteristics of the enzymology of the NOS isoforms determine the 
biological functions of NO derived from each of these NOS isoforms (Table 1.1). 
Transcriptional, pre-translational and post-translational regulations of catalytic 
activity of NOS isoforms differ from each other. Isoform-specific domains 
determine the localization of NOS inside the cellular compartment and are 
directly related to the specificity of NOS expression.
9

















Table 1.1 Characteristics of the enzymology of the nitric oxide synthase isoforms
nNOS iNOS eNOS




Primary biological function 


































~ 1 0 0  nm
yes
The nNOS isoform is expressed in the central and peripheral nervous 
system as well as in skeletal muscles. In the central nervous system (CNS), 
nNOS catalytic activity is related to long-term regulation of synaptic transmission, 
acting as a neuromodulator of important neurologic functions such as sexual 
behavior (Hull etal., 1994), learning and memory (Rose, 2000).
In the peripheral nervous system (PNS) NO acts mainly as a 
neurotransmitter in nitrergic nerves, participating in smooth muscle control, 
gastrointestinal motility and neuroendocrine functions. Although originally 
described only as a constitutive isoform that is developmentally regulated, nNOS 
expression can be up-regulated (induced) by certain pathophysiological stimuli 
such as nerve injury, cerebral ischemia (Coert et al., 1999) and other 
inflammatory conditions of the nervous system (Samdani et al., 1997).
Thus, production of nNOS-derived NO above physiologic concentrations 
mediates neuronal injury during acute periods of cerebral vascular dysfunction as 
well as neurodegeneration in more chronic conditions such as Parkinson’s 
disease (Przedborski et al., 1996), Huntington’s disease (Bredt, 1996) and 
amyotrophic lateral sclerosis (Sasaki et al., 2001). Because the nervous system 
is extremely susceptible to cell injury upon an insult, nNOS-reguiated production 
of NO must be at the site of biological action. The primary form of nNOS 
activation and regulation is through the binding of CaM to the nNOS that occurs 
in response to increases in the intracellular concentrations of Ca*2 (Bredt and 
Snyder, 1990; Christopherson and Bredt, 1997).
The nNOS has a unique regulatory region in its sequence, which is a 300 
amino acid sequence at the NH2-terminus (Wang et al, 1999). This domain 
contains a PDZ (protein-recognition regions) motif that binds to several other 
proteins and directs nNOS to sites of signal transduction. The PDZ recognition 
region makes nNOS longer than the other NOS isoforms. In neuronal tissues, the 
influx of Ca2+ triggered by NMDA receptors induces nNOS catalytic activity. The 
activation of nNOS occurs through the binding of the nNOS PDZ binding motif 
with PDS-93 and PDS-95. Then, the complex PDZ-PDS-93-PDS-95 binds to the 
NMDA receptors. The NH2-terminus of nNOS also contains a binding site for the
11
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widely and highly expressed 89-amino acid protein called PIN (protein inhibitor of 
NOS). The binding of PIN with nNOS causes inhibition of nNOS catalytic activity 
by promoting monomerization of nNOS.
The constitutive isoforms (nNOS and eNOS) have a much higher 
requirement for activation than iNOS. In addition, nNOS and eNOS have 40-50 
amino acid inserts in the middle of the FMN-binding sub-domain, which has been 
described as an auto-inhibitory loop. It has been shown that the function of this 
“loop” is to destabilize CaM binding at low concentrations of Ca2* and by 
inhibiting electron transfer from FMN to the heme in the absence of Ca2+ and 
CaM. Phosphorylation also regulates the activation of nNOS and eNOS. For 
example, phosphorylation of eNOS at Ser1179 increases NO production, whereas 
phosphorylation of nNOS at Ser847 decreases the production of NO. More 
recently, the molecular chaperone heat shock protein 90 has been reported to 
regulate eNOS catalytic activity by allosteric modulation.
Of the three isoforms, eNOS is the only one that is acylated by both 
satured fatty acids myristate and palmitate (Michel et al., 1997). This
phenomenon accounts for eNOS being primarily membrane-bound. 
Palmitoylation is a dynamic and reversible process regulated by agonists such as 
bradykinin, which modifies intracellular concentrations of Caz* and serves to 
stabilize the association of eNOS with the plasma membrane. Palmitoylation of 
eNOS is reversible and it may be related to regulation of eNOS activation. In 
contrast, myristoylation is an irreversible process that is also essential for eNOS 
targeting to the caveloae of the plasma membrane (Busconi and Mitchel, 1993). 
Caveloae are small invaginations in the plasma membrane characterized by the 
presence of caveolin, a transmembrane protein that has been well characterized 
in endothelial cells and myocytes (Anderson, 1993; Parton, 1996). The
oxygenase domain of eNOS binds to caveolin maintaining the inactivation of 
eNOS (Michel et al., 1993). Calcium and CaM regulate this binding and CaM
competitively displaces caveolin out of the oxygenase domain resulting in eNOS
catalytic activation. When intracellular concentrations of Ca2+ decrease, 
calmodulin disassociates from eNOS, the eNOS-caveolin complex reforms and,
12
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ultimately, inactivates eNOS (Michel and Feron, 1997). Because the binding of 
caveolin and CaM are mutually exclusive, it is unlikely that the iNOS isoform 
catalytic activity is regulated by caveolin because iNOS binds irreversibly to CaM.
The only inducible NOS isoform so far identified irreversibly binds CaM at 
very low intracellular Ca2+ concentrations, and is therefore not subjected to 
activation in the presence of variations in intracellular Ca2+ concentrations. Found 
primarily in the cytoplasm, iNOS activity is primarily transcriptionally regulated by 
cytokines rather than changes in intracellular Ca2+ concentrations (Ghosh et al.,
1996). Kalicrin, a proinflammatory protein, appears to inhibit the dimerization of 
iNOS in the CNS (Cho et al., 1995), suggesting a neuroprotective role during 
inflammation in neuronal tissues.
Expression of NOS splice variants is another way of post-transcriptional 
regulation and has been better documented in nNOS isoforms (Huber et al., 
1998). Very little information is available on iNOS splice variants and no eNOS 
splice variants have been reported to date. The biological significance of NOS 
splice variants remains elusive, but may be related to tissue-specific activity. For 
example, some nNOS splice variants are found only in certain specific tissues, 
denoting specific physiological roles yet to be elucidated.
NITRIC OXIDE BIOLOGICAL ACTIONS
Guanvlate Cvclase
The first described mechanism of NO in biological systems was its effect 
on increasing the intracellular concentration of cyclic guanosine monophosphate 
(GMP) in endothelial and smooth muscle cells. The pathway of this effect 
involves the reaction of NO with the ferrous iron (Fe2+) moiety in the heme 
prosthetic group of the soluble guanylate cyclase in smooth muscle cells (Murad,
1994). Guanylate cyclase catalyzes the formation of cyclic GMP from guanosine 
triphosphate. The resulting cyclic GMP from the interaction of NO with guanylate 
cyclase has, in addition to inducing vascular relaxation, many regulatory roles 
such as inhibition of platelet aggregation and adhesion (Radomski et al., 1987), 
inhibition of leukocyte adhesion (Kubes et al., 1991) and changes in vascular 
permeability (Kubes and Granger, 1992). NO-induced cyclic GMP also
13
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synergistically interacts with prostacyclin to promote inhibition of platelet 
aggregation (Sinzinger et al., 1992).
Cvclooxvaenases
Cyclooxygenases (COX) belong to the CYP450 superfamily of enzymes. 
They catalyze the conversion of arachidonic acid into prostacyclins and 
thromboxane A2. It has been reported that NO up-regulates COX activation, thus, 
contributing to the production of proinflammatory prostaglandins. Therefore, NOS 
inhibitors could have another anti-inflammatory effect in addition to inhibiting pro- 
inflammatory NO, that is, the indirect inhibition of prostaglandins. The COX 
pathway, like the L-arginine-NO pathway, has constitutive and inducible isoforms 
(DeWitt and Smith, 1988). One isoform (COX-1) is constitutively expressed in 
virtually every cell except mature erythrocytes. COX-1 is thought to be 
responsible for the production of prostaglandins necessary for maintaining 
homeostasis (Seibert and Masferrer, 1994). Inflammatory stimuli are responsible 
for the expression of another isoform (COX-2) that accounts for the supra- 
physiological production of prostaglandins in inflamed tissues (Gierse et al.,
1995).
The COX pathway shares several similarities with the L-arginine pathway. 
This stimulated researchers to further investigate whether a more direct 
relationship would exist between these important pathways. Both COX-1 and 
COX-2 are expressed in endothelial cells serving to produce prostacyclins, which 
are potent vasodilators and inhibitors of platelet aggregation like NO (Hla and 
Neilson, 1992; Kubes et al., 1991). Cytokines have also been found to induce 
expression of COX-2 and iNOS in diverse tissues.
Dexamethasone, a glucocorticoid with immunosuppressive and anti­
inflammatory effects, inhibits the de novo synthesis of iNOS (Baydoun et al., 
1993) but not eNOS (Radomski et al., 1990). Similarly, dexamethasone has also 
been known as a potent inhibitor of prostaglandins (Smith, 1992), and 
subsequently evidence was found for post-transcriptional regulation of cytokine- 
induced COX-2 transcript isoforms.
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Stimulation of a murine macrophage cell line by Escherichia coli 
lipopolysaccharide caused an increase in the basal release of NO2' and PGE2, 
denoting that the NO and COX pathways were activated. Two known NOS 
inhibitors, NG-monomethyl-L-arginine (L-NMA) and aminoguanidine (AG) inhibited 
the production of both NO2- and PGE2. Furthermore, addition of sodium 
nitroprusside (SNP), a NO donor, increased the production of arachidonic acid- 
stimulated PGE2 by murine recombinant COX-1 and COX-2 (Salvemini et al., 
1993). It seems, however, that this synchronous regulation of iNOS and COX-2 is 
more evident during acute inflammation than during chronic stages of 
inflammatory processes, when dissociation between iNOS and COX-2 is 
detected (Vane et al., 1994). The NO-induced activation of the cyclooxygenase 
pathway appears to be cyclic GMP-independent (Salvemini et al., 1993; Tetsuka 
et al., 1994). While co-regulation of eNOS and COX-1 may be associated with 
maintenance of homeostasis (e.g., vasodilator tone) the dual expression of iNOS 
and COX-2 plays an important role in the pathogenesis of cerebral ischemia 
injury (Nogawa et al., 1998). Activation of COX-2 by NO is likely to be a result of 
a direct stimulation of NO on COX-2 (Salvemini et al., 1993).
Reactive Oxygen Species
The true nature of the antimicrobial and cytotoxic effects of NO is not 
known, but likely results from oxidative injury caused by production of NO- 
derived reactive oxygen species (ROS). This NO-stimulated antimicrobial 
mechanism of defense requires high concentrations of iNOS-derived NO. 
Infections in humans and experimental models are positively correlated with an 
increase in systemic NO production as determined by increased concentrations 
of NO2' and NO3* in plasma and urine (Evans et al., 1993b). The reaction of 
reactive oxygen and NO-derived nitrogen intermediates results in a diverse group 
of chemicals with powerful ability to cause cellular injury.
Peroxynitrite is perhaps the most powerful of these agents with 
antimicrobial activity and is formed from the reaction of NO with O2'. Although 
ONOO' is not a free radical per se, it is highly reactive, participating in the 
oxidation of sulfhydrils, lipids and nitration of tyrosine groups in proteins (Radi et
15
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al., 1991). Peroxynitrite is stable at alkaline pH and its conjugate acid 
(peroxynitrous acid; NOOH) is highly reactive. Conversely, peroxynitrous acid 
can decompose to form relatively unreactive NO3* at physiological pH. Hydroxyl 
radicals that are formed from the reaction of NO with H2O2 are potent oxidants, 
expressing antimicrobial activity mainly in the presence of iron species (Pacelli et 
al., 1995).
Although NO reacts with 0 2' to form ONOO', which is potentially 
neurotoxic, it can also react with a variety of metal complexes to form high-affinity 
nitroso complexes (Lancaster et al., 1992) that promote neuroprotection 
(Garthwaite et al., 1988). Accordingly, neuroprotection evoked by down- 
regulation of N-methyl-D-aspartate (NMDA) receptors, may not only be triggered 
by NO itself (Hoyt et al., 1992), but also indirectly through the formation of redox 
NO-related species (Lipton, 1996), probably involving reactions with cysteine 
sulfhydryls.
NO also reacts with Cu-Fe proteins and Fe-S clusters to generate reactive 
O2 and highly toxic hydroxyl radicals (Anggdrd, 1994). Glycolytic activity is also 
regulated by the binding of NO with thiol groups of important enzymes such as 
glyceraldehyde-3-phosphate dehydrogenase (Mohr et al., 1996). Specific 
antimicrobial action of NO-derived reactive nitrogen intermediates appears to be 
through deamination of DNA (Wink et al., 1991) and oxidative damage to DNA 
strands (Juedes and Wogan, 1996). Cytotoxic activities of NO derivatives involve 
inhibition of cellular metabolic enzymes (Ischiropoulos and Al-Mehdi, 1995), 
membrane receptors (Lipton, 1996; Fang, 1997) and signal transduction 
mechanisms (Murad, 1994). A great part of these complexes results from the 
reaction of NO with oxyhemoglobin and Fe-S-containing proteins present in the 
tricarboxilic acid.
NITRIC OXIDE DONORS
One approach to investigating the biological actions of NO in vitro or in 
vivo would be to administer the pure NO gas to experimental units; however, 
although this approach seems ideal, it is not feasible in light of the inconveniently 
short half life of NO. An alternative method would be the administration of
16
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compounds that spontaneously or enzymatically release NO, called NO 
generators and commonly known as NO donors. Fortunately, several NO donors 
(terminology recommended by the International Union of Pharmacology 
Nomenclature in Nitric Oxide Research) such as nitroglycerin and sodium 
nitroprusside have been used for many years to treat cardiovascular diseases, 
long before they were known to work through the release of NO to effect a 
biological action therapeutically (Needleman eta!., 1972; Ignarro et al., 1981). In 
addition, novel NO donors were developed and used in NO research, and there 
are currently several groups of NO donors including the organic nitrates and 
nitrites, inorganic nitroso compounds, sydnonimines, S-nitrosothiols and 
diazeniumdiolates. In general, most of the NO donors generate NO at 
physiological pH spontaneously or enzymatically (Singh et al., 1996).
Diazeniumdiolates are compounds that contain the anionic N2O2 functional 
group attached to various carrier molecules (e.g., spermine NONOate) and have 
the advantage of generating NO as the compound degrades. Diazeniumdiolates 
spontaneously generate bioactive NO in an aqueous environment and have a 
wide range of half lives that facilitate their use in diverse experimental settings. 
Another advantage is that diazeniumdioaltes generate NO at a rate independent 
of the tissue involved or medium characteristics. Spermine NONOate has a half 
life of 73 min at 37°C in physiological saline solution.
Sodium nitroprusside [SNP; sodium pentacyanonitrosyl ferrate (II)] is an 
iron nitrosyl compound where the iron atom is in the ferrous state and NO is 
formally bound as NO*. Although the effects of SNP on the cardiovascular 
system are well known, its mechanism of NO release is not. It is probable that in 
biological systems both spontaneous and enzymatic release of NO occurs. Either 
way, it is known that the generation of NO from SNP requires irradiation with light 
or one electron reduction. It has been suggested that a membrane-bound 
enzyme may be associated with the generation of NO from SNP. The 
requirement for NADPH or NADH for NO generation has been suggested but not 
demonstrated. Cyanide is released following SNP reduction and formation of 
S-nitrosyl compounds.
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NITRIC OXIDE SYNTHASE INHIBITORS 
The first step of the reaction that generates NO from the amino acid 
L-arginine involves the formation of NG-hydroxy-L-arginine (Stuehr et al., 1991). 
Therefore, the L-arginine/NO pathway can be inhibited by several L-arginine 
analogues (Abu-Soud et al., 1994). The first known NOS inhibitor was a 
compound found to inhibit the L-arginine-induced cytoxicity in murine 
macrophages, before it was even known that L-arginine was a substrate for NO 
generation (Hibbs et al., 1987). This compound, NG-monomethyl-L-arginine (L- 
NMA) was shown to be a competitive inhibitor of the formation of NO and it was 
one of the first NOS inhibitors to be used in NO research (Hibbs et al., 1988). 
Later on, many other analogues of L-arginine were developed to competitively 
inhibit both constitutive and inducible NOS isoforms. It has been reported that 
NG-NG-dimethyl-L-arginine (L-ADMA) and L-NMA are NOS inhibitors naturally 
found in human plasma and urine, suggesting that plasma or urine quantification 
of these inhibitors may be an indicator of imbalances in NO biosynthesis related 
to disease (Flicking et al., 1993). Another class of drugs that inhibit NOS action 
includes non-amino acid compounds that chemically resemble the guanidinium 
moiety of L-arginine.
Recently it was reported that a novel compound (BN-80933) was 
developed to inhibit both nNOS and lipid peroxydation in order to promote 
neuroprotection (Chabrier et al., 1999). The rationale was based on the fact that 
excessive NO production in the brain as well as excessive reactive oxygen 
species stimulated lipid peroxydation. The methyl ester of NG-nitro-L-arginine 
(L-NAME) was shown to inhibit acetylcholine-induced relaxation of aortic rings 
and since then L-NAME has been used in physiological studies. NG-nitro-L- 
arginine methyl ester is far more soluble than its free acid, NG-nitro-L-arginine 
(L-NNA) and, therefore, suits physiological experimentation involving in vivo 
administration to animals or in vitro-cultured cells.
The efficacy of L-NAME as an NOS inhibitor is questionable, because 
L-NAME inhibitory effects are more pronounced in the presence of cellular 
esterases that readily hydrolyze L-NAME into L-NNA, a more potent NOS
18
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inhibitor. N6 -nitro- L-arginine methyl ester has a short half life and the inhibitory 
effects on NOS activity are probably a result of L-NNA action. The hydrolysis rate 
leading to formation of L-NA from L-NAME may vary from tissue to tissue and 
even between the same cell lines cultured under different media. The mechanism 
of transport of L-NAME is unknown, however, perhaps it can be extrapolated 
from studies with other amino acid esters that L-NAME is quickly transported 
inside the cells and subsequently hydrolyzed to its free acid, which becomes 
“trapped” inside the cells. Administration of L-NAME to cell cultures should 
produce approximately 90% NOS inhibition, particularly nNOS and eNOS. L- 
NAME can be administered intravenously to animals and hydrolysis of L-NAME 
to L-NNA should be expected. This explains why administration of L-NAME, an 
agent with a short half live is followed by a prolonged inhibition of NOS, probably 
attributable to L-NNA.
Aminoguanidine (AG) has been reported to inhibit NOS activity. 
Aminoguanidine is a poor inhibitor of constitutively expressed NOS isoforms and 
at high concentrations the inhibitory effect on NOS activity is preferentially toward 
iNOS. Thus, AG has been reported to be a selective inhibitor of iNOS (Corbett et 
al., 1992). First synthesized from the reduction of nitroguanidine in 1892, AG is 
structurally related to the amino acid L-arginine. Chemically, AG is a nucleophilic 
compound containing two guanidine nitrogens that shares many properties with 
hydrazines and is, thus, often classified as a hydrazine. Three chemical forms of 
AG, the hydrochloride, the hemisulfate and bicarbonate salts, are commercially 
available. The most soluble form is the hydrochloride that is freely soluble in 
aqueous solutions and culture media.
Although AG was first known as an explosive, its effects on systemic 
blood pressure and respiratory function have been known for years. The first 
important biological effect of AG was reported in 1952, when it was found that 
AG inhibited diamine oxidase (histaminase), which catalyzes the oxidative 
deamination of histamine and putrescine (Schuler, 1952). Thus, the 
administration of AG to animals could potentially lead to histamine accumulation 
in the body (Nilsson, 1999). Later on, another important biological effect of AG
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was discovered. The administration of AG inhibited the nonenzymatic formation 
of advanced glycosylation end products (AGE; Brownlee et al., 1986). Advanced 
glycosylation end products are formed by glycosylation of cellular or extracellular 
protein constituents and their accumulation has been associated with diabetic 
complications. AGE effects at the tissue and cellular level have been reviewed 
(Singh e ta i, 2001).
Researchers are intensively investigating AG as a pharmacological agent 
for treatment of complicated diabetes. Results of a Phase III trial using 
pimagedine (the generic name for aminoguanidine) in humans suggest that 
inhibition of AGE formation in Type-I diabetic patients may slow diabetes-induced 
nephropathy (Friedman, 1999; Sugimoto et al., 1999; Singh et al., 2001). 
Moreover, human subjects with Type I diabetes that were treated with AG had a 
reduced progression of retinopathy along with lowered plasma lipid 
concentrations (Singh et al., 2001). Similar results were reported for diabetic 
dogs that were treated daily with AG for 5 years. AG-treated dogs did not 
develop retinopathy as control diabetic dogs did; however, this AG-induced effect 
was independent of inhibition of AGE formation (Kem and Engerman, 2001). The 
biochemical mechanism by which AG prevented the onset of retinopathy in 
diabetic dogs remains unclear. Another biological effect of importance is the 
ability of AG to stabilize S-adenosylmethionine decarboxylase, an enzyme 
involved in the metabolism of polyamines. The use of AG in experiments 
investigating the biology of NO should be exercised with care because of several 
other AG-mediated biological effects unrelated to NO-related mechanisms. 
Hemoglobin as a Nitric Oxide Scavenger
The oxidation of NO to NO3' by hemoglobin is thought to be the major 
pathway for elimination of NO from the body (Wennmalm et al., 1992). 
Accordingly, hemoglobin has been used as a NO scavenger in in vitro 
experimental models to elucidate the biological role of NO in a number of 
physiological and pathophysiological processes. Originally the binding of NO with 
hemoglobin was considered uncooperative (Moore and Gibson, 1976), but recent 
work has suggested that the NO-hemoglobin reaction in a physiological milieu
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may serve to secure and deliver it as needed (Stamler et al., 1997; Gow and 
Stamler, 1998). In this aspect, NO was found to bind preferentially to unoccupied 
heme sites in the hemoglobin molecule in a cooperative manner, to nytrosylate 
hemoglobin thiols or to react with available O2*. Superoxide dismutase in 
erythrocytes reacts with 0 2~ and generates NO. The NO produced reacts with 
hemoglobin to form nitrosohemoglobin and nitrosylated hemes that ultimately 
maintain NO in a bioactive state (Gow et al, 1999).
The use of hemoglobin is a very effective means to scavenge NO in vitro 
because NO concentrations are usually much greater than that found in a 
physiological milieu (Eich et al., 1996). Thus, hemoglobin is an important tool to 
study the biochemistry of NO associated with its physiological actions, as it has 
been shown in several studies investigating NO regulation in vasodilation 
(Feelisch and Noack, 1987), neural receptors (McMahon and Ponomareva,
1996), granulosa cell steroidogenesis (Van Voorhis et al., 1994) and in vitro 
bovine embryo development (Lim and Hansel, 1998).
NITRIC OXIDE AND REPRODUCTION 
Soon after the discovery of convincing evidence that NO was the EDRF 
(Furchgott and Zawadski, 1980; Ignarro et al., 1981; Palmer et al., 1987), 
researchers started to investigate the biology of NO and found that NO was 
involved in multiple biological functions responsible for normal homeostasis of 
important systems, such as the gastrointestinal (Kubes, 1993; Moore and 
Seahorn, 1997) and respiratory (Jorens et al., 1993; De Sanctis et al., 1999), in 
addition to the well-described control of vasodilator tone (Calver et al., 1993). 
The biology of NO turned out to be more complex and ubiquitous than previously 
thought, and NO was reported to modulate or participate in pathophysiological 
mechanisms of disease in diverse systems (Moncada etal., 1991). Researchers’ 
attention then turned to investigating the biological effects of NO in the 
reproductive system (Adams et al., 1992; Rosselli et al., 1994a).
Researchers in several laboratories found NO to be involved in regulatory 
processes of the reproductive system, including many biological processes in the 
hypothalamic-hypophyseal-gonadal axis (McCann and Rettori, 1996b; Rosselli et
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al., 1998; Dixit and Parvizi, 2001). Cerebral NO (produced by the NOergic 
neurons) caused the release of gonadotropin releasing hormone (GnRH) from 
the hypothalamus. Results from initial investigations on NO and release of 
luteinizing hormone (LH) were apparently conflicting because evidence was 
found that supported both stimulatory (Rettori eta!., 1992; Bonavera e /a /., 1993; 
Canteros et al., 1995) and inhibitory (Seilicovich et al., 1995; McCann and 
Rettori, 1996a) effects on LH release.
A conciliatory hypothesis was suggested when these initially discrepancy 
results were interpreted to mean that NO was responsible for the pulsatile 
release of LH, causing initiation and termination of neural impulses in the 
hypothalamus (Aguan et al., 1996; McCann and Rettori, 1996b). initiation of the 
LH pulse generator was a result of NO-stimulated up-regulation of PGE2 
(Bonavera et al., 1994). It was postulated that NOergic neurons were activated 
by norepinephrine-stimulated a -1 receptors, resulting in increased intracellular 
Ca2+ concentrations and further activation of CaM to stimulate NOS catalytic 
activity. Typically, NO production would be expected to decrease intracellular 
concentrations Ca2*, as happens with Ca2> concentrations of endothelial cells 
expressing NOS activity. However, it was proposed that in the brain NO would 
increase Ca2+ concentrations, a phenomenom previously detected in pancreatic 
acinar cells that showed a biphasic response to NO stimulation, increasing Ca2+ 
concentrations at low NO concentration and lowering at high concentrations of 
NO (Xu et al., 1994). Because of increased Ca2* concentrations, activation of 
phospholipase A2 catlytic activity caused the conversion of membrane 
phospholipids to form arachidonic acid. The COX pathway was then activated 
resulting in PGE2 formation and GnRH release (McCann and Rettori, 1996b). 
The pulse was shown to terminate through the NO-activation of two different 
mechanisms. The NO released by norepinephrine, entered an ultra short loop 
negative feed-back mechanism to terminate the pulsatile release of LH by 
inhibiting the norepinephrine release at the noradrenergic terminals that, 
ultimately, resulted in a sequential termination of the norepinephrine, GnRH and 
LH pulsatile pulses (Seilicovich eta/., 1995).
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Nitric oxide also stimulated the release of the gamma amino butyric acid 
(GABA), which previously has been shown to inhibit the response of GnRH to 
SNP treatment to median basal hypothalamic explants, adding one more 
pathway of NO-induced inhibiton of GnRH-induced LH pulsatile release (McCann 
and Rettori, 1996a). Interestingly, the release of the follicle-stimulating hormone 
(FSH) was not affected either by NO donors or NOS inhibitors, thus, adding 
additional evidence to the hypothesis that supports the existence of an FSH- 
releasing hormone (FSHRH) that is regulated independently from GnRH release 
(Rettori etal., 1993).
It has been suggested that there are two types of GnRH secreting 
neurons: one group of neurons with axons terminating in the hypophyseal portal 
vascular micro-system and another group of neurons with axons extending to 
areas in the hypothalamus that control sexual behavior (Mani et al., 1994). As 
GnRH has been implicated in the control of mating behavior in rats, further 
experiments suggested that lordosis behavior in female rats was directly linked to 
NO stimulation. Accordingly, administration of SNP stimulated the lordosis 
behavior, whereas administration of NOS inhibitors inhibited the display of 
lordosis (Mani etal., 1994).
The release of hypophyseal hormones also appears to be under NO 
control. The presence of NOS isoforms has been identified in gonadotropes. 
Furthermore, studies using isolated cultures of hypophyseal explants showed 
that secretions of LH and FSH are reduced as a result of the removal of 
hypothalamic regulation, whereas prolactin is released in large quantities 
because of the absence of hypothalamic-derived prolactin-inhibitory factors. 
Addition of NO donors to hypophyseal explants stimulated LH while decreasing 
the output of prolactin. Because cyclic GMP has been found to stimulate both LH 
and FSH release, it was later found that NOS inhibitors also inhibited the release 
of these hormones induced by GnRH. It was concluded that NO would be acting 
through cyclic GMP, a known activator of protein kinase G (Yu et al., 1997). 
Other studies have shown that the administration of NOS inhibitors inhibited the 
preovulatory LH surge in rats, suggesting additional evidence for NO-mediated
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LH release in cycling animals (Bonaventura et a/., 1993; Aguan etal., 1996). Up- 
regulation of nNOS activity has been shown by immunohistochemistry to 
coincide with the LH surge in ovulating rats (Lamar etal., 1999).
NO has also been implicated in the regulation of oxytocin and GABA 
release from the neurohypophysis via the regulatory neuroendocrine peptide 
neurokinin A (De Laurentiis et al., 2000). Results from other studies have shown 
that NO inhibition of neuronal excitability in oxytocin and vasopressin neurons 
involves pre- and post-synaptic potentiation of synaptic activity in GABA- 
containing neurons in the supraoptic nucleus (Lutz-Bucher and Koch, 1994; 
Stem and Ludwig, 2001).
Nitric Oxide and Male Reproductive Phvsioloov
Human testicular nNOS activity was reported to be relatively lower than 
that of vas deferens, prostate and seminal vesicle (Ehren et al., 1994). Further 
research involving NO mechanisms of regulation of penile function and 
dysfunction was the first area of NO research that resulted in the discovery of a 
clinical treatment for a reproductive dysfunction. Studies using isolated strips of 
rabbit corpus cavernosum exposed to electrical field stimulation resulted in 
production of NO (Ignarro et al., 1990). This finding suggested that NO was a 
mediator of penile erection via a noncholinergic nonadrenergic neuroregulation 
(Burnett ef al., 1992).
Immunohistochemistry studies performed in the mouse (Gonzalez- 
Cadavid et al., 2000), rat (Burnett et al., 1995) and human (Burnett et al., 1993) 
determined the presence of nNOS protein disseminated throughout the penile 
innervation and extending into the pelvic ganglion (where their neuronal bodies 
are located). Expression of nNOS and NO production in the penis was intimately 
associated with rat penile erection (Chang et al., 1996) and declined with age 
(Carrier et al., 1997). However, long-term treatment with androgens restored 
penile erection in old rats without affecting NOS expression (Garban etal., 1995).
Furthermore, the presence of eNOS was also found in endothelial cells of 
arteries supplying the mouse penis (Burnett et al., 1996). It was then postulated 
that NO would activate the soluble guanylate cyclase in the smooth muscle of the
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corpus cavemosum to form cyclic GMP. Increased concentrations of cyclic GMP 
would then cause vasorelaxation, allowing arterial blood to enter the penis to 
cause erection (Burnett et al., 1993). This knowledge led researchers to develop 
a phosphodiesterase inhibitor (sildenafil) that when taken orally (Viagra®) would 
inhibit the phosphodiesterase isoform (PDE5) that metabolizes cyclic GMP 
(Boolell et al., 1996). The resulting accumulation of cyclic GMP would facilitate 
the triggering of vascular and vascular-associated neural reflexes responsible for 
penile erection. Sildenafil is used for treatment of erectilte dysfucntion but 
requires prior sexual stimulation. Quality and duration of erection depend on the 
presence of integer vascular-neuro-muscular structure to support penile erection 
(Glossmann etal., 1999).
The testes are a site for NOS expression and a target for NO action 
(Ehren et al., 1994; Burnett et al, 1995). Leydig cells are in close proximity to 
endothelial cells and macrophages (Hutson, 1992), which are a source of 
cytokines that modulate testicular steroidogenesis. Cytokine-modulated 
steroidogenesis may involve NO-mediated cell signaling as the presence of 
nNOS and eNOS activity has been detected in Sertoli cells, Leydig cells and 
endothelial cells of human testes (Davidoff et al., 1995; Zini et al., 1996). Even 
the expression of iNOS induced by cytokines has been reported to occur in 
cultured Sertoli cells (Stephan et al., 1995) and Leydig cells as well (Tatsumi et 
al., 1997). Although the soluble guanylate cyclase and cyclic GMP have been 
found to be co-localized within the cytoplasm of Leydig cells and immature 
spermatids (Davidoff et al., 1995), NO participation in the modulation of 
steroidogenesis might involve mechanisms independent of cyclic GMP activation 
(Del Punta et al., 1996). The NO effect on testicular steroidogenesis is inhibitory 
and possibly reflects the well known ability of NO to bind with CYP450 enzymes 
(Adams et al., 1994). When the mechanism of NO-induced inhibition was studied 
in a murine Leydig tumor cell line and in rat Leydig cell steroidogenesis, it was 
found that NO was inhibiting one of the rate-limiting enzymes, the CYP450 side- 
chain cleavage enzyme (Del Punta et al., 1996), which catalyzes the formation of 
pregnenolone from cholesterol. In a subsequent study, administration of a NOS
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substrate to intact male rats decreased both LH and testosterone concentrations 
(Gaytdn et al., 1997). This effect had been previously reported to be reversed by 
the NOS inhibitor, L-NAME (Adams etal., 1994).
Sperm cell function also appears to be mediated via NO-mediated 
mechanisms (Hellstrom et al., 1994; Rosselli et al., 1995). The role of NO on 
sperm cell motility has been found to be inhibitory under high concentrations of 
NO (Rosselli et al., 1995), whereas low concentrations of NO may be beneficial 
for promoting sperm cell motility (Hellstrom et al., 1994; Lewis et al., 1996). In a 
subsequent study, NO was reported to modulate the progesterone-induced 
acrosomal exocytosis in mouse spermatozoa, therefore, suggesting a role for NO 
in sperm cell capacitation (Herrero et al., 1995). Furthermore, it was found that 
NOS activity was highly expressed in sea urchin sperm cells after activation by 
the acrosome reaction. The resulting NO production at the site of fertilization led 
to nitrosation reactions within the egg before the Ca2*-induced egg activation 
(Kuo et al., 2000). Moreover, microinjection of SNAP or recombinant NOS 
recapitulated the events preceding and occurring during egg activation, whereas, 
microinjection of oxyhemoglobin prevented egg activation after fertilization (Kuo 
et al., 2 0 0 0 ).
Nitric Oxide and Female Reproductive Physiology
The female reproductive model has posed an attractive model to study 
both physiological and pathophysiological regulatory mechanisms for their well- 
known constant and dynamic state of cyclic and hormonally regulated changes. 
Because the discovery of NO as a cell-signaling molecule was related to its role 
as an EDRF (Ignarro et al., 1987), initial work evaluating what role NO would 
have in the female reproductive system was directed to vascular physiology 
studies. Until 1992, very few articles had been published on the biological effects 
of NO in the female reproductive system. At that time, most of the NO research 
on the reproductive system was concentrated on investigating NO-mediated 
effects in the uterine vasculature of pregnant and non-pregnant animals (Weiner 
etal., 1992; Matsumoto etal., 1992; Kimura etal., 1992). However, in 1993, one 
group reported that addition of aminoguanidine to primary cultures of interleukin-
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1-beta-treated rat ovarian dispersates prevented the documented interleukin-1  - 
beta-induced morphologic and cytotoxic changes (Ben-Shlomo et al., 1994). 
Because these changes were thought to reflect tissue-remodeling events 
associated with ovulation, it was postulated that NO would have a role in 
ovulation (Ellman et al., 1993). The results of that study suggested that the NO 
effects on cytotoxicity were shown to be mediated by cyclic GMP.
In 1994, several researchers reported the results of studies suggesting a 
role for NO in mediating events in the female reproductive system. In one study, 
administration of L-NAME to bovine uterine tube segments (ampulla and 
isthmus) enhanced the ET-1 -induced contraction of uterine tube rings suggesting 
a role for NO-mediated uterine tube function (Rosselli et al., 1994b; Bryant et al., 
1995). Later in the year, the same group reported that concentrations of N 02' 
and NO3* in human plasma increased during the follicular phase of ovarian cycles 
that was correlated with a concomitant increase in estradiol (E2) plasma 
concentrations suggesting a role for NO in follicular development in humans 
(Rosselli etal, 1994a).
Because women after menopause are at risk for cardiovascular disease 
and estrogen replacement therapy may have cardioprotective properties, the 
authors of that study examined the serum concentrations of NO metabolites 
(NO2' and NO3 ) at specific stages of follicular development during natural and 
gonadotropin-stimulated cycles (Imthum et al., 1997). A correlation was found 
between NO metabolites and serum E2 concentrations during the progression of 
follicle development; however, elevated serum E2 concentrations during the post- 
ovulatory period when serum progesterone (P4) concentrations were also 
elevated were not correlated with serum NO metabolites. These results 
suggested an up-regulation of the NO pathway during the human follicular phase.
Using a more mechanistic approach, researchers demonstrated that NO 
was implicated in the autocrine regulation of granulosa cell steroidogenesis and 
that this effect was not mediated by the cyclic GMP pathway (Van Vhorris et al.,
1994). It was found that NO caused a dose-dependent decrease in both E2 and 
P4 secretion by human granulosa cells. Results of that study suggested that NO
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directly inhibited CYP450 aromatase activity and it was one of the first studies to 
propose a more specific site of NO action in addition to the well established 
relationship between NO and cyclic GMP. Although the participation of NO in 
reproductive physiological processes is irrefutable, the specific control and 
expression of NO production during reproductive biological events are yet to be 
fully elucidated. The ubiquitous nature of this gas cell-signaling molecule is 
perhaps a clue as to how diverse and complex NO biology is, a phenomenon 
comparable to the seemingly ubiquitous and complex expression of 
prostaglandins.
Molecular Mechanisms of Mammalian Ovulation
Ovulation is a process that is represented by the rupture of the follicle wall 
to release an oocyte that has completed or is completing the process of cellular 
and nuclear maturation, a sine qua non condition for fertilization. The luteinizing 
hormone (LH) surge initiates a cascade of molecular and biochemical events 
occurring in the follicle wall and oocyte that enable the follicle to release the 
oocyte. These LH-induced events take place during a period that is relatively 
constant and species-specific. Administration of human chorionic gonadotropin 
(hCG) typically reproduces LH-stimulated events and is, therefore, used to 
induce ovulation in domestic animals in reproductive experimental models.
The events leading to ovulation can be grouped into three distinct, but 
closely related, processes: vascular changes in the ovary and preovulatory 
follicles; endocrinological shift in the granulosa-thecal cell complex that initiates 
the process of preovulatory luteinization (increased P4:E2 ratio) and structural 
degradation of the follicle and ovarian surface necessary for rupture and release 
of the oocyte. Along with these processes, there is the resumption of oocyte 
maturation, which was arrested in prophase I of the first meiotic division. Similarly 
impressive is the rapid morphological and functional transformation of the 
granulosa-theca cell complex into luteal cells. The preovulatory period and the 
ovulation itself have been compared with an inflammatory-like event (Espey, 
1980), whereas, the post-ovulation period (luteal formation) has been compared 
with a wound-repair process (Silvester and Luck, 1999). Interestingly, Leopold
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and Mironoff (1894) had already noted that rapid preovulatory follicular 
development and ovulation in the human ovary were processes accompanied by 
inflammation and that ovarian congestion was a natural condition present in the 
ovary bearing the preovulatory follicle.
Vascular changes
Perhaps the increase in vascularity is one of the first notable changes 
observed in the preovulatory follicle following LH stimulation. The apparent 
venous congestion in follicles before ovulation has been observed in ovaries of 
frogs (Grohe, 1863), cats (Thomson, 1919), ewes (Marshall, 1904), monkeys 
Heape, 1897) and women (Leopold and Mironoff, 1894). Subsequently, the 
hyperemia and venous congestion of preovulatory follicles were attributed to 
gonadotropins (Zondek et al., 1945). Ovarian blood flow increases after hCG 
stimulation (Murdoch et al., 1983) and hyperemia-associated vascular changes 
are predominantly seen in preovulatory follicles. Interestingly, the area of the 
preovulatory follicle destined to rupture during ovulation is devoid of vascular 
changes (Brannstrom etal., 1998).
The LH surge also induces migration of leukocytes to the preovulatory 
follicle (Brannnstrom et al., 1994). Whereas neutrophils are the predominant cell 
type in sheep (Cavender and Murdoch, 1988) and cows, eosinophils are most 
common in equine preovulatory follicles Kerban et al., 1999). In rats, 
macrophages and neutrophilic granulocytes account for the bulk of leukocytes 
detected before ovulation (Brdnnstrdm, 1993). It has been postulated that 
leukocyte migration may serve as a source of cytokines and proteolytic enzymes 
needed for degradation of the follicle and ovarian surface before ovulation 
(Adashi, 1989; Andreani et al., 1991). Leukocyte supplementation significantly 
increased the LH-induced ovulation rate in perfused rat ovaries as compared with 
LH-stimulation alone (Hellbergh etal., 1991). In another study (BrSnnstrdm etal.,
1995), systemic administration of neutrophil-depleting antibodies to rats 
decreased the rate of LH-induced ovulation. However, severe systemic leukocyte 
depletion induced by cyclosphosphamide or depletion of neutrophils by 
vinblastine did not alter the expected ovulation rate in gonadotropin-stimulated
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immature rats (Chun et al., 1993). Likewise, systemic eosinopenia induced by 
prednisolone did not affect the ovulation rate in ewes nor affected post-ovulation 
luteal formation and, thus, adding evidence to question the role of leukocytes in 
mammalian ovulation (Murdoch and Steadman, 1991). The depletion of 
leukocytes in the periovulatory period may be compensated by the presence of 
theca fibroblasts as an important source of proteolytic enzymes.
Nevertheless, leukocyte-derived vasoactive agents have been implicated 
as playing an important role in mammalian ovulation. Growth factors such as the 
vascular endothelial-permeability growth factor, one of the most important 
inducers of angiogenesis (Carmeliet et al., 1996) and a mitogen for vascular 
endothelium, has been identified in rodent ovaries (Shweiki et al., 1993). It is 
significantly expressed following ovulatory stimulus by LH or hCG administration 
(Koos et al, 1995; Christenson and Stouffer, 1997). Other growth factors, such as 
epidermal growth factor, transforming growth factor-a and insulin-like growth 
factor have also stimulated granulosa cell proliferation and angiogenesis. Tumor 
necrosis factor-a stimulated the NOS and cyclic GMP pathway in bovine theca 
cells stimulated with LH (Brunswig-Spickenheier and Mukhopadhyay, 1997). 
Growth hormone (GH) has also been implicated in follicular dynamics in humans 
(Blumenfeld and Amit, 1996) and, more recently, administration of equine growth 
hormone to anestrous mares increased the hCG-induced ovulation rate 
compared to hCG alone (Cochran, 2000).
The importance of interleukin-1 (3 (IL-1(3) for ovulation has been suggested 
in rats (Brannstrom et al., 1993) and rabbits (Takehara et al., 1994). The 
mechanism of IL-1P on ovulation may involve prostaglandin production (Kokia et 
al., 1992), induction of formation of hyaluronic acid and proteoglycan synthesis 
(Kokia et al., 1993), cumulus expansion during oocyte maturation (Chen et al., 
1993), induction of plasminogen activator and gelatinase activities (Hurwitz et al. 
1993; Hurwitz et al., 1997), and activation of the NOS pathway (Ben-Sholomo et 
al., 1994; Bonello et al., 1996). Furthermore, another interleukin (IL-8 ) has been 
found to mediate hCG-stimulated ovulation in rabbits, primarily by inducing 
neutrophil accumulation and activation (Ujioka etal., 1998).
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Prostaglandins are also considered essential for ovulation, especially in 
regard to vascular changes (hyperemia, edema) and the process of follicular 
rupture and, to a lesser extent, the preovulatory luteinization phenomenon. 
Administration of hCG induces the expression of cyclooxygenases (COX), 
resulting in production of prostaglandins F2a and E2 and lipooxygenases (LOX), 
resulting in production of peptidic and nonpeptidic leukotrienes (Espey et al., 
1989; Tanaka et al., 1989; Yoshimura et al., 1991; Higuchi ef al., 1995). 
Administration of indomethacin, a COX inhibitor, or nordihydroguaiaretic acid, a 
LOX inhibitor, significantly decreased ovulation rates in rats and rabbits but did 
not impede the hCG-induced luteinization of granulosa and theca cells. Inhibitors 
of the LOX pathway inhibited ovulation in rats in vivo (Reich et al., 1983) and in 
vitro perfused ovaries (Mikuni et al., 1998). Furthermore, indomethacin reduced 
the LH-induced hyperemia in rabbits (Lee and Novy, 1978) and in ewes 
(Murdoch et al., 1983). In the rat, hCG-stimulated vascular changes, such as 
increase in vascular permeability were also significantly inhibited by 
administration of COX and LOX inhibitors (Abisogun etal., 1988).
More recently, the expression of cyclooxygenase 2 (the inducible isoform) 
has been identified in granulosa cells of rats, cows, horses and humans. The 
time of expression of COX-2 mRNA in relation to hCG stimulation varies among 
these species (rats, 4 h; cows. 16 h; mares, 30-32 h); however, ovulation in these 
three species occurs invariably 10 h after COX-2 expression (Sirois et al., 1992; 
Sirois, 1994; Liu et al., 1997; Sirois and D or6,1997). It has been suggested that 
COX-2 expression may be a determinant of hCG-induced ovulation and accounts 
for species-specific differences in the length of estrus among these species 
(Sirois and Dore, 1997).
Platelet-activating factor (PAF) is a very potent mediator of inflammation, 
modulating changes in vascular permeability and systemic blood pressure. 
Administration of PAF antagonists decreased hCG-induced ovulation rates in rats 
(Abisogun etal., 1989) and mice (Kikukawa etal., 1991).
Bradykinin is a nonapeptide generated in inflamed tissues and is 
generated from the proteolytic cleavage of plasma kininogens by kallikrein.
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Bradykinin is a potent vasoactive agent that augments local vasodilation in 
inflammed tissues, increased vascular permeability and cell proliferation. Espey 
et al. (1986) demonstrated the presence of bradykinin in gonadotropin-stimulated 
rat ovaries. Furthermore, evidence exists suggesting that bradykinin and other 
kinins modulate ovulation in rabbits (Yoshimura et al., 1988) and in rats 
(Hellbergh et al., 1991) probably by stimulating the production of prostaglandins 
in preovulatory follicles.
Histamine is a well-known vasoactive substance derived from the 
enzymatic decarboxylation of histidine. It is mainly stored in the metachromatic 
granula of mast cells and basophils. The participation of histamine in the 
ovulatory process has been suggested (Szego and Gitin, 1964). Subsequently, 
reports suggested that administration of antihistaminic drugs inhibited ovulation 
in vivo and in vitro, whereas administration of histamine caused ovulation. 
Histamine induced increased hyperemia in the preovulatory follicle wall after 
gonadotropin stimulation (Espey, 1980). However, a pivotal role for histamine is 
yet to be demonstrated, as several studies have questioned a role for histamine 
in ovulation in mares (Watson and Sertich, 1991), sheep (Halterman and 
Murdoch, 1986) and rabbits (Kitai etal., 1985).
Angiotensin II regulates blood pressure and fluid homeostasis. The same 
enzyme that converts angiotensin I to angiotensin II also acts as a kininase to 
degrade bradykinin. There is evidence indicating a primary role for angiotensin II 
in ovarian steroidogenesis and ovulation. Prorenin forms the enzyme that 
converts angiotensinogen into angiotensin I. Prorenin is present in ovarian 
follicles and its concentration increases after an ovulatory stimulus. The 
expression of the angiotensin II receptor varies with species and stages of 
follicular development. An ovulatory stimulus increases the ovarian renin- 
angiotensin system activity in the ovary. The specific role of angiotensin II in 
ovulation has not been clearly identified. Angiotensin II induced ovulation in 
perfused rabbit ovaries by stimulating prostaglandin production (Yoshimura etal., 
1993) whereas administration of the angiotensin II antagonist saralasin inhibited 
ovulation in perfused rat ovaries (Peterson et al., 1993). However, other reports
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questioned the importance of angiotensin for ovulation when the use of the 
converting enzyme inhibitor captopril failed to find significant effects in ovulation 
or ovarian steroidogenesis in rats (Daud et al., 1990).
The LH surge is associated with an increase in generation of reactive 
oxygen species in the preovulatory follicle. When the scavenging enzyme 
superoxide dismutase (SOO) was added to perfused rabbit ovaries, LH-induced 
ovulation was significantly decreased (Miyasaki et al., 1991). This is in 
agreement with one study that found that hCG supplementation depleted 
ascorbic acid in the perfused rat preovulatory follicle and a similar effect was 
noted when menadione (a generator of oxygen free radicals) was added to the 
perfusion medium (Guamaccia et al., 2000).
Proteolysis
Although LH-induced events necessary for ovulation to occur take place 
before follicular rupture, the process of ovulation, strictly, refers to follicular 
rupture and final expulsion of the oocyte. Follicle rupture requires the degradation 
of otherwise healthy ovarian tissue. Degradation of a specific area of the follicle 
and ovarian surface where ovulation will occur is a precise process, if one 
considers that follicles continue to increase their diameter until ovulation takes 
place. The process of degradation involves intense proteolytic activities in 
the extracellular matrix and collagen fibers present primarily in the theca 
externa and tunica albuginea (Brannnstrom et al., 1988). The main proteolytic 
enzymes are plasminogen-activating factor (PLAF), kallykreins and coilagenases 
(metalloproteinases; Tsafriri etal., 1989).
Quiescent fibroblasts become fully active after the LH surge. 
Plasminogen-activating factor is a serine protease that is secreted from 
fibroblasts in association with coilagenases. Several studies have identified the 
presence of PLAF in the granulosa cell layer and theca externa. The appearance 
of PLAF activity has been linked to steroid and eicosanoid modulation. Kallikreins 
are also serine proteases that are present in inflamed tissues. Besides producing 
kinins (vasoactive substances like bradykinin), they also convert procollagenase 
into collagenase (active form).
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The importance of collagenolytic activity for ovulation comes from studies 
showing that inhibitors of collagenase prevented ovulation. Coilagenases are 
enzymes that are members of a group of enzymes collectively known as matrix 
metalloproteinases (MMPs) that also include gelatinases, stromelysins and 
membrane-type matrix MMPs. Inhibitors of MMPs inhibited ovulation. It has been 
speculated that interstitial collagenase and collagenase-3 may be responsible for 
the initial degradation of the follicle wall before ovulation. Gelatinases A and B 
are noted for their ability to cleave gelatin and type IV collagen, which are 
components of basement membranes. One study reported that equine ovarian 
stromal cells cultured in vitro were able to produce gelatinases A and B along 
with tissue inhibitors of MMPs (Song etal., 1999).
In summary, although the literature contains conflicting reports on the 
mechanisms of activation and modulation of PLAF, kallykrein and collagenase, it 
is generally accepted that their activation is temporally related as, apparently, is 
their modulation by prostaglandins and steroids (primarily P4). Furthermore, it has 
been postulated that accumulation of ligands in the ovary after the LH surge may 
initiate an action potential to the fibroblasts to generate signal transduction 
mechanisms that self perpetuate and propagate, resulting in intense proteolytic 
activity until ovulation takes place.
Ovarian steroids
After the LH surge, granulosa and theca cells collectively start to produce 
more P4 than E2 and androgens. Results of several studies support the concept 
of a steroidogenesis shift that increase the P4:E2 ratio in response to endogenous 
LH or administration of hCG. Decreases in CYP450 side chain cleavage enzyme, 
CYP450 aromatase and steroidogenic acute regulatory protein expression 
accounts for increased production of P4 (Bao et al., 1998). The highly significant 
increase in P4 concentrations in the follicular fluid after the LH surge incited 
diverse experimental approaches to establish the importance of this steroid for 
ovulation. Epostane is an inhibitor of 3(3-hydroxysteroid dehydrogenase (3(3- 
HSD) that prevents the formation of pregnenolone into P4 (Tanaka et al., 1991). 
Administration of epostane inhibited follicular steroidogenesis and ovulation in
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rats that could be reversed by exogenous P4 (Snyder et al., 1984). The P4 
antagonist mifepristone (RU486) inhibited the mid-cycle gonadotropin surge and 
delayed ovulation in humans. Inhibition of LH release and 3f3-HSD activity appear 
to be mediated by RU486. Aminoglutethimide (another anti-steroid agent) 
administration inhibited ovulation in some studies but had no effect in others. 
Overall, administration of exogenous P4 reversed the inhibitory effect of anti­
steroid agents. The detailed mechanism of P4 action in the ovulatory process 
remains to be determined. Participation of P4 in activation of collagenase and 
consequent proteolytic activity has been suggested as well as its role as an anti­
inflammatory agent in the follicular milieu.
Nitric Oxide and Ovulation
There is unanimous agreement among researchers involved in NO 
research that NO is essential for normal follicular maturation and ovulation to 
occur. Shukovski and Tsafriri (1994) first reported the in vivo effects of NO 
inhibition on ovulation rate of rabbits. Following that report, effects of NO on 
ovulation have been reported in mice (Powers et al., 1995; Klein et al., 1998; 
Jablonka and Olson, 1998; Drazen et al., 1999; Jablonka-Shariff et al., 1999b), 
rats (Shukovski and Tsafriri, 1994; Bonello et al., 1996; Jackrisson et al., 1996, 
Faletti etal., 1999; Nakamura etal., 1999) rabbits (Kugu etal., 1995; Hesla etal., 
1997; Yamauchi et al., 1997) and mares (Pinto et al, 2000).
Mice made genetically deficient (knockout) for nNOS (Klein et al., 1998), 
eNOS (Jablonka-Shariff and Olson, 1998) and iNOS (Jablonka-Shariff et al., 
1999b) clearly demonstrated that all three NOS isoforms play important ovulation 
mediator roles, at least in mice. The effects of NOS gene disruption observed in 
mice include abnormalities of estrous cyclicity, oocyte maturation, ovulation and 
oocyte tubal transport that, ultimately, lead to lower pregnancy and litter size 
rates. These same NOS-deficiency-induced reproductive abnormalities are 
mimicked by chronic inhibition of NO production (Dunnam et al., 1999) and by 
temporary administration of NOS inhibitors to cycling animals (Shukovski and 
Tsafriri, 1994; Powers etal., 1995; Hesla etal., 1997; Faletti etal., 1999).
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Evaluation of NOS inhibition on ovulation rates of ovaries perfused in vitro 
has also yielded results comparable to those derived from in vivo studies 
(Bonello etal., 1996; Hesla etal., 1997; Yamauchi etal., 1997). Furthermore, the 
in vivo administration of a NO donor significantly counteracted the NOS 
inhibition-induced inhibition of ovulation (Shukovski and Tsafriri, 1994) or 
mimicked hCG-like ovulation rates (Powers etal., 1995).
Although mainly eNOS and iNOS have been found to play a significant 
role on ovulation, scientists still debate which NOS isoform is more relevant to 
the ovulatory process. The participation of iNOS in ovulation has been 
substantiated by studies showing its immunolocalization and even up-regulation 
after a hormonal ovulatory stimulus (Dunnam et al., 1996; Faletti et al., 1999). 
Expression of iNOS activity during early follicular development has been found to 
influence follicle survival via inhibition of apoptotic mechanisms leading to atresia 
(Chun et al., 1995; Matsumi et al., 1998; Matsumi et al., 2000). Moreover, the 
administration of drugs showing a relative specificity for iNOS, such as AG, 
resulted in significant inhibition of ovulation. (Shukovski and Tsafriri, 1994; 
Yamauchi etal., 1997).
In an interesting study, the expression of eNOS and iNOS activity in 
gonadotropin-stimulated rats was measured following the conversion of labeled 
l-[14C] arginine into [14C]citrulline as described by Bredt and Snyder (1989). It 
was found that both NOS isoforms were up-regulated following ovarian 
stimulation with equine chorionic gonadotropin (eCG) and reached the highest 
activity 10 h after hCG (administered 48 h after eCG administration). However, 
iNOS was the only isoform that significantly increased after hCG administration 
denoting a specific and defined role of iNOS in ovulation in rats. Moreover, the 
temporal expression of iNOS activity as it was determined in that study coincides 
with the hCG-stimulated ontogeny of prostaglandins (Sirois etal., 1992).
Therefore, both eNOS and iNOS were up-regulated in response to eCG 
administration and only iNOS activity was further increased following hCG 
administration. These results are an example of a constitutive isoform being 
induced to perform a physiological function (follicle growth and ovulation).
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Conversely, evidence that favors eNOS as a primary NOS isoform for 
follicle development and ovulation comes from studies using eNOS- and iNOS- 
knockout mice (Jablonka-Shariff et al., 1999b). Ovulation rates and ovarian 
steroidogenesis were significantly decreased in mice genetically engineered to 
lack the genes encoding for eNOS and iNOS as compared with wild-type mice. 
Interestingly, mice lacking the gene for the nNOS isoform also displayed infertility 
and abnormal ovarian physiology (Klein etal., 1997).
Nitric Oxide and Ovarian Steroidogenesis
Recent studies suggest the existence of a nitric oxide-generating system 
in the ovaries of quail (Van Nassauw et al., 1999), small laboratory animals (Van 
Voorhis etal., 1995; Chatterjee etal., 1996; Zackrisson etal., 1996; Hesla etal.,
1997), cows (Basini etal., 1998), humans (Van Voorhis etal., 1994) and horses. 
Expression of eNOS and iNOS, but not nNOS was determined in the ovaries of 
rats (Van Voorhis et al., 1995) and that expression was up-regulated by the 
administration of gonadotropins. Other studies also demonstrated that the 
immunolocalization and the degree of expression of NOS isoforms varied 
according to the stage of the estrous cycle (Zackrisson et al., 1996; Jablonka- 
Shariff and Olson, 1997).
Van Voorhis et al. (1994) noted that when NOS inhibitors were added to a 
human granulosa cell culture, E2 production by the granulosa cells was 
significantly increased, whereas no change resulted in P4 production. The 
addition of a NO generator, S-Nitroso-L-acetyl penicillamine (S-NAP), caused a 
significant inhibition of both E2 and P4 production; however, the E2 production 
was inhibited more than P4 production. Similar findings of NO-induced inhibition 
of follicular steroidogenesis have been reported in rats (Dave et al., 1997; 
Dunnam et al., 1999), rabbits (Yamauchi et al., 1997) and cultured bovine 
granulosa cells (Basini etal., 1998).
It appears that the NO-mediated inhibitory effect on steroidogenesis 
follows a cyclic GMP-independent pathway (Snyder et al., 1996). The 
independence of the activation of guanylate cyclase was evident when the 
addition of cyclic GMP analogues did not reproduce the inhibition on
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steroidogenesis as NO did (Snyder et at, 1996). The steroidogenesis pathway is 
regulated by CYP450 enzymes that are responsible for rate-limiting steps of 
steroid production including aromatization of androgens to form estrogens (Peter 
and Dubuis, 2000). Long-term regulation of steroidogenesis is intimately related 
with the precise molecular regulation of CYP450 enzymes (Peter and Dubuis, 
2000).
The CYP450 enzymes are heme-containing molecules. Because one of 
the primary mechanisms of NO biological action is through the binding with heme 
groups, studies were carried out to determine the mechanism(s) of NO-induced 
inhibition of steroidogenesis. NO was found to inhibit CYP450 aromatase gene 
expression as evidenced by a 26% decrease in CYP450 aromatase mRNA in 
human granulosa cells as determined by northern analysis after 16 h of 
incubation with a NO donor (Van Voorhis et at, 1994; Snyder et at, 1996). 
However, the effect of adding a NO donor to cultured granulosa cells promoted a 
rapid onset of inhibition of E2 production by the granulosa cells that could not be 
solely accounted for by the decrease in mRNA expression. It was then 
hypothesized that NO was probably directly inhibiting the CYP450 aromatase 
catalytic activity.
Using microsomes derived from human placentae, it was verified that NO 
decreased as much as 80% of microsomal aromatase activity. A Lineweaver- 
Burke plot of the data showed that the NO inhibition of CYP450 aromatase was 
non-competitive. Although the mechanism of NO inhibition of CYP450 aromatase 
has not been clearly elucidated, it was speculated that NO-induced nitrosylation 
of aromatase cysteine groups could be part of this mechanism, independent of 
NO-binding with heme groups as it was originally hypothesized (Van Voorhis et 
at, 1994). Accordingly, binding of CYP450 aromatase heme groups with CO did 
not inhibit the enzyme activity. The hypothesis of NO-stimulated nitrosylation of a 
cysteine adjacent to the heme aromatase (Snyder et at, 1996) is reinforced by 
the fact that there are several cysteine groups in the CYP450 aromatase enzyme 
including one essential cysteine at amino acid 437 in human CYP450 aromatase. 
The importance of this cysteine for CYP450 aromatase function has been
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confirmed by in vitro mutational analysis (Ito et al., 1993). Apparently this 
cysteine is required for normal fertility as one report describes the complete 
absence of CYP450 aromatase activity in an infertile human patient bearing a 
missense mutation in amino acid position 437 (Conte etal., 1994).
Studies using rat granulosa cells found that the NO donors SNAP and 
SNP significantly decreased P4 production, whereas exposure of cultured 
granulosa cells to the NOS inhibitor L-NAME, but not AG, reversed the SNAP- 
induced inhibition of P4 production (Ahsan et al., 1997; Dave et al., 1997). 
Inhibition of P4 was determined in cultured ovarian dispersates treated with SNP, 
but no significant effects were found after treatment of granulosa cells with AG 
(Ahsan et al., 1997). However, a direct comparison between NO donor effects 
and NOS inhibitor effects on P4 in this study (Ahsan et al., 1997) is difficult 
because different cell preparations were used for SNP-treated wells (ovarian 
dispersates) and AG-treated wells (granulosa cells). Neither SNAP nor L-NAME 
affected granulosa cell viability as determined by the Trypan Blue dye exclusion. 
In agreement with Van Voorhis et al. (1994) were the results of a study using 
porcine granulosa cells for 24 h, which showed that the NO-stimulated inhibition 
of granulosa cell steroidogenesis was independent of guanylate cyclase 
activation (Masuda et al., 1997). Hanke et al. (1998) arrived at the same 
conclusion after showing that NO inhibited aldosterone synthesis by inhibiting the 
CYP450 side chain cleavage, through a guanylate cyclase-independent effect.
Using a different approach from Van Voorhis et al. (1994) and Snyder et 
al. (1996), Japanese researchers showed that neither NO catabolites nor a 
peroxynitrite-releasing compound (3-morpholynosydnonimine-hydrochloride; 
SIN-1) inhibited the CYP450 aromatase activity of human granulosa cells. It was 
concluded that the inhibitory action of NO donors on CYP450 aromatase activity 
must be related to the release of NO itself and independent of activation of 
guanylate cyclase (Kagabu et al., 1999). In contrast, Ishimaru et al. (2001) 
suggested that NO-stimulated inhibition of steroidogenesis in immature rat 
granulosa cells was involved the cyclic GMP pathway. These authors had 
previously reported that cyclic GMP inhibited the FHS-stimulated production of E2
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by rat granulosa cells (LaPolt and Hong, 1995) and investigated, in a subsequent 
experiment, the role of NO on this phenomenon. Accordingly, increased levels of 
cyclic GMP accompanied NO-mediated inhibition of E2 production by rat 
granulosa cells. Moreover, treatment of rat granulosa cells with a cyclic GMP 
analogue resembled the NO-induced inhibition on E2 production, in addition, they 
showed that NO inhibited accumulation of FSH-induced cyclic AMP, denoting 
that NO can act distally to the FSH receptor. It was concluded that, as opposed 
to previous reports (Van Voorhis et al., 1994; Snyder et a i, 1996; Masuda et al., 
1997; Kagabu et al., 1999), that mechanisms of NO-induced inhibition of 
granulosa cell steroidogenesis may involve cyclic GMP antagonism on cyclic 
AMP-stimulated steroidogenesis (LaPolt and Hong, 1995; Ishimaru etal., 2001).
Inhibitory effects of gossypol appear to be mediated by up-regulation of 
the NO-generating system in porcine granulosa cells (Vranova et al., 1999). 
Because reduction in bovine fertility has been associated with deficiency in 
selenium (Allison and Laven, 2000), culturing bovine granulosa cells with 
selenium were shown to increase the FSH-stimuiated E2 production while 
decreasing the production of NO (Basini and Tamanini, 2000). The same group 
had previously reported that NO donors inhibited steroidogenesis in bovine 
granulosa cells from both small (< 5mm) and large ovarian follicles (> 8 mm) that 
were cultured for up to 72 h (Basini et al., 1998).
The role of cytokines in granulosa cell steroidogenesis is yet to be clearly 
elucidated as studies that have exposed granulosa cells to interleukin-1 (3 (IL-1f3), 
interleukin-6 , granulocyte-macrophage colony-stimulating factor or tumor 
necrosis-a have reported inhibitory (Andreani et al., 1991), stimulatory 
(Brannstrbm et al., 1993; Tobai and Nishiya, 2001) or no effects at all (Shakil and 
Whitehead, 1994). The NO modulation of granulosa cell steroidogenesis may 
also involve the activation of iNOS, as interieukin-lp stimulated NO production in 
rat cultured granulosa-thecal cells (Ellman et al., 1993; Ben-Shlomo et al., 1994) 
and PGE in human granulosa cells (Hurwitz et al., 1995). In another study, 
effects of IL-1P on NO and prostaglandin synthesis were seen only in ovarian 
dispersate cells, but not in cultured rat granulosa cells (Ahsan et al., 1997). IL-1(3
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treatment decreased the production of P4 by ovarian dispersates in response to 
forskolin stimulation. This is in contrast with other studies that showed that IL-1p 
facilitated ovulation by increasing P4 in rat ovaries perfused in vitro (BrannstrOm 
etal., 1993; Bonelloefa/., 1996).
Nitric Oxide in Ovarian Follicular Fluid
Only recently the presence of NO in ovarian follicular fluid has begun to be 
investigated and the scarce literature on this matter shows discrepant 
observations. The discrepant observations are most likely a result of different 
methodologies employed and, more importantly, a consequence of inherent 
constraints associated with the human in vitro fertilization (IVF) model. Human 
intrafollicular NO concentrations, as evidenced by N02* and NO3' analyses, have 
been detected in follicular fluid of women undergoing in vitro fertilization (IVF) 
procedures (Arnteby et al., 1996; Sugino et al., 1996;Tao et al., 1997; Manau et 
al., 1999; Barroso et al., 1999; Manau et al., 2000; Lee et al., 2000; Reis et al., 
2000; Barrionuevo et al., 2000). A negative correlation between human IVF 
outcome and concentrations of NO metabolites in donor follicles has been 
reported (Barroso etal., 1999; Barrionuevo etal., 2000). Furthermore, one study 
found no correlation between intrafollicular NO concentrations and ovarian 
response markers such as oocyte maturation, oocyte quality and pregnancy 
outcome (Lee et al., 2000; Manau et al., 2000). While two studies failed to show 
a significant correlation between NO and follicle size (Sugino et al., 1996; Tao et 
al., 1997), another study reported a significant correlation between NO and 
follicle size and between NO and E2 concentrations (Anteby et al., 1996).
To date, only one study reported the concentrations of NO metabolites in 
animals, using bovine ovaries obtained from a slaughterhouse (Basini et al.,
1998). Intrafollicular NO concentrations from small follicles were significantly 
higher than those determined in larger follicles. Granulosa cells obtained from 
these follicles were cultured for up to 144 h and exposed to a NO donor (SNAP), 
which decreased the production of both E2 and P4 (Basini et al., 1998).
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Nitric Oxide and Physiology of Vagina. Cervix and Uterus
NOS isoforms have been identified in the vagina, cervix and uterus of 
mice (Grozdanovic etal., 1994; Boquet etal., 1998), rats (Chatterjee etal., 1996; 
Dong et al., 1998; Al-Hijji et al., 2001), rabbits (Batra and Al-Hijji, 1998; Al-Hijji et 
al., 2000), sows (Majewski et al., 1995; Wu et al., 1998), cows (Majewski et al., 
1995; Rosselli et al., 1996) and humans (Hoyle et al., 1996). The temporal 
pattern of expression of these NOS isoforms probably reflect hormonal and 
tissue-remodeling events characteristic of the estrous cycle and also changes 
associated with the pregnancy status (Buhimschi et al., 1995). Although the 
presence of NOS isoforms in the genital tract is unquestionable, as is their 
impact on uterine function in non-pregnant and pregnant animals, a clear and 
complete biological characterization of these functions is yet to be fully 
elucidated. For example, this particulate form of eNOS had greater activity than 
the cytosolic isoform in the uterus of nonpregnant sheep (Figueroa and 
Massman, 1995) and pregnant rabbit (Sladek et al., 1993). However, in 
nonpregnant sheep NOS activity was highly sensitive to Ca2+ modulation, 
whereas in the pregnant rabbit NOS activity was significantly insensitive to Ca2+ 
oscillations. In another study using nonpregnant rabbits (Batra and Al-Hijji, 1998), 
the cytosolic form of iNOS was more predominant than the particulate one, and 
both were highly Ca2+ dependent. Cyclic changes associated with tissue 
remodeling of the genital tract are intimately dependent on control by ovarian 
steroids (Al-Hijji et al., 2001). Accordingly, E2 (Zancan et al., 1999) and P4 (Al- 
Hijji et al., 2000; Rupnow et al., 2001) have been found to modulate NOS activity 
in the genital tract in nonpregnant and pregnant females. Expression of nNOS 
and eNOS are differentially regulated by E2 in the sheep uterus (Zhang et al.,
1999). Expression of nNOS by E2 may regulate myometrial activity and glucose 
metabolism in the uterus, whereas the E2-mediated regulation of eNOS 
expression may be related with the control of uterine blood flow.
The role of NOS isoform activities in the vagina seems to be to control the 
blood supply and relaxation of smooth muscle, which denote important functions 
for sexual excitement, copulation and functioning as a birth canal (Berman et al.,
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1998). Al-Hijji et al. (2000) reported NOS activity in the rabbit vagina that was 
nearly 4-fold higher than in the uterus, pointing to a tissue-specific NOS 
regulation under the influence of the same hormonal milieu. Expression of iNOS 
just before and after labor has been implicated in the human cervical ripening 
process (Bansal etal., 1997; Tschugguel etal., 1999).
In the nonpregnant uterus NOS activity may be associated with local 
events that are primarily under the control of steroids. The vagina, cervix and 
uterus undergo notable physiologic changes during estrus that are preparatory 
for copulation, gamete and early conceptus transport, and establishment of 
pregnancy. These changes depend on proper control of blood flow, endometrial 
glandular secretion and myometrial activity.
In summary, P4, while maintaining uterine quiescence in cooperation with 
uterine catalytic expression of NOS isoforms, acts to decrease the expression of 
NOS isoforms in cervical tissues. Upon the initiation of events leading to labor, 
uterine NOS activity decreases whereas cervical NOS isoforms up-regulate, 
facilitating cervical softening (ripening) and dilation (Buhimschi et al., 1997). It 
seems that eNOS is mainly decreased in the uterus, whereas, iNOS and nNOS 
are up-regulated in the cervix as parturition approaches (Yallampalli et al., 1993). 
These hypotheses are supported by results of studies using an antiprogesterone 
agent (onapristone) that mimicked the changes in eNOS and iNOS expressions 
in uteri and cervices of rats during labor (Ali et al., 1997).
Nitric Oxide and Luteal Function
Luteinization is a process that starts before ovulation is completed in 
response to the LH surge. In the horse, the initiation of luteinization is evidenced 
by an increase in follicular concentrations of P4 and decreased E2 production by 
the granulosa cell. Histologically, there is an increase in pyknotic cells in theca 
intema, whereas, granulosa cell double in thickness after hCG stimulus. These 
histological changes are accompanied by severe edema, hyperemia and 
hemorrhages of theca intema and theca externa. After ovulation, angiogenesis is 
accelerated and neovascularization invade the former avascular granulosa- 
derived luteal cells. The corpus luteum becomes a potent endocrine gland, being
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highly vascularized and with a growth rate only comparable to fast-growing 
tumors.
Van Voorhis et al (1994) reported the presence of NOS isoforms in human 
granulosa cells from women undergoing infertility treatments. It was noted that 
the addition of NOS inhibitors to the cell culture system resulted in a higher 
steroid production by granulosa cells, whereas addition of NO donor agents 
significantly suppressed steroid production. It was then concluded that NO ahs a 
strong anti-steroidogenic activity. Later, Olson et al., (1996) reported the 
presence of eNOS and, to a lesser extent, iNOS in rat luteal cells. Inhibition of 
NOS activity as evidenced by lower nitrite concentrations in the culture medium 
was achieved by treatment with AG or L-NAME. Addition of SNP to cultured 
luteal cells inhibited both E2 and P4 productions by rat luteal cells (Olson et al.,
1996).
Similar results have also been reported for human ovaries confirming the 
presence of NOS isoforms in luteal cells (Vega et al., 1998) and a role for NO in 
luteal regression has been suggested (Friden et al., 2000). In rabbits, 
prostaglandin F2q (PGF2a) up-regulated the expression of NOS isoforms that was 
followed by a marked decreased in P4 production (Gobbetti et al., 1999). These 
authors subsequently reported that NO modulation in luteal cells was mediated 
by PKC/PKA signal transduction pathways (Boiti et al., 2000). Intra-luteal 
administration of L-NAME resulted in extended lifespan of the corpus luteum that 
prolonged diestrus in Holstein heifers, suggesting a role for NO on luteal 
regression in cows (Jaroszewski and Hansel, 2000).
Nitric oxide and embryonic development
The role of NO on embryonic development is not clear. Administration of a 
NO donor agent to a bovine embryo culture system inhibited embryonic 
development (Lim and Hansel, 1998) but a similar result was noted when NO 
production was inhibited in a mouse embryo culture system (Gouge et al., 1998). 
The addition of hemoglobin, a NO scavenger, significantly promoted bovine 
embryonic development (Lim et al., 1999). In a more elaborated study 
investigating the role of NO in mouse oocyte maturation and embryonic
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development, it was found that low doses of SNP promoted oocyte maturation, 
increased the percentage of embryos reaching blastocyst stage and enhanced 
trophoblast outgrowth (Sengoku et al., 2001). The latter result denotes a role for 
NO in the implantation process as it has been previously suggested for rats 
(Biswas etal., 1998).
HYPOTHESES
I decided to investigate the role of NO in equine and bovine follicular 
dynamics and steroidogenesis seeking to answer questions that had not been 
addressed before: 1) does the systemic inhibition of NO cause permanent 
inhibition of ovulation, leading to follicular atresia, or only delay ovulation, once 
NO inhibition subsides?; 2) How does the anti-steroidogenic activity of NO relate 
to its participation in the ovulatory process?; 3) is NO involved in the process of 
hCG-induced preovulatory follicular luteinization in vivo?; 4) is NO involved in the 
process of in vitro functional luteinization?; and 5) what are the pharmacokinetics 
and hemodynamics of L-NAME, a potent nonspecific NOS inhibitor, in horses?
The hypotheses for the present study were:
1) The systemic administration of NOS inhibitors will block hCG- 
induced ovulation in mares and cows.
2) The systemic administration of hCG to mares in estrus will up- 
regulate the NO pathway in the equine preovulatory follicle.
3) Cultured equine and bovine granulosa cells treated with NOS 
inhibitors will have lower P^E2 ratios (an indicator of functional 
luteinization.
4) The systemic administration of bolus injection of L-NAME will cause 
transient systemic and pulmonary hypertension due to its short half 
life.
The primary goals of this study were to use large animals such as mares 
and cows, which can be routinely examined by transrectal ovarian 
ultrasonography, to determine how parameters of follicular dynamics such as 
follicular growth and ovulation would be affected by administration of NOS 
inhibitors. Analyses of follicular concentrations of P4, E2 and NO, before hCG and
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36 h after hCG administration will provide information on whether the NO 
pathway is up-regulatory following an ovulatory stimulus or not. Furthermore, 
analyses of P4:E2 ratios of granulosa cells treated with NOS inhibitors and a NO 
donor agent will show how NO relates to the phenomenon of in vitro luteinization. 
Finally, I sought to characterize the pharmacokinetic and cardiovascular 
parameters associated with an intravenous bolus administration of L-NAME.
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CHAPTER 2
EFFECTS OF NITRIC OXIDE SYNTHASE INHIBITORS ON 
OVULATION IN hCG-STIMULATED MARES
INTRODUCTION
During the past three decades researchers have investigated the 
regulation of follicular dynamics and ovulation (Espey and Lipner, 1994; Tsafriri 
and Reich, 1999). In addition to hypophyseal and ovarian steroid hormones, it is 
now known that growth factors (Koos, 1995), proteolytic enzymes (BrSnnstrdm et 
al., 1988; Tsafriri et al., 1989) and cytokines (BrSnnstrOm et al., 1994; Ujioka et 
al., 1998) play a significant role in overall ovarian function. It has been 
hypothesized that imbalances in any of these factors may lead to ovarian 
dysfunction. Nitric oxide (NO) has emerged as one of the most recently 
discovered modulators of ovarian function (Van Voorhis et al., 1994; Rosselli 
et al., 1998). Nitric oxide is a small molecule that is the product of the enzymatic 
conversion of L-arginine to citruliine. The reaction is catalyzed by the enzyme 
nitric oxide synthase (NOS). To date, three different genes have been cloned 
encoding for different NOS isoforms. Two isoforms, neuronal NOS (nNOS) and 
endothelial NOS (eNOS), are mainly constitutively expressed, whereas the 
expression of a third isoform (iNOS) is induced by cytokines and 
lipopolysaccharides (Moncada et al., 1991). The action of NO is autocrine and 
paracrine in nature as a result of its high diffusion rate in cell membranes, high 
solubility and ultra short half life (Moncada et al., 1991; Rosselli et al., 1998).
Nitric oxide isoforms have been found in ovarian cells of rats (Van Voorhis 
et al., 1995; Zackrisson et al., 1996; Jablonka-Shariff and Olson, 1997), rabbits 
(Hesla et al., 1997), horses (Pinto et al., unpublished) and humans (Van Voorhis 
et al., 1994). The expression of ovarian NOS seems to be under gonadotropin 
regulation (Van Voorhis et al., 1995; Chatteqee et al., 1996; Zackrisson et al., 
1996; Srivastava etal., 1997 Jablonka-Shariff and Olson, 1997; Nakamura etal., 
1999). In addition, iNOS and eNOS expression appear to modulate follicular 
steroidogenesis and the ovulation process, as suggested by studies investigating
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specific and non-specific inhibition of these isoforms (Bonello et al., 1996; 
Shukovski and Tsafriri, 1994; Ahsan etal., 1997,).
The addition of iNOS and eNOS inhibitors into human granulosa cell 
cultures increased E2 secretion by granulosa cells and had little or no effect on P4 
secretion (Van Voorhis et al., 1994). When NO generator agents were added into 
the granulosa cell culture, E2 and P4 secretion by granulosa cells decreased 
considerably (Van Voorhis et al., 1994). Similar findings were reported by Basini 
et al. (1998) working with bovine granulosa cells exposed to a NO generator.
In other studies, inhibition of iNOS and eNOS performed in vivo (Hesla et 
al., 1997) or using ex vivo ovarian perfusion (Yamauchi et al., 1997) invariably 
resulted in a significant reduction in the ovulation rate in rabbits treated with 
human chorionic gonadotropin (hCG). When NO generators were used 
concomitantly with NOS inhibitors, ovulation rates were similar to that of controls 
(Shukovski and Tsafriri, 1994). In some studies, administration of NO generators 
alone to rabbits and rats caused ovulation to occur at a time similar to animals 
treated with hCG (Yamauchi ef al., 1997; Mitsube etal., 1999).
Ovulation and pregnancy rates in mice genetically engineered by a 
knockout procedure to be deficient in iNOS or eNOS were lower than those of 
wild-type animals (Jablonka-Shariff and Olson, 1998). In that study, impairment 
of ovulation was also accompanied by a higher than normal incidence of oocyte 
meiotic abnormalities. In a subsequent study, iNOS and eNOS knockout mice 
displayed irregular estrous cycles, disruption of normal E2 and P4 plasma profiles, 
a reduced number of developing follicles in the ovaries and lower ovulation rates 
(Jablonka-Shariff et al., 1999b). Abnormalities of the estrous cycles were more 
evident in eNOS-knockout than in iNOS-knockout mice.
In studies performed in laboratory animals, subjects are euthanatized to 
examine the reproductive tract at specific times after hCG administration. 
Because ovaries are only examined postmortem, the specific fate of individual 
follicles is not known. Unfortunately, when this investigative approach is used 
and an animal is categorized as having lower ovulation rates, it is uncertain 
whether the ability of the remaining follicles to ovulate would be blocked
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permanently (leading to anovulation followed by atresia) or temporarily blocked 
resulting in delayed ovulation. Thus, the results of those studies do not provide 
information on the fate of unruptured follicles if the ovarian reproductive cycles 
were allowed to proceed.
To answer these questions, horse and pony mares, a species with a 
prolonged estrus (5 to 7 days) and a long ovulatory phase (36 to 48 h after hCG 
induction), were used to evaluate what effects administration of NOS inhibitors 
might have on follicular dynamics and on ovulation pattern. The two possible 
fates of ovarian follicles, ovulation or anovulation (followed by either regression 
or luteinization of the unruptured follicle), are routinely evaluated in mares using 
palpation per rectum and transrectal ultrasonography. In the present study, 
aminoguanidine (AG), a relatively specific iNOS inhibitor, and NG-nitro-L-arginine 
methyl ester (L-NAME), a nonspecific NOS inhibitor, were administered to mares 
in estrus and the effects of NOS inhibitor administration on follicular growth rate 
and ovulation pattern were documented. The hypothesis was that administration 
of NOS inhibitors would delay hCG-induced ovulation in estrous mares.
MATERIALS AND METHODS 
Experimental Animals and Agents
Mares used in this study were treated according to a protocol approved by 
the Institutional Animal Care and Use Committee of the School of Veterinary 
Medicine, Louisiana State University, in accordance with NIH guidelines for the 
care and use of animals for research. Forty cycling mares in good body condition 
(2 0  horse and 2 0  pony mares) of varying ages were allotted by breed type across 
the treatment groups.
Aminoguanidine hemisulfate (AG) and NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME) were purchased from Sigma Chemical Company 
(St. Louis, MO).
Experimental Design and Procedures
Palpation per rectum and ovarian ultrasonography were performed twice 
daily to assess follicular development from the beginning of estrus until ovulation 
was detected. When an ovarian follicle was at least 27 mm in diameter, but less
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than 35 mm, mares were subjected to one of the following treatments twice daily 
as follows: saline solution 0.9% (n = 20, w/v, iv, q 12 h), L-NAME (n = 10, 148 
pmol/kg, iv, q 12 h or AG (n = 10,406 pmol/kg, iv, q 12 h). The L-NAME and AG 
solutions were prepared using saline solution, 10% (w/v) and 30% (w/v) 
concentrations, respectively. The AG treatment was started 24 h before the hCG 
administration, whereas, L-NAME treatment was begun only 12 h before the hCG 
administration. This schedule was based on the fact that inhibition of iNOS by AG 
in horses likely starts 12 h after administration (Hunter et al, 1999), whereas, 
L-NAME inhibitory action was evident during the first hour after iv administration 
(Kubes and Granger, 1992). In the control group, 10 mares received a matched 
volume of saline solution (Control I) for the AG group (starting 24 h before hCG 
administration) and 10 mares received a matched volume (control II) for the 
L-NAME group (starting 12 h before hCG administration). Because horses 
typically have a long period from hCG administration to ovulation, all treatments 
(saline solution, L-NAME and AG) continued until 24 h after hCG administration, 
so that L-NAME and AG-treated animals received a total of 4 and 5 
administrations, respectively, as did their matched controls.
After treatment was initiated and when a follicle > 30 mm in diameter was 
present on one of the ovaries, mares were administered hCG (2,500 iu, iv) to 
induce ovulation. Mares continued to be examined twice daily to document 
follicular development and time of ovulation. The degree of endometrial edema 
observed ultrasonographically during estrus was classified (score of 1 = minimal, 
2 = moderate, 3 = strong, 4 = very strong) and a recorded mean score was 
calculated for each mare during the time treatments were administered (until 24 h 
post-hCG) and analyzed for detection of effects of treatment on endometrial 
edema.
Blood samples were taken daily by jugular venipuncture from the 
beginning of the treatment until 2  days after ovulation and once a week thereafter 
to document the pattern of P4 secretion. Plasma samples were stored at -70 °C 
until assayed for P4 as previously described (Thompson etal., 1983).
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Some mares (Control group, n = 6 ; L-NAME treated group, n = 3; AG 
treated group, n = 4) participating in this study were part of a breeding program 
and the resulting pregnancy rates were recorded using transrectal uterine 
ultrasonography performed at d 14 and d 25 post-ovulation. Breeding 
management consisted of mating mares in estrus to a proven stallion every other 
day until ovulation was detected.
Statistical Analyses
Experimental data are expressed as mean ± SEM. Time of ovulation after 
hCG administration was analyzed among treatment groups by the Kruskai-Wallis 
ANOVA on ranks test (Shott, 1990). Pair-wise comparisons were made using the 
Mann-Whitney rank sum test after being adjusted by the Bonferroni method 
(Shott, 1990). The follicle growth rate from 12 h before hCG administration until 
ovulation detection was analyzed using one-way ANOVA. When appropriate, 
post-hoc comparisons were made using Tukey’s test (Shott, 1990). 
Concentrations of plasma P4 were analyzed by ANOVA. A P value < 0.05 was 
considered significant for all tests.
RESULTS
Side effects associated with L-NAME administration were not noted in any 
of the treated mares. However, six lactating pony mares receiving AG became 
anorectic and sick during or shortly after the end of AG treatment. These sick 
mares were treated with fluids but three died within 5 d after being identified as 
sick. The remaining three pony mares recovered uneventfully. Necropsy of these 
animals confirmed the provisional diagnosis of hepatic lipidosis.
The relationship between systemic administration of AG and incidence of 
hepatic lipidosis is yet to be clarified. In mice, oral administration of AG caused 
the formation of a Schiff base of AG with pyridoxal phosphate resulting in lower 
concentrations of free pyridoxal phosphate in the liver than of control mice 
(Taguchi etal., 1998). Pyridoxal phosphate, the coenzyme form of vitamin B6 , is 
essential for many biochemical reactions in the body. The potential depletion of 
hepatic pyridoxal phosphate in pony mares treated with AG resulting in impaired
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liver function remains to be further investigated. These six animals were not 
included in the present study.
All mares ovulated in this experiment. Anovulation followed by luteinization 
or atresia of preovulatory follicles was not detected in any of the mares used in 
this study. The L-NAME- and AG-treated groups each had one mare that had 
double ovulation during estrus. The time to ovulation after hCG administration in 
the treatment groups were as follows: saline solution, 41.4 ± 2.5 h; L-NAME, 87.6 
± 9.5 h; AG, 61.2 ± 6.9 h;. There was no significant difference between the 
groups treated with AG or L-NAME (P = 0.06), however, these groups were 
different from the control group (P < 0.05; Figure 2.1).
The follicle size documented at the last ovarian ultrasonographic 
examination before ovulation did not differ among treatment groups (saline 
solution, 41.4 ±1 .0  mm; L-NAME, 38.7 ± 2.7 mm; AG, 35.5 ± 1.9 mm; P > 0.10, 
Figure 2.2). Similarly, the net follicular growth (change in size) from 12 h before 
hCG administration until the last examination before ovulation was not 
significantly different among the treatment groups (saline solution, 9.4 ± 0.9 mm; 
L-NAME, 11.9 ± 2.7 mm; AG, 7.3 ± 1.5 mm; P > 0.10, Figure 2.3), however, the 
pattern of follicle growth was different (saline solution, Figure 2.4; L-NAME, 
Figure 2.5; AG, Figure 2.6). The follicular growth rate (defined as the net follicular 
growth divided by the number of days counted from 1 2  h before the 
administration of hCG until the detection of ovulation) was 3.9 ± 0.4 mm/day, 2.3 
± 0.4 mm/day and 2.0 ± 0.3 mm/day for saline solution treated group, L-NAME 
treated group and AG treated group, respectively. The L-NAME- and AG-treated 
mares had significantly lower follicular growth rates than did control mares 
(P < 0.05; Figure 2.7). Mares treated with L-NAME or AG remained in estrus 
longer than mares treated with a control saline solution (P < 0.05; Figure 2.8)
Four mares in the L-NAME group had follicles that did not show any 
change in diameter for 5 days and then resumed rapid follicular growth (12 to 23 
mm increase in follicle diameter) approximately 36 h before ovulation. In the AG 
treated group three mares displayed protracted follicle evacuation that took 24 to 
36 h to complete. The prolonged evacuations of the follicular fluid from these
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slowly ovulating follicles were assessed by successive measurements of the 
follicle diameters performed at 12-h intervals. Nevertheless, all 42 ovulations in 
the present study resulted in apparently normal appearing corpora lutea, as 
assessed by characteristic luteal echogenicity upon ultrasonography 
examination. No differences were detected in the plasma concentrations of P4 of 
treated and control mares during estrus (P > 0.10), similarly, no differences were 
detected in plasma P4 concentrations during diestrus (P > 0 .1 0 ).
Mean uterine edema score were different in the L-NAME treatment group 
(1.3 ± 0.2) when compared with control mares (2.0 ± 0.1; P < 0.05), but no 
difference was detected when compared with the mean score from AG-treated 
mares (1.9 ± 0.2; P > 0.05).
Pregnancy rates were 100% (6 /6 ), 33.3% (1/3) and 75% (3/4) for control, 
L-NAME and AG treatment groups, respectively. The objective was to report that 
mares treated with L-NAME or AG could get pregnant, but conclusions on how 
NOS inhibitors affect normal fertility could not be drawn from this study. Thus, 
statistical analysis for pregnancy rates was not performed.
DISCUSSION
The main objective of this study was to investigate the effects of NOS 
inhibition on the follicular dynamics of mares in estrus. These results clearly 
demonstrate that L-NAME and AG significantly delayed ovulation in hCG- 
stimulated mares. Moreover, this is the first report to document the follicular 
dynamics associated with NOS inhibitors administered continuously throughout 
estrus in live animals. Previous studies in mice (Jablonka-Shariff et al., 1999), 
rats (Bonello et al., 1996; Jablonka-Shariff et al., 1999) and rabbits (Hesla etal., 
1997, Yamauchi et al., 1997) have shown that inhibition NOS inhibited ovulation. 
In these studies, ovulation rates and the quality of ovulated oocytes of animals 
treated with NOS inhibitors were significantly decreased.
The previous studies were conducted in small laboratory animals and 
repetitive ovarian examination could not be performed. Experimental subjects 
had to be euthanatized according to a time schedule to determine the effects of
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Figure 2.1 Time to ovulation (mean ± SEM) after hCG administration to mares in 
estrus. Note that mares treated with NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME; n = 1 0 ) or aminoguanidine hemisulfate (AG; n = 10) had 
a mean time to ovulation greater than 48 h, whereas control mares (n = 20) had a 
mean time to ovulation within 48 h post-hCG administration. Bars with different 
letters are significantly different; P < 0.05.
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Figure 2.2 Follicle diameter (mean 1  SEM) recorded during the last transrecta! 
ovarian ultrasonography exam before ovulation was detected, did not differ 
among mares treated with saline solution (Control; n -  20), NG-nitro-L-arginine 
methyl ester hydrochloride (L-NAME; n = 10) or aminoguanidine hemisulfate 
(AG; n = 10). (P > 0.10).
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Figure 2.3 Net follicular growth (mean ± SEM) of preovulatory follicles from 
mares in estrus treated with saline solution (Control; n = 20), NG-nitro-L-arginine 
methyl ester hydrochloride (L-NAME; n = 10) or aminoguanidine hemisulfate 
(AG; n = 10). (P > 0.10).
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Figure 2.4 Representative pattern of follicular growth during estrus in mares 
treated with saline solution (Control). Follicles of control mares generally 
increased in diameter throughout the estrus period.
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Figure 2.5 Representative pattern of follicular growth during estrus in mares 
treated with NG-nitro-L-arginine methyl ester hydrochloride (L-NAME). Note that 
there is a marked inhibition of follicular growth that reinitiates abruptly 24 h before 
ovulation.
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Figure 2.6 Representative pattern of follicular growth during estrus in mares 
treated with aminoguanidine (AG). Note the apparent slowing of follicular growth 
rate as the mare progresses toward ovulation.
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Figure 2.7 Follicular growth rate (mean ± SEM) was expressed as the net 
follicular growth from beginning of treatment until the last transrectal ovarian 
ultrasonography examination before detection of ovulation divided by the number 
of days of that period. Mares treated with NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME; n =10) or aminoguanidine hemisulfate (AG; n = 10) had 
a lower follicular growth rate than control mares (n = 20). Bars with different 
letters are significantly different; P < 0.05.
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Figure 2.8 Total number of days (mean ± SEM) in estrus of mares treated with 
saline solution (Control; n = 20), NG-nitro-L-arginine methyl ester hydrochloride 
(L-NAME; n = 10) or aminoguanidine hemisulfate (AG; n = 10). Note that mares 
receiving L-NAME or AG remained in estrus longer. Bars with different letters are 
significantly different; P < 0.05.
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NOS inhibition on follicular dynamics. Furthermore, in these previous studies, 
assessment of the number of follicles ovulated was performed when normal 
ovulation was expected to occur in relation to hCG administration. Thus, the fate 
of unruptured follicles found on the ovaries after euthanasia could not be 
determined. However, in one study, examination of diestrus ovaries from eNOS 
“knockout" mice revealed luteinized follicles and follicles undergoing atresia 
(Jablonka-Shariff et al., 1999b). In contrast, in the present study horse and pony 
mares receiving AG or L-NAME during estrus had their ovulation only temporarily 
blocked as assessed by transrectal ovarian ultrasonography. In fact, regression 
and atresia of the preovulatory follicle was not found in any of the treated mares. 
The fact that some mares did not ovulate until 5 d after hCG administration 
suggested that inhibition of NO production, while inhibiting follicular growth and 
ovulation, maintained the potential for follicle development and subsequent 
ovulation. It is noteworthy that all mares participating in the present study 
ovulated.
The phenomenon of delayed ovulation noted in the present study probably 
resulted from local effects of NOS inhibition in the ovary, because all mares 
received hCG to induce ovulation, bypassing the potential central effect of NOS 
inhibition on luteinizing hormone (LH) release (Traystman et al., 1995; McCann 
and Rettori, 1996b). In the rabbit ovary, NO has been implicated in mediating 
vascular changes, prostaglandin production and inhibition of steroidogenesis 
(Yamauchi et al., 1997). Ovarian vascular changes include vasodilatation of 
intraovarian arterioles and altered microvascular permeability leading to edema 
formation (Hughes et al., 1990; Powers et al., 1995; Anteby et al, 1996; Kerban 
et al., 1999). In addition, NO is involved in the blood-follicle barrier, which is 
disrupted after hCG stimulation or administration of NO generators (Powers et 
al., 1995; Powers et al., 1996). The equine preovulatory follicle undergoes a 
marked hyperemia after hCG administration (Kerban et al., 1999), such that it is 
possible to pinpoint the oocyte location in a dissected follicle without 
magnification. This is probably due to the presence of enhanced vascularization 
in the theca intema over the area that corresponds to the site of the cumulus, an
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observation already made by Thomson (1919) when working with preovulatory 
human follicles. Nitric oxide may have a direct effect on these vascular changes 
in addition to the suggested role of prostaglandins on follicular vasculature 
(Espey, 1980).
The induction of the inducible isoform of cyciooxygenase (COX-2) in 
response to an hCG ovulatory stimulus has been shown in rats (Sirois et al., 
1992), cows (Sirois, 1994; Liu eta l., 1997) and horses (Sirois and Dor6 , 1997). 
Enhanced prostaglandin production was detected in preovulatory follicles of 
rabbits and the authors of that study proposed that this was, at least in part, 
stimulated by NO (Yamauchi et al., 1997). It has also been suggested that NO 
mediates hCG-induced prostaglandin E2 production in rat oocyte-cumulus 
complexes (Jawerbaum et al., 1997). The interrelationship between iNOS and 
COX-2 has been investigated in other tissues (Salvemini etal., 1993; Posadas et 
al., 2000). It seems that both inducible pathways (COX-2 and iNOS) play mutual 
modulatory roles in an inflammatory response (Posadas et al., 2000). It is 
possible that this interrelationship also occurs in the rat ovary, especially after 
hCG administration (Faletti etal., 1999).
These NO mechanisms of action suggest that NO may act to signal or 
modulate the inflammatory-like events associated with follicle maturation and 
ovulation. The biochemical and cellular events leading to ovulation have been 
compared to an inflammatory process (Espey, 1980), with this model being 
further substantiated in recent years (Cavender and Murdoch, 1988; Espey, 
1992; Espey, 1994). The equine preovulatory follicle displays a series of cellular 
and vascular changes after hCG stimulation that include extensive remodeling of 
the granulosa cell layer, degeneration of the theca cell layer, eosinophilia, 
follicle wall hyperemia, vasodilatation of follicle wall vessels, edema and 
hemorrhage (Kerban et al., 1999). However, the extent to which NO affects 
these periovulatory events is yet to be determined. It has been suggested 
that several events related to the phenomenon of inflammation appear to be 
mediated or modulated by NO, such as an increased ovarian blood flow after 
gonadotropin stimulation (Anteby etal., 1996; Powers etal., 1995), modulation of
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microvascular permeability (Kubes and Granger, 1992), edema formation (lalenti 
et al., 1992) and prostaglandin production (Yamauchi et al., 1997; Faletti et al., 
1999). Thus, NO may be an important folliclular mediator of molecular 
mechanisms preceding ovulation.
In the present study, ovulation was significantly delayed in mares 
receiving AG, thus suggesting a role for iNOS-derived NO in ovulation in mares. 
The expression of COX-2 and consequently prostaglandin production in the 
equine follicle has been shown to be significant at 33 h post hCG (Kerban et al., 
1999). A half life of 11.04 h has been reported for AG in the circulation of the 
horse (Hunter et al., 1999). In the present study, the last treatment administration 
was 24 h post-hCG in all 3 treatment groups and plasma concentrations of AG 
after 36 h were likely not great enough to interfere with the hCG-induced follicular 
production of prostaglandins. Whether administration of AG beyond 24 h post- 
hCG would have caused a more pronounced delay in ovulation is not known at 
this time.
In three AG-treated mares follicle evacuation was not completed until 36 h 
after the first ultrasound examination that showed initial signs of follicle 
evacuation. This prolonged follicle evacuation differs from the normal rapid 
pattern of follicle evacuation (varying from seconds up to 7 min) previously 
described (Townson and Ginther, 1989). This protracted follicle evacuation could 
be explained by an incomplete rupture of the follicle wall, indicating that the 
proteolytic cascade was not fully functional. Interactions involving NO and 
proteolytic enzymes during the ovulatory process are another aspect of ovarian 
physiology yet to be studied.
Other mechanisms of action of AG in addition to iNOS inhibition are 
possible. First, AG inhibits diamine oxidase (DAO), an enzyme that catalyzes the 
oxidative deamination of histamine and putrescine (Schuler et al, 1952). The AG 
dose used in this study (406 umol/kg) was sufficient to cause inhibition of DAO 
in guinea pigs, cats and humans (Nilsson, 1999). Inhibition of DAO could 
potentially lead to an increase in histamine concentration, resulting in a 
histamine-induced increased hyperemia in the preovulatory follicle wall after
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gonadotropin stimulation (Espey, 1980). The histamine-induced increased follicle 
wall hyperemia could have a facilitating role in ovulation (Szego and Gitin, 1964; 
Schmidt et al., 1986), however, this contrasts with the delayed ovulation noted in 
mares receiving AG. W e speculate that the inhibition of NOS by AG overrode any 
increase in histamine or its action in the ovary, or that a compensatory 
methylation catalyzed by histamine methyltransferase (another pathway for 
histamine catabolism) was able to metabolize any excess of histamine. Thus, the 
present study provides indirect evidence to support previous studies that 
questioned a role for histamine in ovulation in mares (Watson and Sertich, 1991), 
sheep (Halterman and Murdoch, 1996) and rabbits (Kitai etal., 1985). The extent 
of an AG-induced increase in ovarian histamine concentrations in the mare has 
not yet been reported.
Another potential action of AG is stabilization of the active site of the 
enzyme S-adenosylmethionine decarboxylase that is a key enzyme in the 
synthesis of polyamines such as spermine and spermidine (Stjernborg and 
Persson, 1993). The significance of polyamine excess or depletion on ovarian 
physiology is presently unknown. Studies utilizing AG as an iNOS inhibitor should 
consider all additional potential effects of AG not related to NOS inhibition. It is 
recommended that further studies investigating the effect of the iNOS inhibition 
on ovarian physiology utilize a more specific iNOS inhibitor than AG.
The extent of the participation of each NOS isoform in the ovulatory 
process has not yet been unequivocally determined. In one study, it was 
concluded that both iNOS and eNOS contributed to an increase in NO production 
after hCG administration in rats (Jablonka-Shariff and Olson, 1997). Other 
studies in mice and rats provided evidence that animals treated with nonspecific 
inhibitors, or eNOS-knockout animals, showed a greater blockade of ovulation 
than did iNOS-knockout animals or after treatment with iNOS inhibitors 
(Jablonka-Shariff et al., 1999b; Mitsube et al., 1999). Moreover, in one study, 
ovulation rates in control and AG-treated in rat ovaries perfused in vitro were not 
significantly different, as opposed to lower rates of ovulation detected in 
L-NAME-treated ovaries (Mitsube etal., 1999). On the contrary, a lower inhibition
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of ovulation rates in rats treated with NG-methyl-L-arginine (a nonspecific 
inhibitor) as opposed to a stronger inhibition induced by administration of AG has 
been reported (Shukosvi and Tsafriri, 1994).
Delayed ovulation in L-NAME and AG-treated mares was accompanied by 
a clear slowing of follicular growth. In general, follicles had a decreased growth 
rate and some follicles did not show any increase at all during the estrus period. 
For four mares in the L-NAME group, follicle growth stopped during treatments 
and remained unchanged in size for 5 days when, unexpectedly, follicle growth 
resumed 24 to 36 h before ovulation. Remarkably, some follicles in these mares 
increased more than 15 mm in diameter in a 24-h period 4 days after hCG 
administration, increasing their diameter from 33 mm to 50 mm before ovulation. 
This marked increase in follicle diameter within a 24-h period by follicles that had 
not shown any significant change in follicle diameter in the previous 5 days 
during estrus is noteworthy but still remains unexplained.
A decrease in uterine edema was also observed mainly in mares receiving 
L-NAME. This was subjectively assessed by the degree of endometrial folding 
observed during ultrasonographic examination. The decrease in uterine edema 
was evident 12 h after the first L-NAME administration. This in agreement with 
previous studies that found L-NAME blocked the formation of estradiol-induced 
uterine edema in rats (Rao et al., 1995). In sheep, a local uterine intraarterial 
administration of L-NAME antagonized the increase in uterine blood flow induced 
by E2 administration (Van Buren etal., 1992).
The importance of the results reported in this paper is two-fold. First, this 
study attests to the presence of a NO-mediated mechanism on follicular growth 
and ovulation in mares; secondly, it raises the possibility that delaying ovulation 
might be an additional breeding management strategy in brood mares. Because 
mares have a long estrus, synchronization of ovulation poses a problem for the 
equine industry. Estrous cycles are generally manipulated using drugs that 
create an artificial luteal period (progestins) or shorten the luteal period 
(prostaglandins). Ovulation is usually induced with hCG or a gonadotropin- 
releasing hormone analogue. Nevertheless, a high degree of variability among
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mares and within estrous cycles causes economic losses in equine embryo 
transfer/artificial insemination programs when ovulation is not successfully 
synchronized.
Delaying ovulation could be an aid in synchronizing mares for timed 
artificial insemination or preparation of recipients for embryo transfer or oocyte 
transfer (or gamete intrafallopian transfer). Delaying ovulation could also be used 
for management of natural mating in stud farms. The use of agents that delay 
ovulation in association with ones that stimulate it would better accommodate the 
booking of mares for a specific stud. It is important to note that in the present 
study all treatments were conducted with hCG-stimulated mares. Therefore, it is 
plausible to consider that the delay of ovulation in the present study could have 
been enhanced if hCG would not have been used. Experiments with more 
elaborate treatment schedules (doses, frequencies, etc) using safe and highly 
effective NOS inhibitors will help to determine whether delaying ovulation can be 
used reliably in the equine breeding industry. Although breeding mares was not a 
primary goal of this study, some mares treated with L-NAME or AG became 
pregnant and delivered healthy foals. However, the effects of NOS inhibitors and 
delaying ovulation on the fertility of the mare need to be further investigated in a 
subsequent study.
In conclusion, the present study demonstrates that administration of well- 
known NOS inhibitors to mares in estrus until 24 h after hCG administration 
caused a temporary delay in ovulation up to 5 days after hCG stimulation. The 
characteristic estrous uterine edema was significantly inhibited in L-NAME- 
treated mares. The specific mechanism(s) by which administration of NOS 
inhibitors caused delayed ovulation remains speculative. Based on recent 
research, mechanisms accounting for this phenomenon could include: effects on 
ovarian and follicular blood flow (Bonello et al., 1996; Anteby et al., 1996), 
modulation of the blood-follicle barrier (Powers et al., 1995), modulation of 
follicular apoptosis (Chun et al., 1995; Matsumi et al., 2000) and follicular 
prostaglandin and steroid production (Ahsan e ta l, 1997; Faletti etal., 1999).
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CHAPTER 3
CONCENTRATIONS OF NITRIC OXIDE IN EQUINE 
PREOVULATORY FOLLICLES BEFORE AND AFTER 
ADMINISTRATION OF HUMAN CHORIONIC GONADOTROPIN
INTRODUCTION
Nitric oxide (NO) has emerged in recent years as a novel cell-signaling 
molecule implicated in several physiological and pathophysiological mechanisms 
(Moncada et al., 1991). After NO was identified as being the endothelial-derived 
relaxing factor (Ignarro et al., 1987), researchers soon started to characterize the 
ubiquitous nature of this important molecule in many other systems (Moncada 
et al., 1991), including the reproductive system (McCann and Rettori, 1996b; 
Rosselli et al., 1998; Tsafriri and Reich, 1999). Nitric oxide is produced from the 
amino acid L-arginine, a reaction catalyzed by a family of enzymes collectively 
known as nitric oxide synthases (NOS). Three isoforms of NO have been 
identified. Two isoforms, endothelial (eNOS) and neuronal (nNOS) are 
constitutively expressed and have calcium-dependent regulation. The third 
isoform (iNOS) is induced in response to host defense and immune-mediated 
mechanisms. These isoforms are responsible for the diversity of NOS expression 
in various tissues in the body and for the complexity of NO regulation in many 
physiological and pathophysiological processes (Moncada etal., 1991).
Nitric oxide has been implicated in several processes involving the 
hypothalamic-hypohyseal-gonadal axis such as sexual behavior (Mani et al., 
1994), LH release (Rettori ef al., 1993), penile erection (Burnett et al., 1992; 
Melis et al., 1994), cervical ripening (Denison et al., 1999), ovulation and 
granulosa cell steroidogenesis (Tsafriri and Reich, 1999). The participation of NO 
in the ovulatory process was suggested by studies in mice (Powers et al., 1996; 
Jablonka-Shariff and Olson, 1998), rats (Shukovski and Tsafriri, 1994; Jablonka- 
Shariff ef al., 1999; Faletti etal., 1999; Mitsube etal., 1999), rabbits (Hesla etal., 
1997; Yamauchi et al., 1997) and horses (Pinto et al., 2000) using various
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protocols that administered NOS inhibitors or NO-generating drugs (NO donors) 
to animals or to in vitro perfused ovaries.
In one study, intraperitoneal administration of aminoguanidine (AG), a 
relatively specific inhibitor of iNOS, concomitantly with human chorionic 
gonadotropin (hCG) to gonadotropin-stimulated immature rats resulted in a 54% 
inhibition of ovulation when compared with rats treated with saline solution 
(Shukovski and Tsafriri, 1994). This inhibitory effect of AG on the ovulation rate 
was reversed by administration of sodium nitroprusside (SNP, an NO donor). 
This group reported that administration of the nonspecific NOS inhibitor 
NG-monomethyl-L-arginine (L-NMA) significantly reduced the ovulation rate, but 
less so than AG (Shukovski and Tsafriri, 1994).
An opposing finding was reported in the same species (Mitsube et al, 
1999). It was noted that the addition of L-NMA to perfused rat ovaries reduced 
the ovulation rate, whereas, the addition of AG to the perfusate did not change 
the ovulation rate. In another study, administration of NG-nitro-L-arginine methyl 
ester hydrochloride (L-NAME, a non specific NOS inhibitor) to rabbits resulted in 
a 63% reduction in the normal ovulation rate (Hesla et al., 1997). Recent work 
from our laboratory suggests that systemic administration of L-NAME or AG to 
estrous mares temporarily inhibited hCG-induced ovulation (Chapter 1 ). 
Ovulation was delayed in L-NAME-treated mares for up to 5 days after hCG 
administration, however, permanent inhibition of ovulation (leading to follicle 
regression and atresia) was not detected. The mechanisms of NO-induced 
ovulation have been proposed to be via vascular effects in the preovulatory ovary 
(Powers et al., 1995; Bonello et al., 1996), up-regulation of hCG-induced 
prostaglandin production (Yamauchi et al., 1997; Faletti et al., 1999) and 
modulation of ovarian steroidogenesis (Bonello et al., 1996; Ahsan ef al., 1997; 
Yamauchi etal., 1997).
The diversity of NO-mediated modulation of cellular processes has been 
attributed to the fact that NO acts not only through the activation of soluble 
guanylate cyclase, but also by binding to enzymes of the cytochrome P450 
(CYP450) family, such as cyclocxygenase (Salvemini et al., 1993) and CYP450
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aromatase (Snyder et al., 1996), regulatory enzymes for the production of 
prostaglandins and E2, respectively. Binding of NO to cyclooxygenase activates 
the complex (Salvemini et al., 1993) and may explain the reported 
interrelationship between NO and the hCG-induced intrafollicular production of 
prostaglandins (Sirois and Dore, 1997; Yamauchi et al., 1997; Faletti et al., 
1999). Conversely, binding of NO to CYP450 aromatase enzyme inhibits its 
action (Snyder et al., 1996). This may be one mechanism regulating the 
diminished CYP450 aromatase activity noted after hCG administration, thereby, 
decreasing E2 production (Voss and Fortune, 1993; Boerboom et al., 1999; 
Chaffin and Stouffer, 2000). If we consider the evidence that NO is involved in 
the ovulatory process along with the fact that the equine granulosa and theca 
interna cells start to luteinize before ovulation in response to an ovulatory 
stimulus (Collins et al., 1997; Kerban et al., 1999), then one might propose that 
NO may modulate, at least in part, the process of luteinization in the preovulatory 
follicle.
The present study was performed to determine the pattern of NO, 
progesterone (P4) and E2 concentrations in follicles of estrous mares sampled 
before and 36 h after hCG administration. It was hypothesized that the 
administration of hCG would result in a higher intrafollicular concentration of NO 
in control mares sampled at 36 h post hCG when compared with control follicles 
sampled before hCG administration. In addition, the increased NO concentration 
of control follicles at 36 h after hCG would likely parallel the hCG-induced 
increased P4:E2 ratio (a marker of hCG-induced preovulatory luteinization) 
expected to occur in these same follicles. Our final aim was to determine the 
effects of AG, a specific iNOS inhibitor, and L-NAME, a nonspecific NOS inhibitor 
on the concentration of NO and steroids in the follicular fluid.
MATERIALS AND METHODS 
Experimental Animals and Agents
During the spring and summer of 1999 and 2000, 40 normally cycling 
mares (2 0  pony and 2 0  light horse mares), as determined by palpation per 
rectum and ovarian ultrasonography, in good health, were used in this study. All
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mares were treated according to a protocol approved by the Institutional Animal 
Care and Use Committee of the School of Veterinary Medicine, Louisiana State 
University, in accordance with NIH guidelines for the care and use of animals for 
research.
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) and 
aminoguanidine hemisulfate (AG) were obtained from a commercial source 
(Sigma, St. Louis, MO).
Experimental Design
The study was carried out in the spring and summer of 1999 and 2000. 
Mares were teased daily with a stallion and those displaying behavioral estrus 
were examined by transrectal uterine/ovarian ultrasonography twice daily. When 
an ovarian follicle was at least 27 mm in diameter, but less than 35 mm, mares 
were subjected to one of the following treatments: saline solution 0.9% (n = 20, 
w/v, iv, q 12 h), L-NAME (n = 10, 148 pmol/kg, iv, q 12 h) or AG (n = 10, 406 
pmol/kg, iv, q 12 h). The L-NAME and AG were dissolved in saline solution, 10% 
(w/v) and 30% (w/v) solutions, respectively. The L-NAME treatment started 12 h 
before the hCG injection, whereas, the AG treatment started 24 h before hCG 
administration. This schedule was based on the fact that the nonspecific 
inhibition of NOS by L-NAME starts during the first hour after iv administration 
(Mills et al., 1999), whereas, the inhibitory action of AG in horses starts 12 h after 
intravenous administration (Hunter et al., 1999). In the control group, 10 mares 
received a matched volume of saline solution, starting 12 h before hCG 
administration, for the L-NAME (Control L-NAME) and 10 mares received a 
matched volume of saline solution, starting 24 h before hCG administration, for 
the AG group (Control AG). The L-NAME, AG, Control L-NAME and Control AG 
groups were each divided in two groups whereby each mare underwent 
preovulatory follicle aspiration one time, either before hCG administration or 36 h 
after hCG administration (Table 3.1).
Experimental Procedures
Follicular aspiration was performed using a 60-cm, 17-gauge needle and a 
guided ultrasound scanner (Sonovet 600, Universal Ultrasound, NY, NY)
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equipped with a 7.5 MHz transvaginal sector transducer. Immediately before 
aspiration mares were sedated with detomidine hydrochloride (0.5 mg/kg, iv) and 
butorphanol (0.02 mg/kg, iv). Care was taken to stabilize the ovaries by palpation 
per rectum before the follicle was punctured to minimize infiltration of follicular 
fluid with blood. Once the needle was advanced inside the follicle, the follicular 
fluid was aspirated using a 60 ml syringe connected to an extension set coupled 
to the aspiration needle. Immediately after aspiration, the follicular fluid was 
centrifuged (2000 x g, 4°C) for 10 min, divided into multiple aliquots and stored at 
-70°C until assayed for NO, P4 and E2. Blood samples were taken daily by jugular 
venipuncture into heparinized tubes and the harvested plasma was also stored at 
- 70°C until assayed for P4 and E2.
Hormonal and Nitric Oxide Analyses
Follicular fluids and plasma without extraction were analyzed for P4 and E2 
using radioimmunoassay procedures previously described (Thompson et al., 
1983). Intra-assay coefficients of variation for P4 and E2 analyses were 7.2% and 
6.5%, respectively. The inter-assay coefficients of variation were 9.8% and 
11.5%, respectively.
Table 3.1 Number of mares randomly allotted to each treatment group along 
with respective time-matched control mares. NG-nitro-L-arginine methyl ester 
(L-NAME) hydrochloride is a nonspecific inhibitor of nitric oxide synthase and 
aminoguanidine (AG) is a relatively specific inhibitor of the inducible nitric oxide 
synthase isoform.
Treatment
No. of mares 
per group
No. of mares 
aspirated before 
hCG
No. of mares 
aspirated 36 h 
after hCG
L-NAME 10 5 5
Control L-NAME 1 0 5 5
AG 1 0 5 5
Control AG 10 5 5
Total 40 2 0 2 0
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Concentrations of NO in the follicular fluids were determined using a 
chemiluminescence detector (Nitric Oxide Analyzer NOA™, Model 280, Sievers 
Instruments, Inc., Boulder, CO). Although the follicular fluid samples analyzed in 
this study were not grossly contaminated with blood from the follicle wall, a small 
pellet of erythrocytes at the bottom of the centrifuge tube was observed in 
several samples after centrifugation. Nitric oxide is quickly oxidized to NO3' in the 
presence of hemoglobin (Moncada and Higgs, 1993). Because as little as 0.2 
mmol of hemoglobin (4% of normal blood concentration) has been reported to 
scavenge NO (Lancaster, 1997) to produce the metabolite NO3', the follicular 
samples were then analyzed for their NO3' contents. Follicular NO3' is converted 
into NO when in contact with a satured solution of VCL3 in 1N HCI. Intra- and 
inter-assay coefficients of variation for the NO chemiluminescence assay were 9 
% and 14.2 %, respectively.
Statistical Analyses
Concentrations of NO, P4 and E2 were analyzed by two-way analysis of 
variance (SigmaStat 2.0, Jandel Corporation, San Rafael, CA). All data were 
reported as mean 1  SEM of pmol concentrations. When the statistical model 
showed significance, post-hoc tests (Tukey’s test) were conducted. Data that did 
not pass the normality or equal variance tests were transformed into logarithms 
for comparisons.
RESULTS
Identification of Mares in Estrus
The combination of teasing and frequent transrectal ovarian 
ultrasonography was an effective method to detect mares at the initial stage of 
estrus. Ultrasonographic examination was also performed on the uterus, 
revealing the presence and degree of endometrial edema, which is a landmark of 
mares approaching or in estrus (Figure 3.1). Furthermore, follicular diameter was 
measured at each examination and presumptive preovulatory follicles were 
mapped at least 10 days before the aspiration procedure (Figure 3.2). Thus, 
follicular growth status of ovarian follicles was ascertained after repeated 
ultrasonographic examinations that accurately classified them regarding their
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state of dominance and progression to the preovulatory stage. Concentrations of 
plasma P4 (less than 1 ng/ml) as determined by radioimmunoassay verified the 
classification of mares in estrus.
Follicular Fluids
Follicular fluids from control mares obtained before (0 h) hCG 
administration had lower concentrations of NO than those from control mares 
obtained 36 h after hCG administration (58.3 ± 17.8 pmol vs. 340.4 ± 57.7 pmol; 
respectively; P < 0.05; Figure 3.3). Similarly, lower concentrations of P4 were 
detected in control follicles harvested before hCG administration than those 
sampled 36 h after hCG (1.2 ± 0.4 pmol vs. 26.9 ± 4.2 pmol; P < 0.05; Figure 
3.4). In control mares, E2 concentrations of follicles sampled before hCG 
administration were higher than those sampled 36 h after hCG (0.41 ±0.1 pmol 
vs. 0.23 ± 0.1 pmol; P < 0.05; Figure 3.5).
Intrafollicular concentrations of NO in L-NAME or AG-treated mares were 
not different from control mares before hCG administration, but were significantly 
lower than in control mares at 36 h post-hCG administration (P < 0.05; Figure 
3.3). Intrafollicular NO concentrations of L-NAME-treated mares were greater 
before hCG than 36 h after hCG administration, whereas intrafollicular NO 
concentrations of AG-treated mares did not change overtime (Figure 3.3).
Intrafollicular concentrations of P4 in L-NAME- and AG-treated mares were 
significantly lower those that of control samples before and 36 h after hCG 
administration (P < 0.05; Figure 3.4). The E2 concentrations in follicles of mares 
treated with L-NAME or AG did not differ between follicles sampled before and 
36 h after hCG (P >0.10; Figure 3.5), whereas, E2 concentrations in follicles of 
control mares were greater in those sampled before than 36 h after hCG 
administration (P < 0.5; Figure 3.5).
The P4:E2 ratios were calculated based on the intrafollicular 
concentrations of these hormones determined in follicles of each treatment group 
before and after hCG administration. Control mares had higher P4:E2 ratios than 
L-NAME- and AG-treated mares before and 36 h after hCG (Figure 3.6). The 
diameter of follicles punctured before hCG administration did not differ among
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treatment groups (P > 0.10), however, follicles from L-NAME- and AG-treated 
mares punctured at 36 h after hCG administration were significantly smaller than 
follicles from time-matched control mares (Figure 3.7; P < 0.05). Although 
hormonal concentrations in the follicular fluids among treatment groups showed 
changes before and after hCG administration, plasma concentrations of P4 and 
E2 did not show these changes.
DISCUSSION
The results of the present study suggest that intrafollicular production of 
NO in equine ovaries is up-regulated following administration of an ovulatory 
dose of hCG. The concentration of NO in the follicular fluid of control mares was 
significantly greater at 36 h after hCG administration than in mares sampled at 
0 h (without hCG stimulation). This increase in NO concentration in follicles of 
control mares paralleled a temporally related increase in intrafollicular 
concentration of P4 and decrease in E2 concentration in relation to hCG 
administration. These results suggest that the purported participation of NO in 
the ovulatory process may also involve modulation of an intrafollicular shift in 
steroidogenesis known to occur in response to an ovulatory stimulus (hCG) in 
mares (Watson and Hinrichs, 1988; Watson and Sertich, 1991; Collins et al., 
1997; Kerban et al., 1999). The decrease in CYP450 aromatase activity has 
been shown to be one of the first biochemical changes in follicular 
steroidogenesis that characterizes the transformation of the preovulatory follicle 
from a primarily E2-producing tissue into an active P4-secreting endocrine 
structure. Nitric oxide has been shown to inhibit CYP450 aromatase activity in 
human cultured granulosa cells (Snyder et al., 1996) and this may be one of 
roles of hCG-induced production of NO hereby documented in equine 
preovulatory follicles.
Nitric oxide also appears to inhibit steroidogenesis of in vitro cultured 
granulosa cells (Snyder et al., 1996; Yamauchi et al., 1997). Addition of NOS 
inhibitors to cultured luteinized granulosa cells of rats (Dave et al., 1997), cows 
(Basini et al., 1998) and humans (Van Voorhis etal., 1994) invariably resulted in
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Figure 3.1 Ultrasonographic pictures depicting endometrial edema in the left and right uterine horns (a) and in the uterine 
body (b) of a mare in estrus.
\
77





2  300 - 










Before nCG 36 h after hCG*
Figure 3.3 Nitric oxide (NO) concentration (mean ± SEM) in follicular fluid before 
and 36 h after hCG administration. Note the increase in NO concentrations in 
control mares 36 h after hCG administration. Mares treated with the NO synthase 
inhibitors NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) or 
aminoguanidine hemisulfate (AG) did not have a significant increase in NO 
concentrations. Bars with different letters are significantly different; P < 0.05.
* See Table 3.1 for the number of animals in each group.
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Figure 3.4 Progesterone (P4) concentration (mean 1  SEM) in follicular fluid 
before (left y-axis) and 36 h after hCG (right y-axis) of mares treated with saline 
solution (Control), NG-nitro-l-arginine methyl ester hydrochloride (L-NAME) or 
aminoguanidine hemisulfate (AG). Note the increase in intrafollicular P4 
concentrations in control mares after hCG stimulation as compared with to the 
modest increase noted in mares treated with L-NAME and AG. Bars with different 
letters are significantly different; P < 0.05.
* See table 3.1 for the number of animals in each group.
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Before hCG * 36 h after hCG *
Figure 3.5 Estradiol (E2) concentration (mean ± SEM) in follicular fluid before 
and 36 h after hCG administration. There were no significant differences between 
intrafollicular E2 concentrations before and 36 h after hCG in mares treated with 
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME) or aminoguanidine 
hemisulfate (AG). However, E2 concentrations of control mares were lower 36 h 
after hCG than before hCG administration. Bars with different letters are 
significantly different; P < 0.05.
* See table 3.1 for the number of animals in each group.
80
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
O «
»  9  « *
“  2 





Before hCG * 36 h after hCG *
Figure 3.6 Progesterone:estradiol (P4:E2) ratio (mean ± SEM) based on 
intrafollicular P4 and E2 concentrations before hCG (see left y-axis) and 36 h after 
hCG (see right y-axis) of mares treated with saline solution (Control), NG-nitro-L- 
arginine hydrochloride (L-NAME) or aminoguanidine hemisulfate (AG). Note the 
marked increase in ratios of control mares after hCG stimulation resulting both 
from increased intrafollicular P4 production as well as decreased E2 production. 
Bars with different letters are significantly different; P < 0.05.
* See table 3.1 for the number of animals in each group.
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Before hCG * 36 h after hCG
Figure 3.7 Follicle diameter (mean ± SEM) determined immediately before 
follicular aspiration performed before hCG or 36 h after hCG administration. 
There were no differences in follicles sizes among the treatment groups when 
aspiration was performed before hCG. Note, however, that follicles from mares 
treated with NG-nitro-L-arginine hydrochloride (L-NAME) or aminoguanidine 
hemisulfate (AG) did not increase in diameter after hCG stimulation and were 
smaller than follicles from time-matched controls. Bars with different letters are 
significantly different; P < 0.05.
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increased E2 production by the granulosa cells and little or no effect on P4 
production, whereas, addition of NO donors into culture wells resulted in a 
significant inhibition of steroidogenesis, primarily E2 production. Moreover, 
decreased production of androstenedione was found in genetically altered mice 
deficient in eNOS and iNOS (Jablonka-Shariff et al., 1999b). In the present study, 
increased concentrations of NO in follicular fluid were associated with low 
concentrations of E2 after hCG administration. Mechanisms mediating NO- 
induced inhibition of steroidogenesis involve direct inhibition of NO on CYP450 
steroidogenic enzymes, mainly the CYP450 aromatase (Van Voorhis etal., 1994; 
Snyder et al., 1996), and NO-stimulated activation of soluble guanylate cyclase 
(Ishimaru ef al., 2001).
The administration of hCG to mares in estrus induces ovulation and 
triggers biochemical events leading to preovulatory luteinization that translates 
into augmented P4 production and diminished E2 production by equine granulosa 
cells. The declining intrafollicular E2 concentrations found in hCG-stimulated 
equine preovulatory follicles reflect hCG-induced regulation of CYP450 
aromatase that involves dual regulation of promoter II- and promoter 1f-derived 
transcripts in granulosa cells. A switch in the expression of these two promoters 
has been suggested (Boerboom et al., 1999). Administration of hCG down- 
regulates promoter ll-derived P450 mRNA transcripts and induces promoter 
1f-derived transcripts in the granulosa cells. Loss of CYP450 aromatase activity 
derived from down-regulation of promoter II is evident within 24 h post-hCG 
administration.
Furthermore, down-regulation of CYP450 17a-hydroxylase mRNA in theca 
cells at 33 h post-hCG is likely a result of theca interna cell degeneration. Loss of 
CYP450 17a-hydroxylase activity is coincidental with the loss of steroidogenic 
acute regulatory protein mRNA in cells of the theca intema and accounts for the 
scarcity of androgen substrates for aromatization. One might consider that 
changes in follicular steroidogenesis induced by hCG may be perceived as anti- 
steroidogenic but, in reality, hCG only steers the potential for follicular 
steroidogenesis toward P4 production. Molecular regulation of these complex
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mechanisms controlling the steroidogenesis shift after hCG stimulation may be 
well modulated, at least in part, by NO and NO-derived nitrosothiols with 
biological action. Therefore, the role of NO as an anti-steroidogenic molecule 
needs to be redefined.
Accordingly, results from research using the in vitro ovarian perfusion 
model or human follicular fluid analysis have suggested that the relationship 
between NO and follicular steroidogenesis may be more complex than just 
classifying NO as an anti-steroidogenic molecule. For example, in addition to 
providing evidence that NOS inhibitors blocked hCG-induced ovulation in 
perfused rat ovaries, it has been also reported that addition of L-NAME to the 
perfusion system resulted in decreased E2 production by the perfused ovary 
(Bonello et al., 1996). In another study using the perfused rat ovary model, 
addition of a nonspecific NOS inhibitor (N-monomethyl-l-arginine) and AG did 
not alter the pattern of steroid production as compared with ovaries perfused with 
saline solution (Mitsube et al., 1999). However, stimulation of steroidogenic 
activity was evident, because the addition of a diazeniumdiolate NO donor agent 
(spermine NONOate) to the perfusion medium resulted in a significant increase 
in P4 secretion by the perfused ovary.
in the present study, mares treated with L-NAME or AG did not experience 
the expected decrease in intrafollicular E2 concentrations after hCG 
administration. These findings suggest that inhibition of NO may have served to 
presen/e CYP450 aromatase activity despite the luteinizing action of hCG 
administration. Conversely, intrafollicular P4 concentrations of NOS inhibitor- 
treated mares modestly increased over time after hCG administration suggesting 
a partial hCG-induced action in follicular luteinization of these treated mares. 
However, the hCG-induced increase in intrafollicular P4 concentrations of NOS 
inhibitor-treated mares were significantly lower than the increase noted in follicles 
from control mares.
In contrast to the results of the present study, NO metabolites (NO3 and 
N 02) were positively correlated with E2 concentration in follicular fluid obtained 
from women undergoing in vitro fertilization (IVF) procedures (Anteby et al.,
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1996). Unfortunately, P4 concentrations in the follicular fluid were not measured 
in that study. In subsequent study study, no differences were found in NO 
concentrations in human follicular fluid samples aspirated from large, medium 
and small follicles 34h after hCG administration (Sugino et al., 1996). Similar 
results were reported in a subsequent study (Tao et al., 1997), where no 
correlation was found between NO metabolites and steroids (P4 and E2) 
measured in human follicular fluid obtained from follicles classified as primary or 
secondary follicles (based on size). It is important to note that these studies in 
human subjects used follicular fluids from hCG-stimulated follicles of various 
sizes and stages of follicular maturation.
Because hCG administration is known to induce pivotal processes leading 
to follicular maturation and ovulation (Watson and Hinrichs, 1988; Watson and 
Sertich, 1991; Collins etal., 1997; Kerban etal., 1999; Chaffin etal., 2000), we 
feel that a better model to investigate the relationship between NO and follicular 
dynamics or maturation would utilize follicles either undergoing growth or atresia, 
before and after hCG administration. In that aspect the human IVF model is 
limited and offers constraints to providing meaningful information on these 
follicular dynamics variables.
However, using mares in studies of follicular dynamics is an attractive 
model because palpation per rectum and ultrasonography of ovaries can be 
performed repeatedly throughout the estrous cycle and more information can be 
gained for a given time frame. Collectively, the results of previous studies 
exemplify how different experimental approaches may lead to discrepant 
conclusions about the involvement of NO in follicular steroidogenesis, for 
example, inhibition of steroidogenesis (based on granulosa cell culture studies), 
stimulation of steroidogenesis (in vitro ovarian perfusion studies) or absence of 
correlation between NO and variables of follicular dynamics and maturation 
(IVF-derived follicular fluid studies).
Much evidence exists suggesting the participation of NO in the ovulatory 
process in mice (Jablonka-Shariff et al., 1999b), rats (Shukovski and Tsafriri, 
1994; Mitsube et al., 1999), rabbits (Hesla et al., 1997; Yamauchi et al., 1997)
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and mares (Pinto et al., 2000). If expression and up-regulation of NO were truly 
necessary for ovulation to occur, what would its role be in relation to follicular 
steroidogenesis, specifically in regard to the hCG-induced preovulatory 
luteinization? In the present study, preovulatory luteinization as evidenced by 
increased intrafollicular concentrations of P4 and decreased E2 was accompanied 
by a significant increase in intrafollicular NO concentrations after hCG 
stimulation.
This increase in P4 was partially, but significantly blocked by 
administration of L-NAME or AG, which disrupted the expected hCG-induced 
pattern of steroid production and increased NO concentrations in follicular fluids 
as detected in follicles of control mares. We failed to detect any difference in 
intrafollicular E2 concentrations in both groups of animals treated with L-NAME 
(a nonspecific inhibitor) or AG (an iNOS specific inhibitor) and before and after 
hCG administration, suggesting that inhibition of NO likely contributed to 
preserving CYP aromatase activity. Furthermore, intrafollicular P4 concentrations 
in these treatment groups were significantly lower than those of control mares 
after hCG stimulation, indicating that both eNOS and iNOS isoforms may be up- 
regulated following hCG administration in mares.
The effects of the administration of systemic NOS inhibitors, L-NAME and 
AG, in the present study contrast with those from our granulosa cell culture study 
(Chapter 4) where it was noted that L-NAME and AG affected the P4:E2 ratio 
primarily by increasing E2 production by equine granulosa cells and not P4. In the 
present study, systemic administration of NOS inhibitors likely resulted in 
vascular changes in the ovaries, effects obviously absent in the granulosa cell 
culture study. Differences in these two experimental approaches may explain the 
discrepancy between the results reported herein and Chapter 4. However, a 
common conclusion that is drawn from these studies is that NOS inhibitors 
prevented or partially inhibited the normal pattern of hCG or LH-induced 
luteinization of the granulosa cells, as evidenced by the decreased P4: E2 ratio 
documented in the equine granulosa cell culture study and in the present study.
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Using the equine model, repeated ovarian ultrasonography showed the 
initiation of development of specific follicles toward their state of dominance and 
progression to the preovulatory stage. Moreover, each follicle aspiration 
procedure was performed in a way to minimize blood contamination of follicular 
fluid samples and, because oocyte searches were not a goal of this study 
(in contrast to a human IVF clinical setting), follicular fluid samples were 
minimally exposed to room atmosphere and samples were rapidly processed and 
stored in the freezer. This experimental approach likely enabled us to detect 
significant up-regulation of NO production in the follicular fluid in response to an 
hCG stimulus, a phenomenon not yet reported in any other species.
In summary, results of the present study suggest the presence of an NO- 
generating system in the equine ovary that is up regulated following an 
intravenous ovulatory dose of hCG. Increases in intrafollicular concentrations of 
NO after hCG administration paralleled the hCG-induced preovulatory 
luteinization, providing a conciliatory explanation for the purported role of NO in 
ovulation and the seemingly conflicting NO-induced inhibition of steroidogenesis 
in cultured granulosa cells (Dave et al., 1994; Ahsan et al., 1997; Basini et al.,
1998).
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CHAPTER 4
EVIDENCE FOR A NITRIC OXIDE-MEDIATED MODULATION OF 
EQUINE GRANULOSA CELL STEROIDOGENESIS
INTRODUCTION
Several recent studies suggest the existence of a nitric oxide-generating 
system in the ovaries of quail (Van Nassauw et al., 1999), small laboratory 
animals (Van Voorhis et al., 1995; Chatterjee et al., 1996; Zackrisson et al., 
1996; Hesla et al., 1997), cows (Basini et al. 1998), humans (Van Voorhis et al., 
1994) and horses (Pinto et al., 2000). Nitric oxide (NO) is synthesized as a result 
of the conversion of L-arginine into citrulline, a reaction catalyzed by the enzyme 
nitric oxide synthase (NOS). The expression and regulation of NOS have been 
suggested to be under gonadotropin control during the reproductive cycles of rats 
(Jablonka-Shariff and Olson, 1997; Nakamura etal., 1999), rabbits (Hesla etal.,
1997) and humans (Anteby etal., 1996; Rosselli etal., 1994a). Both the inducible 
(iNOS) and the endothelial (eNOS) isoforms of NOS have been implicated in 
mechanisms regulating follicular dynamics. It appears that NO, a small gas 
molecule with an ultra short half life, modulates follicular growth and atresia 
through apoptotic mechanisms (Chun et al., 1995) and also acts as an important 
signaling molecule in the ovulatory process of mice, rats and rabbits (Tsafriri and 
Reich, 1999).
The role of NO in the ovulatory process of rats is, at least in part, 
attributed to its vascular effects in the ovary such as increased blood flow that is 
characteristic of preovulatory follicular physiology (Shukovski and Tsafriri, 1994; 
Anteby et al., 1996; Kerban et al., 1999). However, nonvascular effects of NO on 
ovulation in rats have also been suggested (Bonello et al., 1996). In the latter 
study, administration of N°-nitro-L-arginine methyl ester (L-NAME) to in vitro 
perfused rat ovaries caused a 46% decreased flow rate in the perfusion system 
and a significant decline in ovulation rate. Artificially adjusting the flow rate of 
ovaries perfused with luteinizing hormone (LH) and interleukin-1 p to that same 
extent did not suppress the ovulation rate thereby, showing that the L-NAME-
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induced inhibition of ovulation was not caused solely by decreased perfusion. In 
addition L-NAME treatment caused a reduction in estradiol (E2) secretion by LH- 
treated perfused ovaries.
However, most studies that exposed cultured granulosa cells of rats, 
rabbits and humans to (NOS) inhibitors or NO donors suggest that NO modulates 
steroidogenesis by inhibiting cytochrome P450 (CYP450) aromatase activity 
(Snyder et al., 1996). Van Voorhis et al. (1994) noted that when NOS inhibitors 
were added to a human granulosa cell culture, E2 production by the 
granulosa cells was significantly increased, whereas, no change resulted in 
progesterone (P4) production. The addition of an NO generator, S-Nitroso-L- 
acetyl penicillamine (S-NAP), caused a significant inhibition of both E2 and P4 
production; however, the E2 production was inhibited more than P4 production. 
Similar findings of NO-induced inhibition of follicular steroidogenesis have been 
reported in rats (Dave et al., 1997; Dunnam et al., 1999), rabbits (Yamauchi et 
al., 1997) and cultured bovine granulosa cells (Basini etal., 1998).
Follicular steroidogenesis is essential to the dynamics of ovarian 
functioning in response to hypothalamic and hypophyseal hormonal signals. In 
mares, the theca interna and granulosa cells are thought to act in unison to 
balance the production of progesterone, androgens and estrogens depending 
upon the stage of follicular growth or maturation and atresia (Sirois et al., 1990; 
Gerard and Monget, 1998). After an ovulatory stimulus, granulosa cells of the 
equine preovulatory follicle start to increase P4 production while the production of 
E2 decreases. This shift in steroidogenesis increases the P4:E2 ratio in the 
follicular fluid and has been used as a marker of mature follicles approaching 
ovulation (Watson and Sertich, 1991; Collins etal., 1997).
In this study, cultured equine granulosa cells were exposed to NOS 
inhibitors or an NO generator. Accordingly, AG, a relatively specific iNOS 
inhibitor, L-NAME, a non specific NOS inhibitor, or SNP, an NO generator, were 
added to cultured equine granulosa cells and E2 and P4 concentrations in the 
media were determined after 24 h of incubation. Our hypothesis was that the 
addition of NOS inhibitors to equine granulosa cells would result in greater
89
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
steroidogenesis output than similar granulosa cells cultured without the addition 
ofL-NAME, AG or SNP.
MATERIALS AND METHODS 
Experimental Aoents and Culture Medium
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), aminoguanidine 
hemisulfate (AG) and sodium nitroprusside (SNP) were purchased from Sigma 
Chemical Company (St. Louis, MO). Cell culture media were prepared using 
TCM-199 (Gibco, Grand Island, NY) in combination with 5% fetal bovine serum, 
2% SerXtender™ (Irvine Scientific, Santa Ana, CA), 10 ng/ml FSH (Sigma, St. 
Louis, MO), 1 pg/ml LH (Sigma, St. Louis, MO), 10'7 M androstenedione (Sigma, 
St. Louis, MO), and 1% (v/v) antibiotic-antimycotic (100 IU penicillin, 100 mg 
streptomycin, 0.25 pg amphotericin-B (Sigma, St. Louis, MO). All media used in 
this study were filtered through a 0 .2  pm filter.
Preparation of Equine Granulosa Cells (EGC)
Ovaries utilized in this study were obtained from cycling mares that were 
euthanized for reasons unrelated to reproductive problems. Mares were palpated 
before the euthanasia, and the stage of the estrous cycle was estimated based 
on transrectal ultrasonography of the ovaries and uterus. Only ovaries from 
mares with a follicle >30 mm and well-developed uterine edema were used in this 
study. Post-mortem examination of the uterus (presence of well-developed 
uterine edema), ovaries (large preovulatory follicle and absence of the corpus 
luteum) and plasma P4 concentrations <1.0 ng/ml confirmed the antemortem 
ultrasound findings.
Equine granulosa cells were obtained from follicles that were classified as 
preovulatory follicles from three estrual mares. Only one follicle was harvested 
per mare and cultures of EGC were completely separately for each mare. Using 
careful dissection, follicles were isolated from the ovarian stroma and mural 
granulosa cells were obtained by gently scraping the inside of the follicle wall 
with a scalpel blade. Granulosa cells were placed into a 15-ml centrifuge tube 
with 10 ml of TCM-199, but without hormones, and centrifuged at 600 x g. After 
10  min, the supernatant was replaced with fresh medium and the tube was
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centrifuged for an additional 10 min. After centrifugation, EGC were counted 
using a hemacytometer and cell viability was assessed using 0.4% trypan blue 
dye exclusion technique.
Experimental Desion
Granulosa cells (500,000 cells/well) were placed into a multiwell plastic 
culture dish (24 wells/dish; Costar, Cambridge, MA) with 1,000 pi of culture 
medium. A minimum of three wells was allotted for each of the treatments for 
each of the three follicles used in this study. Once in the culture wells, cells were 
exposed to one of the following treatments: control (no additional agents added), 
L-NAME (10-4 M), AG (10-4 M) and SNP (10^ M). After 24 h in culture (38°C, 
humidified 5% C 0 2 in air), media were collected and stored at -20°C until 
hormonal analyses were performed. Immediately after removal of the medium, 
the EGC were trypsinized and the percentage of viable cells was determined. 
Statistical Analyses
Medium from each well was analyzed for P4 and E2, using 
radioimmunoassay techniques previously described (Thompson et al., 1983). 
Samples were directly analyzed without extraction. Concentrations of P4 and E2 
and P4:E2 ratios were analyzed by analysis of variance (ANOVA). All data were 
reported as mean ± SEM per 100,000 cells. Whenever the statistical model 
showed significance, a Tukey’s test was conducted. Data that did not pass the 
normality or equal variance tests were transformed into logarithms. Intra-assay 
coefficients of variation for P4 and E2 were 7.2% and 6.5%, respectively. The 
inter-assay coefficients of variation for P4 and E2 were 9.8% and 11.5%, 
respectively.
RESULTS
Progesterone concentrations produced by control and treated EGC were 
not different (P > 0.10, Figure 4.1). Estradiol concentrations were significantly 
greater in L-NAME and AG-treated cells than in control cells, whereas SNP- 
treated cells had a lower concentration than control cells ( P < 0.05; Figure 4.2). 
The P4:E2 ratios were calculated for each well and analyzed. The P4:E2 ratios
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Figure 4.1 Progesterone (P4) concentration (mean ± SEM) in medium from 
equine granulosa cells cultured for 24 h. Each treatment group was run in 
triplicate in three different and independent experiments. There were no 
significant differences in P4 concentrations among media of control cells and of 
cells treated with NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), 
aminoguanidine hemisulfate (AG) or sodium nitroprusside (SNP). (P > 0.10).
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Figure 4.2 Estradiol (E2) concentration (mean ± SEM) in medium from equine 
granulosa cells cultured for 24 h. Each treatment group was run in triplicate in 
three different and independent experiments. Medium of cells treated with the 
nitric oxide synthase inhibitors NG-nitro-L-ariginine methyl ester (L-NAME) or 
aminoguanidine hemisulfate (AG) had significantly higher E2 concentrations than 
medium of control cells. Medium of cells treated with sodium nitroprusside (SNP) 
had lower E2 concentrations than that of control cells. Bars with different letters 
are significantly different; P < 0.05.
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Figure 4.3 Progesterone:estradiol ( P ^ )  ratio (mean ± SEM) in medium from 
equine granulosa cells cultured for 24 h. Each treatment group was run in 
triplicate in three different and independent experiments. Medium of equine 
granulosa cells treated with the nitric oxide synthase inhibitors NG-nitro-L-arginine 
hydrochloride (L-NAME) or aminoguanidine hemisulfate (AG) had lower ratios 
than control cells, whereas, medium of equine granulosa cells treated with the 
nitric oxide donor agent sodium nitroprusside (SNP) had greater P4:E2 ratio than 
control cells. Bars with different letters are significantly different; P < 0.05.
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from SNP-treated cells were significantly greater than those of the control 
granulosa granulosa cells ( P < 0.05). The L-NAME treated cells and the AG- 
treated cells P4:E2 ratios were three-fold lower than control ratios (P < 0.05, 
Figure 4.3).
Cell viability was not different among EGC obtained from each mare (mare 
1, 73%; mare 2, 80%; mare 3, 68%; P = 0.15). Similarly, percentage values of 
cell viability (mean ± SEM) before and after a 24-h culture interval for the 
treatment groups were not different (before: 73.7 ± 3.5%; after: L-NAME, 73.7 ± 
3.3%; AG, 63.3 ±4.2% ; SNP, 68.0 ±4.1%; P > 0.10).
DISCUSSION
The results of the present experiment suggest that NO can modulate 
equine granulosa cell steroidogenesis. In addition, the results of the present 
study are in agreement with other studies that found the NO-mediated inhibition 
of ovarian steroidogenesis in rats and rabbits to be primarily directed to E2 
production (Van Voorhis et al., 1994). The addition of a nonspecific (L-NAME) or 
a specific (AG) NOS inhibitors, or an NO generator (SNP) did not affect P4 
concentration when compared with that of control cells. However, E2 production 
was significantly lower in SNP-treated ceils than in control and L-NAME or AG- 
treated cells.
Estradiol production in L-NAME or AG-treated cells was three-fold higher 
than control cells. Moreover, E2 concentrations in media of L-NAME and AG- 
treated cells were not different from each other. These results suggest that both 
iNOS and eNOS isoforms modulate equine granulosa cell steroidogenesis, 
especially in regard to E2 production. However, findings from recent research 
using the rat model show that the effects of NO in steroidogenesis still do not 
present unequivocal evidence as to which NOS isoform (endothelial, inducible or 
both) plays a major role in ovarian physiology and follicular dynamics (Jablonka 
and Olson, 1998; Faletti et al., 1999).
The absence of significant effects on P4 production by the EGC resulting 
from the addition of NOS inhibitors or an NO generator is in agreement with 
studies in rats, rabbits and humans that reported a more significant NO
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modulation of ovarian steroidogenesis targeted to E2 production and minor or 
insignificant effects on P4 production (Van Voorhis et al., 1994; Olson et al., 
1996; Yamauchi et al., 1997; Dunnam et al., 1999). Mitsube et al. (1999) 
reported that the addition of NOS inhibitors (AG and NG-monomethyl-L-arginine) 
to an ex-vivo perfused rat ovary system did not affect steroid concentrations, 
whereas the addition of an NO generator (spermine NoNoate) increased P4 
production in the perfusion medium.
In a study performed in rabbits, Yamauchi et al. (1997) reported that 
ovaries perfused with AG or L-NAME had significantly increased E2 production, 
but not P4 production. In that study, addition of SNP reversed the AG-induced 
increase in E2 production, but perfusion with SNP alone did not affect the basal 
production of P4 and E2. Another NO generator (S-NAP), when added to ovarian 
explants derived from NO-deficient rats (Dunnam et al., 1999), not only failed to 
inhibit P4, but also increased concentrations of ovarian P4, following 
administration of equine and human chorionic gonadotropins (eCG and hCG). 
Estradiol production was, however, significantly decreased by the addition of S- 
NAP to the perfusion medium.
Scientific publications on NO and its role in ovulation and steroidogenesis 
are conflicting. Most authors agree that NO plays a role in ovulation, but its role 
in P4 and E2 production by ovarian steroidogenic cells remains controversial. For 
example, Boneilo et al. (1996) reported that L-NAME reduced the ovulation rate 
in rats in vivo and in vitro; however, L-NAME decreased the secretion of E2 but 
not of P4 in perfused ovaries. The same authors ruled out the possibility that this 
effect could be attributed to blood flow changes. It was then suggested that there 
is a role for NO in ovulation, but not in follicular luteinization. However, 
preovulatory follicular luteinization is a well-documented phenomenon intrinsically 
related to the ovulatory process (Collins et al., 1997, Kerban et al., 1999). 
Therefore, a unifying hypothesis for the role of NO in ovulation and follicular 
steroidogenesis, specifically regarding the process of preovulatory luteinization, 
is lacking.
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The global hypothesis of the present study was that NO, in addition to its 
participation in the ovulatory process, modulates, at least in part, the process of 
follicular luteinization. Evidence linking NO to the ovulatory process as well as to 
follicular steroidogenesis cannot be overlooked. If NO is essential for ovulation to 
occur, what would its role be in follicular steroidogenesis before ovulation? To 
answer this question hypothetically, the hormonal events within the preovulatory 
follicle wall must be understood. First, in most domestic species, it has been 
documented that after an ovulatory stimulus (e.g., hCG or gonadotropin-releasing 
hormone administration) granulosa cells start to luteinize regardless of whether 
ovulation will occur or not (Abel et al., 1975; Edwards and Steptoe, 1975; 
Oieleman et al, 1983; Watson and Hinrichs, 1988). This phenomenon is further 
supported by studies showing hCG-induced changes in steroidogenic acute 
regulatory protein (StAR) and aromatase activity in follicles of rats, cows and 
mares (Voss and Fortune, 1993; Kerban et al., 1999). Moreover, hormonal 
analyses of follicular fluid samples obtained from equine preovulatory follicles 
after hCG administration demonstrated increasing concentrations of P4 and 
decreasing E2 concentrations as evidence of proximity and readiness for 
ovulation (Watson and Hinrichs, 1988; Watson and Sertich, 1991; Collins eta/., 
1994).
This shift in steroidogenesis also is accompanied by up-regulation of 
cyclooxygenase-2 (COX-2) induced by hCG. The hCG-induced COX-2 up- 
regulation is highly conserved among species (e.g., rats, cows, horses, 
monkeys), usually occurring approximately 10 h before expected ovulation (Sirois 
eta!., 1992; Sirois, 1994; Sirois and Dor6, 1997; Duffy and Stouffer, 2001). A link 
between NO and follicular prostaglandin production also has been suggested by 
several authors (Yamauchi etal., 1997; Ahsan et al., 1997; Falletti et al., 1999). 
Thus, it is conceivable that NO may be a key signaling molecule (actively or 
permissively) mediating important hormonal events preparatory for ovulation, 
such as the increase in follicular blood flow, up-regulation of follicular 
prostaglandins and inhibition of aromatase activity. As discussed in Chapter 3,
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NO concentrations in preovulatory follicles of mares in estrus increase after hCG 
administration, paralleling the increasing intrafollicular P4 concentrations.
In conclusion, results of the present study show that addition of an NO 
generator to cultured equine granulosa cells resulted in higher P4:E2 ratios, 
whereas culture cells treated with L-NAME or AG had lower P4:E2 ratios than 
control cells. The altered P4:E2 ratios noted in medium harvested from cells 
treated with NOS inhibitors (L-NAME or AG) or an NO donor (SNP) appear to be 
derived mainly from effects on E2 production than on P4 production. We propose 
that an involvement of NO in the process of preovulatory follicular luteinization in 
the equine ovary is conceivable in light of its purported role in ovulation and 
inhibition of E2 production by in vitro cultured granulosa cells in the experiment 
reported herein.
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CHAPTER 5
EFFECTS OF Ng-NITRO-L-ARGININE METHYL ESTER 
(A NONSPECIFIC NITRIC OXIDE INHIBITOR) ON BOVINE 
FOLLICULAR DYNAMICS AND STEROIDOGENESIS
INTRODUCTION
Soon after nitric oxide (NO) was found to have properties identical to the 
endothelial-derived relaxing factor its role in other biological systems became 
evident (Moncada eta!., 1991; Rosselli et al., 1998;. The biochemical properties 
and the complex molecular regulation of nitric oxide synthases (NOS), which are 
enzymes that catalyze the production of NO, account for NO participation in most 
physiological and pathobiological processes in mammals (Moncada etal., 1991; 
Alderton et al., 2001). In the reproductive system, NO was found to modulate 
important biological processes involving hypothalamic, hypohyseal and gonadal 
functions (McCann and Rettori, 1996b; Rosselli etal., 1998; Tsafriri and Reich,
1999).
In the ovary, NO was found to be a molecule that promotes ovulation 
because inhibition of NO production resulted in inhibition of ovulation, whereas, 
administration of a NO donor agent induced ovulation in a fashion similar to 
human chorionic gonadotropin (hCG; Shukovski and Tsafriri, 1994, Powers etal., 
1995; Yamauchi et al., 1997). Different experimental approaches confirmed this 
regulatory role of NO in mammalian ovulation in several species including mice 
(Powers etal., 1995), rats (Shukovski and Tsafriri, 1994, Falletti etal., 1999) and 
rabbits (Hesla et al., 1997, Yamauchi et al., 1997). Studies using granulosa cell 
culture systems as an experimental approach to investigate the role of NO in 
ovarian steroidogenesis also provided circumstantial evidence of a role for NO in 
ovulation in cows (Basini etal., 1998) and humans (Van Voorhis etal., 1994).
Accordingly, administration of NOS inhibitors to mice, rats and rabbits 
showed that inhibition of NO inhibited or significantly impaired ovulation in 
gonadotropin-stimulated animals, whereas, administration of NO donor agents 
produced ovulation rates comparable with those noted in animals that were
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administered hCG. Parameters of ovarian response such as follicular 
development, ovulation rates, ovarian steroidogenesis and estrous cycle 
regularity were also altered when rats were chronically administered NOS 
inhibitors added to drinking water offered ad libitum (Dunnam et al., 1999) or 
when mice were genetically engineered to lack the gene for eNOS (Drazen et al., 
1999; Jablonka-Shariff etal., 1999b) oriNOS (Jablonka-Shariff etal., 1999b).
Pregnancy rates and litter size were reduced in mice made genetically 
deficient for genes encoding for both constitutive (nNOS and eNOS) and 
inducible (iNOS) NOS isoforms (Klein ef al., 1998; Jablonka-Shariff et al., 1998; 
Drazen et al., 1999; Jablonka-Shariff et al., 1999b). However, the relative 
importance of a given NOS isoform for ovarian function is yet to be unequivocally 
demonstrated as evidence exists that favors greater participation of the iNOS 
(Falletii et al., 1999) or eNOS (Jablonka-Shariff et al., 1999b) as the main isoform 
related to NO production during the ovulatory process.
Although the participation of NO in follicular dynamics has been relatively 
well documented in laboratory animals, evidence suggesting a role for NO in 
ovarian physiology of other domestic animals and humans is limited. Information 
on the role of NO in ovarian physiology of cows (Basini et al., 1998) and women 
(Van Voorhis et al., 1994) has been derived from studies investigating the effects 
of NOS inhibitors and NO donor agents in cultured granulosa cell 
steroidogenesis. These reports seem to agree that NO is an anti-steroidogenic 
molecule. Addition of NOS inhibitors to cultured bovine and human granulosa 
cells increased the production of estradiol (E2) and progesterone (P4), whereas, 
the addition of an NO donor agent inhibited the production of both steroids. 
Inhibition of cytochrome P450 (CYP450) aromatase activity has been shown to 
be one of the mechanisms whereby NO inhibits steroidogenesis whereas other 
investigators have suggested that the cyclic GMP pathway is involved in the NO- 
mediated inhibition of steroidogenesis (Van Voorhis et al., 1994; Snyder et al., 
1996). Analyses of human and bovine follicular fluid were inconclusive in 
providing meaningful information on the role of NO in ovarian dynamics. Taken
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together, the major finding reported for NO in human and bovine ovarian 
dynamics is that NO acts mainly as an anti-steroidogenic molecule.
The finding that NO appeared to be an anti-steroidogenic molecule was 
apparently discrepant and did not contribute to explaining the purported role of 
NO in ovulation. Nitric oxide has been shown to up regulate the cyclooxygenase 
pathway (COX) in several systems including hCG-stimulated production of 
prostaglandins (Yamauchi etal., 1997; Falletti etal., 1999). The confusion arises 
when one examines the scientific literature that shows that indomethacin (COX 
inhibitor) and epostane (3(3-hydroxysteroid dehydrogenase inhibitor) inhibited 
ovulation and impaired follicular steroidogenesis (Tanaka etal., 1991).
Thus, the information that NO production is temporally related to 
intrafollicular prostaglandin production along with the evidence that NO has 
strong anti-steroidogenic activity is not congruent in elucidating its role in 
mammalian ovulation. Therefore, scientific evidence is missing that links the role 
of NO in promoting ovulation based on in vivo studies with its inhibitory effect on 
steroidogenesis based on granulosa cell culture studies. The only report that 
presented data suggesting a role for NO as an autocrine modulator of bovine 
granulosa cell function used serum-free culture medium, thus, effects of NO on in 
vitro luteinization of granulosa cells could not be examined (Basini etal., 1998).
Luteinization of bovine granulosa and theca interna cells after the 
luteinizing hormone (LH) surge is a marker of follicle maturation and proximity of 
ovulation. In the last follicular wave occurring during the late stages of bovine 
diestrus, a group of follicles is selected to grow and at least one reaches a stage 
of dominance reflected by comparatively increased follicle diameter and greater 
steroidogenic output (Ginther et al., 1997; Fortune et al., 2001). The dominant 
follicle and, therefore, the presumptive preovulatory follicle, produces a relatively 
large amount of E2 that eventually triggers an endogenous LH surge (Voss and 
Fortune, 1993; Komar et al., 2001). One of the first biochemical events triggered 
by endogenous LH (or exogenous hCG) noted in functions of the preovulatory 
follicle is a shift in the character of steroidogenesis production from E2 to P4 
production (Voss and Fortune, 1993; Liu et al., 1997)). During proestrus, the
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preovulatory follicle is predominantly a steroid-producing endocrine gland that 
changes to predominantly P4 production after hCG stimulation. Therefore, hCG- 
induced preovulatory luteinization is initiated before ovulation (follicular rupture) 
occurs and, consequently, before definite morphological transformation of bovine 
granulosa and theca interna cells into luteal cells is established (Komar et al., 
2001).
Administration of GnRH (Kot and Ginther, 1999), LH (Quintal-Franco et 
al., 1999) or hCG (Schmitt et al., 1996) induces ovulation in cows. Based on this 
information, I decided to investigate the role of NO in bovine hCG-induced 
ovulation in vivo. In the present study, cows in proestrus were administered the 
NOS synthase inhibitor L-NAME, an L-arginine analogue that competitively and 
nonspecifically binds to NOS, therefore, blocking NO production. Ovarian 
response parameters to hCG administration such as follicular dynamics and 
ovulation pattern were examined by transrectal ovarian ultrasonography. Plasma 
P4 concentrations before and after ovulation were also measured by RIA 
analyses. It was hypothesized that cows treated with L-NAME would have altered 
follicular growth and ovulation patterns when compared with control cows 
receiving saline solution vehicle.
MATERIAL AND METHODS 
Experimental Animals and Estrus Synchronization
Cycling multiparous Holstein cows in good health were grouped in a 
15-acre pasture and supplemented with a 12% crude protein ration at 
1.2 kg./cow/day and free choice Gulf rye grass. Cows were subjected to an 
estrus synchronization protocol that involved administration of PGF2Q, GnRH and 
hCG. Estrus synchronization was conducted in two phases during the spring of 
2000. The first phase, pre-synchronization, was comprised of administration of 
PGF2„ (25 mg Lutalyse®, Pharmacia & Upjohn, Kalamazoo, Ml; im) twice 14 d 
apart to bring the cows into an approximate similar stage of the luteal period after 
the second PGF2q injection. The second phase of the synchronization was 
carried out using a modification of a protocol known as OVSYNCH (Pursley et 
al., 1995) that does not rely on estrus detection before artificial insemination. The
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OVSYNCH synchronization protocol consists of an injection of GnRH 
administered in any stage of the estrous cycle, an injection of PGF2a 7 d later, 
and a second injection of GnRH 48 h after the PGF2a injection. In the present 
study, hCG was substituted for the second injection of GnRH. All cows were 
treated with GnRH im (100 pg Cystorelin®, Rhone Merieux, Athens, GA) 12 d 
after the second injection of PGF2Q. At 7 d following injection of GnRH cows were 
treated with PGF2Q again. At 48 h following PGF2a injection, all cows were treated 
with hCG iv (2,000 i.u. Chorulon®, Intervet, Millsboro, DE) to induce ovulation. 
Experimental Design
Cows (n = 16) were randomly allotted to two groups that were treated with 
three injections of either saline solution (n = 1 0 , matched volume, iv, q 1 2  h) or 
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME; n = 6 , 148 pmol/kg, iv, 
q 12 h) starting 12 h before hCG administration. Most cows (n =13) were not 
lactating, whereas, 3 cows were at least beyond 45 d postpartum. Two of these 
lactating cows were allotted to the control (saline solution) group and the 
remaining cow to the treatment (L-NAME) group.
Palpation per rectum and transrectal ovarian ultrasonography were 
conducted once daily during the estrus synchronization protocol, twice daily after 
the last injection of PGF2a, every 6  h starting 24 h post-hCG administration until 
ovulation, and once daily 1, 3, 7,11 and 16 d after ovulation. Transrectal ovarian 
ultrasonography was performed using an ultrasound scanner (Sonovet 600, 
Universal Ultrasound, NY, NY) equipped with a 5-MHz linear-array transrectal 
transducer. Care was taken to minimize manipulation of the ovaries and uteri of 
cows being palpated and scanned. Ovaries were examined during each 
ultrasonography session for the presence of corpora lutea and follicles. 
Regression of corpora lutea as well as follicular development after PGF2Q 
injection was documented by ovarian ultrasonography. Ovarian follicle 
measurements are the average of two diameters taken at right angles to each 
other.
Blood samples were collected immediately before each ultrasound 
examination during the estrus synchronization protocol, treatments and post-
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ovulation examinations. Blood was collected by venipuncture of the coccygeal 
vein into heparinized tubes and placed on ice until centrifugation. Plasma was 
separated and stored at -2 0  °C until assayed for P4 using routine 
radioimmunoassay techniques (Thompson etal., 1983).
Statistical Analyses
All experimental data were expressed as mean ± SEM. Follicle diameters 
(mm) and plasma P4 (nmol) were analyzed by two-way repeated measures 
analysis of variance using a general linear model (SigmaStat 2.0, Jandel 
Corporation, San Rafael, CA). Time to ovulation after hCG administration was 
analyzed by Fischer’s exact test. Differences in the mean values between 
treatment groups were considered significant when a probability < 5% was 
accepted as an indication that the differences that occurred could not be 
attributed to random variability.
RESULTS
Estrus Synchronization and Plasma Progesterone Concentrations
All cows had plasma P4 concentrations greater than 7 nmol at the time of 
the administration of the PGF2q injection following GnRH administration (Figure 
5.1). Luteolysis was achieved in all cows as plasma P4 concentrations were less 
than 2.1 nmol when hCG was administered. At 4 d after hCG, concentrations of 
plasma P4 in L-NAME-treated cows were lower than control cows, whereas, no 
differences were noted in plasma P4 concentrations of both groups at d 11 or d 
16 after ovulation (Figure 5.1).
Follicular Dynamics and Ovulation
Follicle diameters were not different between treatment groups when final 
luteolysis was induced with PGF2a (Figure 5.2). Similarly, no difference in follicle 
diameter was found between groups at the start of treatments 12 h before hCG 
injection as well as between follicle diameters measured at the last ultrasound 
scanning before detection of ovulation (Figure 5.2).
All control cows (100 %) had ovulated by 30 h after hCG administration, 
whereas, three L-NAME-treated cows (50%) ovulated by 30 h and the remaining 
3 cows by 36 h (50%) after hCG. Statistical analysis using Fisher's test detected
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significant differences in the proportion of cows ovulating at 30 or 36 h post-hCG 
administration (Figure 5.3). Ovulation and formation of corpora hemorrhagica 
were unremarkable as examined by transrectal ovarian ultrasonography. Mature 
corpora lutea in either group did not show marked morphological differences 




In the present study, cows underwent an estrus synchronization protocol 
to minimize random variability that could have originated from environmental 
conditions, such as season of the year, pasture and experimental factors (source 
of chemical agents, preparations of intravenous solutions). Using estrus 
synchronization likely reduced individual variability owing to the phenomenon of 
follicular waves. Two major modifications were applied to the estrus 
synchronization protocol employed in the present study known as OVSYNCH 
(Pursley et al., 1997), a protocol that does not rely on estrus detection before 
artificial insemination.
The OVSYNCH protocol consists of an injection of GnRH randomly 
administered during any stage of the estrous cycle, an injection of PGF2„ 7 d 
later, and a second injection of GnRH 48 h after the PGF2a injection. The first 
modification adopted in the present study was the inclusion of a pre- 
synchronization with 2 injections of PGF2q performed before the beginning of the 
OVSYNCH. The first GnRH injection was administered 12 d after the second 
PGF2q injection when cows were thought to be between d 5 and d 10 of diestrus, 
which has been suggested to be a better period to start the synchronization 
program (Vasconcelos et al., 1999; Moreira et al., 2000; Thatcher et al., 2001). 
The second modification was the substitution of hCG for the second injection of 
GnRH. In summary, the use of a pre-synchronization treatment with PGF2a and 
the use of hCG instead the second injection of GnRH resulted in a uniform 
synchronization of the estrous cycles before treatments were applied.
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17 d posthCG
Control L-NAME
Figure 5.1 Plasma progesterone (P4) concentration (mean ± SEM) of controls 
(n = 10) and cows treated with the nitric oxide synthase inhibitor NG-nitro-L- 
arginine methyl ester hydrochloride (L-NAME; n = 6 ). Each time point was named 
in relation to an ovulatory dose of hCG. Note that -48 h refers to the day when 
PGF2a was administered. Experimental treatments were administered at -1 2  h, 
0 h and 12 h in relation to the hCG injection. Note that the L-NAME-treated cows 
had lower concentrations of plasma P4 at d 4 post-hCG than control cows but no 
differences were detected between control and treated cows at mid cycle (d 1 2  to 
17 post-hCG). Bars with different letters are significantly different; P < 0.05.
106
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
-12 h hCG 
At ovulation
Control L-NAME
Figure 5.2 Follicle diameter (mean ± SEM) of controls (n = 10) and cows treated 
with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME; n = 6 ). Follicle sizes were determined by averaging two 
measurements obtained at right angles from images stored during transrectal 
ovarian ultrasonography. Note that follicle measurements were recorded at the 
time of PGF2a injection (48 h before hCG), first treatment administration (1 2  h 
before ovulation) and at the last ultrasonographic examination before ovulation 
was detected (at ovulation). Bars with different letters are significantly different; 
P < 0.05.
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30 h 36 h
Figure 5.3 Number of cows treated with saline solution (n = 10) or Nc-nitro-L- 
arginine methyl ester hydrochloride (L-NAME; n = 6 ) that ovulated by 30 or 36 h 
post-hCG administration. Note that all control cows (n = 10) ovulated by 30 h 
after hCG administration. Delayed ovulation was noted in L-NAME-treated cows. 
P < 0.05.
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The pre-sycnhronization protocol provided that cows at initiation of the 
OVSYNCH were at the same stage of the estrous cycle, i.e., between d 5 and 
d 10 of the estrous cycle (Thatcher et al., 2001). Synchronization of estrous cycle 
and ovulation using OVSYNCH has been shown to vary if treatment is initiated 
on different days of the estrous cycle in dairy cows (Vasconcelos et al., 1999; 
Moreira et al., 2000). This variation of synchronization is associated with 
increased rates of premature ovulation in relation to the timing of artificial 
insemination and reduced fertility rates (Vasconcelos etal., 1999).
Pre-synchronization using two PGF2a injections resulted in higher 
pregnancy rates than that obtained from cows not pre-synchronized before 
OVSYNCH (Thatcher et al., 2001). The plasma P4 concentrations and absence 
of significant differences in follicle diameters evidenced the success of such 
synchronization in the present study when animals were randomly allotted to the 
experimental groups. All cows had low P4 plasma concentrations at the time of 
hCG administration. The tight synchronization of ovulation documented in control 
animals further reaffirmed the success of the synchronization protocol. 
Accordingly, premature ovulation or anovulation after hCG was not noted in the 
present study as all control cows ovulated between 24 and 30 h post-hCG 
administration.
Follicular Dynamics and Ovulation
There were only 16 cows were used in the present study. This relatively 
low number could have posed a problem to detecting statistical differences 
between control and treated cows. As the power of the study was compromised, 
the risk of failing to reject the null hypothesis was increased. However, because 
all cows were subjected to a pre-synchronization protocol before mOVSYNCH 
that resulted in adequate synchronization of ovulation in control cows, the 
probability of detecting significant differences between control and L-NAME 
treated cows was likely enhanced.
The results of the present study suggested that treatment with the 
nonspecific NOS inhibitor agent L-NAME delayed ovulation in dairy cows 
subjected to an estrus synchronization protocol. Furthermore, as we have noted
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with mares treated with L-NAME (Chapter 2), none of the preovulatory follicles of 
treated cows underwent follicular atresia and anovulation. The L-NAME-induced 
delayed ovulation in cows, as we have previously suggested for mares treated 
with NOS inhibitors, likely resulted from NO inhibition in the ovary bearing the 
preovulatory follicle. Potential effects of NO inhibition in the hypothalamic- 
hypophyseal axis (McCann and Rettori, 1996) were likely circumvented by 
administration of hCG that acts locally in the ovary.
If the original OVSYNCH protocol had been used, that includes an 
injection of GnRH to induced ovulation, then any alteration in the ovulation 
pattern could have been attributed to central effects of NOS inhibition in the brain 
in addition to ovarian effects. It remains to be investigated in a subsequent study 
whether the administration of L-NAME in the proestrus stage would alter the 
endogenous LH surge, resulting in a more prolonged inhibition of ovulation than 
that documented in the present study. Inhibition of ovulation resulting in cystic 
follicles has been reported following administration of estradiol valerate 
(Nadaraja and Hansel, 1976) or P4 (Sirois and Fortune, 1990) in late diestrus that 
resulted in lowered LH secretion and altered E2 and P4 plasma concentrations.
When L-NAME was administered to mares in estrus, a significantly lower 
growth rate of preovulatory follicles in treated mares was noted as compared with 
that of control mares. In contrast to the equine study, no significant differences in 
follicle growth rate or follicle size at the time of hCG administration and ovulation 
were noted between cows treated with L-NAME or saline solution. Administration 
of experimental drugs started 36 h after luteolysis was induced with PGF2Q. The 
mean diameter of presumptive preovulatory follicles was already at a 
preovulatory size (Control, 15.3 ± 0.8 mm; L-NAME 15.8 ±1.1 mm) and likely at 
a stage of development that the effects of NOS inhibition on follicle growth could 
not have been perceived. In the equine study (Chapter 2), administration of NOS 
inhibitors started at the very beginning of estrus and follicles had not yet reached 
preovulatory diameters (27 to 29 mm). This fact in association with a relatively 
longer estrus period in mares likely contributed to more noticeable effects of NOS
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inhibition of the growth rate of preovulatory follicles in mares than was noted in 
cows.
The reported inhibition of ovulation following administration of NOS 
inhibitors in small laboratory animals (Shukovski and Tsafriri, 1994, Powers etal., 
1995; Bonello et al., 1996; Hesla et al., 1997) has been suggested to involve 
vascular and nonvascular effects of NO in the ovulatory process. At least two 
studies (Powers et al., 1995; Bonello et al., 1996) provided evidence that NO 
may modulate ovarian blood flow regulation. Increase in diameter of the 
preovulatory follicle is more evident at the proestrus and estrus stage when 
increased hyperemia is present in the presumptive preovulatory follicle. 
Exacerbation of follicular hyperemia and the appearance of edema in the cells of 
the theca interna and externa are apparent after endogenous the LH surge or 
exogenous hCG administration when preovulatory follicles of cows and mares 
experience a final spur of growth. Thus, increased blood flow to the preovulatory 
follicle is associated with dynamic follicular growth.
As previously discussed, no differences were noted in follicular growth in 
the present study, yet ovulation was significantly delayed in cows treated with 
L-NAME. Therefore, it is likely that the delayed ovulation induced by L-NAME 
documented in the present study was not primarily related to altered blood flow 
induced by L-NAME-induced inhibition of ovarian NO. Consequently, one might 
speculate that L-NAME-induced delayed ovulation involved another important 
aspect of mammalian ovulation that NO may modulate, that is follicular 
steroidogenesis (Van Voorhis et al., 1994; Yamauchi et al., 1997; Falletti et al., 
1999).
In addition to hCG-induced vascular effects in the ovary and preovulatory 
follicle, a steroidogenesis shift from E2 to P4 production by the granulosa-theca 
interna cell complex is noted after an ovulatory stimulus (Voss and Fortune, 
1993; Komar et al., 2001). This favored intrafollicular P4 production is a result of 
decreased CYP450 aromatase activity (Voss and Fortune, 1993; Tian et al.,
1995). Analysis of intrafollicular fluids of cows and horses at different times after 
hCG stimulation has shown a gradual increase in P4 concentrations as ovulation
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approaches (Edwards, 1974; Dieleman et al., 1983). The participation of NO in 
steroidogenesis events between hCG stimulation and ovulation are presently 
unknown, but a role for NO modulation of granulosa cell steroidogenesis has 
been suggested (Van Voorhis et al., 1994; Yamauchi et al., 1997; Falletti et al., 
1999). However, most reports agree that NO inhibits steroidogenesis, primarily 
E2 production and, to a lesser extent, P4 production. One might ask how to 
reconcile the anti-steroidogenic activity of NO with the proposed role in promoting 
ovulation?
A conciliatory answer to this question came from results of a subsequent 
study investigating the role of NO on bovine granulosa cell in vitro luteinization 
(Chapter 6 ). In that study, addition of L-NAME to bovine granulosa cells cultured 
for 72 h had lower P4:E2 ratios than control cells that displayed increased ratios 
over time. The lower P4:E2 ratio noted in L-NAME-treated cells was mainly 
attributed to a significantly higher E2 production at 48 and 72 h while maintaining 
P4 production at levels that did not differ from control cells. The conclusion was 
that one of the mechanisms of NO participation in the ovulatory process might 
involve modulation of the steroidogenesis shift that occurs in response to an 
ovulatory stimulus. This hypothesis is supported by a previous research showing 
that NO inhibits CYP450 aromatase by directly inhibiting the enzyme activity and 
also by decreasing CYP450 aromatase mRNA (Van Voorhis etal., 1994; Snyder 
et al., 1996). Therefore, the anti-steroidogenic NO activity may actually be 
directed to aromatase activity, thus, being permissive to enhanced P4 production 
by bovine granulosa cells after hCG administration.
The suggestion that L-NAME may have disrupted the pattern of hCG- 
induced follicular steroidogenesis and, therefore, delayed ovulation, was further 
reinforced by observing lower plasma P4 concentrations in L-NAME treated cows 
than in control cows 3 d after ovulation. No differences in P4 concentrations were 
noted at mid cycle. The pattern of follicle evacuation in both treatment groups 
was unremarkable as were the ultrasonographic features of early corpora 
hemorrhagica of both control and L-NAME-treated cows. Therefore, the lower 
plasma P4 concentrations of L-NAME treated cows at the beginning of diestrus
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were likely attributed to effects of NO inhibition on the process of preovulatory 
and postovulatory luteinization. A prolonged effect of L-NAME, a compound that 
has a very short half life, may be expected in cows because it is known in rats 
(Pfeiffer et al., 1996) and horses (Chapter 7) that L-NAME is rapidly metabolized 
to NG-nitro-L-arginine (L-NNA), a compound with a longer half life than L-NAME 
(~ 20 h in horses). Thus, inhibitory effects of L-NAME on NO production could 
have been present at the time most L-NAME-treated cows had ovulated or were 
in the process of completing ovulation.
Although L-NAME was shown to prolong diestrus when administered in 
late diestrus to cows (Jaroszewski and Hansel, 2000) and, thus, denoting a role 
for NO in the luteolytic process, it is likely that NO inhibition at the very initial 
stages of luteinization may impair it. In that regard, NO biological function in the 
ovary may be comparable to that of prostaglandins, which have been shown to 
participate both in the ovulatory process (Liu et al., 1997) and luteolysis (Tian 
etal., 1994). All cows in the present study had plasma P4 concentrations greater 
than 7 nmol at d 17 post-hCG administration suggesting that none of either 
control or L-NAME-treated cows experienced shortened diestrus and likely 
resumed normal cyclicity.
In summary, results of the present study suggest that up-regulation of the 
NO pathway may be necessary for ovulation and luteinization to occur 
uneventfully in cows, as indicated by L-NAME-treated animals displaying delayed 
ovulation and lower metestrus plasma P4 concentrations than time-matched 
control cows. Vascular effects resulting from L-NAME administration were likely 
not involved in the phenomenon of delayed ovulation documented in the present 
study. Follicular growth, an event dependent on normal blood flow to the ovary, 
proceeded unaltered in both control and L-NAME-treated cows.
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CHAPTER 6
EFFECTS OF NITRIC OXIDE INHIBITORS ON BOVINE 
GRANULOSA CELL STEROIDOGENESIS
INTRODUCTION
After nitric oxide (NO) was associated with the cyclic events of the human 
menstrual cycle (Rosselli et al., 1994a), thus suggesting a potential relationship 
between NO and ovarian physiology, researchers started to investigate what role 
NO may have in ovarian physiological functions. In 1994, two reports described 
evidence that linked NO to the process of ovulation in rats (Shukovski and 
Tsafriri, 1994) and a role for NO-induced modulation of human granulosa cell 
steroidogenesis (Van Voorhis et al., 1994).
The results of studies investigating the role of NO in ovarian 
steroidogenesis pointed out a strong anti-steroidogenic activity of NO in 
granulosa cell function. That NO inhibits estradiol (E2) and progesterone (P4) 
production has been shown by studies using rat (Olson et al., 1996), mouse 
(Jablonka-Shariff et al., 1999b), rabbit (Yamauchi etal., 1997), swine (Masuda et 
al., 1997; Grasselli et al., 2001), bovine (Basini et al., 1998) and human (Van 
Voorhis et al., 1994) granulosa cells. A few studies, however, found that NOS 
inhibitors decreased only E2 production in perfused rat ovaries (Bonello et al.,
1996) or reported an absence of significant effects on steroidogenesis (Yamauchi 
etal., 1997).
Conclusive evidence relating the biological significance of the role of NO 
in ovarian steroidogenesis is lacking. The apparent discrepancy that arises from 
reports stating that NO increases, decreases or has no effect at all on 
steroidogenesis may derive from differences in experimental approaches using 
granulosa cell cultures or ovarian perfusion systems. Furthermore, whereas, 
most investigators elected to assay the spent media or ovarian perfusate for P4 
and E2, others only assayed for P4 (Dave et al., 1994). However, most reports 
agree that NO affects steroidogenesis by preferentially inhibiting E2 production 
(Vega etal., 1998).
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Enzymes of the cytochrome P450 (CYP450) superfamily are abundant in 
several steps of the steroidogenic pathway (Voss and Fortune, 1993) and are 
speculated to be another mechanism which NO utilizes to exert its inhibitory 
action on steroidogenesis (Snyder et al., 1996; Hanke et al., 1998). Inhibition of 
human CYP450 aromatase activity was the first mechanism suggested by which 
NO may inhibit steroidogenesis (Van Voorhis et al., 1994; Snyder et al., 1996). 
Inhibition of CYP450 aromatase activity was shown to be at the transcriptional 
and post-translational levels (Snyder et al., 1996). Other studies suggested that 
NO-induced inhibition of steroidogenesis might involve stimulation of guanylate 
cyclase and consequent cyclic GMP activation (Grasselli et al., 2001).
However, if NO is essential for ovulation how does the NO anti- 
steroidogenic activity fit in the ovulatory process? Before we hypothetically 
consider the answer to this question, well established aspects of bovine ovarian 
physiology should be considered. Follicular dominance of the presumptive bovine 
preovulatory follicle is established in late diestrus and early proestrus and is 
evidenced by increased follicular diameter over the subordinate follicles, as well 
as, by pronounced steroidogenic activity. Relatively high levels of follicle- 
stimulating hormone (FSH) that stimulate CYP450 aromatase activity and 
luteinizing hormone (LH) receptors in the granulosa cells support increased 
follicular steroidogenic activity.
As follicular growth proceeds unabated throughout proestrus, high plasma 
E2 concentrations trigger the LH surge that marks the onset of estrus. The LH 
surge or exogenous administration of human chorionic gonadotropin (hCG) 
initiates a cascade of biochemical and morphological events in the preovulatory 
follicle in the period preceding ovulation that leads to follicle and oocyte 
maturation, ovulation and the commencement of transformation of the granulosa- 
theca cell complex into luteal cells. One of the primary changes induced by LH is 
the shift in steroidogenesis from E2 to P4 production by the granulosa-theca 
intema cell complex. This conversion in steroidogenesis is a result of decreased 
activity of CYP450 17a-hydroxylase and CYP450 aromatase that accounts for 
diminished availability of aromatizable androgens and decreased aromatization
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of E2 precursors. The temporal regulation of down-regulation of these two 
important CYP450 cytochrome enzymes may vary among species, but it has 
been suggested that in cattle, androgen production and the capacity of granulosa 
cells for aromatization is coordinately and synchronously decreased after the LH 
surge (Voss and Fortune, 1993; Komar et al., 2001). Therefore, luteinization of 
granulosa and theca interna cells is initiated before ovulation is completed by 
follicular rupture (Murphy, 2000).
Bovine granulosa cells spontaneously luteinize when placed in culture and 
exposed to fetal bovine serum (Edwards, 1974; Luck et al., 1990; Legault e ta t, 
1999). The degree of luteinization can be evident morphologically as cells adhere 
to the culture plate and more importantly, through determination of increased P4 
production that causes an increase in the P4:E2 ratio (Norman and Greenwald, 
1971). The increase in P4:E2 ratios is even more evident when cells are treated 
with LH and FSH. The addition of FSH to cultured bovine granulosa cells 
stimulates adenylate cyclase activity that generates cyclic AMP (Legault et al., 
1999). The increase in cyclic AMP up regulates FSH and LH receptors, thus 
amplifying steroidogenic activity. Addition of serum to the culture increases 
granulosa cell responsiveness to LH stimulation (Dain et al., 1995). The 
phenomenon of in vitro luteinization of bovine granulosa cells may therefore be 
considered as a model for endocrine events induced by endogenous LH surge 
(or exogenous administration of hCG) in vivo. Because the current scientific 
literature has only reported the effects of NO on granulosa cell steroidogenesis 
using serum-free culture systems, the effects of NO on the phenomenon of in 
vitro luteinization are presently unknown.
In the present study, bovine granulosa ceils were placed in a culture 
system containing fetal bovine serum to promote luteinization of granulosa cells 
for 72 h. Cultured bovine granulosa cells were then treated with NOS inhibitors 
L-NAME and AG, and SNP, an NO donor agent. The E2 and P4 concentrations 
produced by treated and control bovine granulosa cells were measured at 24, 48 
and 72 h of incubation. It was hypothesized that addition of NOS inhibitors 
(L-NAME and AG) would disrupt the pattern of in vitro granulosa cell luteinization
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as evidenced by the analysis of P4:E2 ratios in treated and control granulosa cell 
cultures over 72 h of incubation, whereas, ceils treated with SNP would have 
P4:E2 ratios similar to that of control cells.
MATERIAL AND METHODS
Experimental Procedures
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), aminoguanidine 
hemisulfate (AG) and sodium nitroprusside (SNP) were obtained from one 
commercial source (Sigma Chemical Company, St. Louis, MO). Cell culture 
media were prepared using TCM-199 (Gibco, Grand Island, NY) in combination 
with 5% (v/v) fetal bovine serum (FBS), 2% (v/v) SerXtender™ (Irvine Scientific, 
Santa Ana, CA), 10 ng/ml FSH (Sigma, St. Louis, MO), 1 pg/ml LH (Sigma, St. 
Louis, MO), 10'7 M androstenedione (Sigma, St. Louis, MO), and 1% (v/v) 
antibiotic-antimycotic (100 IU penicillin, 100 pg streptomycin, 0.25 pg 
amphotericin-B; Sigma, St. Louis, MO). Ail media used in this study were filtered 
through a 0 .2  pm filter.
Bovine granulosa cells (BGC) were obtained from follicles > 4mm in 
slaughterhouse ovaries by follicular puncture with a 6 -ml plastic syringe 
containing 2 ml of aspiration medium (TCM-199 , 1% FBS, 20 lU/ml sodium 
heparin and 1% antibiotic-antimycotic) connected to a 22-gauge needle. After 
aspiration, BGC were placed into 15-ml centrifuge tubes and passed twice 
through a 25-gauge needle to disperse the BGC. Bovine granulosa cells were 
placed into a 15-ml centrifuge tube with 10 ml of aspiration medium and 
centrifuged at 600 x g. After 10 min, the supernatant was replaced with fresh 
medium and the tube was centrifuged for an additional 10 min. After 
centrifugation, BGC were counted using a hemacytometer and cell viability was 
assessed using 0.4% trypan blue dye exclusion technique.
Experimental Design
Granulosa cells (1,000,000 viable cells/well) were placed into a multiwell 
plastic culture dish (24 wells/dish; Costar, Cambridge, MA) with 1,000 pi of 
culture medium. A minimum of three wells was allotted for each of the 
treatments. Each experiment was repeated three times in an independent
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experimental setting. Once in the culture wells, BGC were exposed to one of the 
following treatments: control (no additional agents added), L-NAME (10*4 M), AG 
(10-4 M) and SNP ( If f 4 M). At 24, 48 and 72 h in culture (38°C, humidified 5% 
C 0 2 in air), media were collected and stored at -20°C until hormonal analyses 
were performed. Fresh media with respective treatment agents were added 
immediately after collection of spent media at each time point. Immediately after 
removal of media after 72 h of incubation, the BGC were trypsinized and the 
percentage of viable cells was determined as described above.
Statistical Analyses
Medium from each well was analyzed for P4 and E2, using 
radioimmunoassay techniques previously described (Thompson et al., 1983). 
Samples were directly analyzed without extraction. Concentrations of P4 and E2 
and P4:E2 ratios were analyzed by two-way analysis of variance (ANOVA) having 
time as one factor and treatment as the other factor. All data were reported as 
mean ± SEM per 1,000,000 viable cells. Whenever the statistical model showed 
significance, a Tukey’s test was conducted. Data that did not pass the normality 
or equal variance tests were transformed into logarithms. Intra-assay coefficients 
of variation for P4 and E2 were 5% and 7%, respectively. The inter-assay 
coefficients of variation for P4 and E2 were 7.5% and 10.5%, respectively.
RESULTS
The P4 concentrations in spent media of control cells and those treated 
with the NOS inhibitors, L-NAME or AG, were not different at 24 (Figure 6.1), 48 
(Figure 6.2) and 72 h (Figure 6.3) of incubation, whereas, cells treated with the 
NO donor agent SNP had lower P4 concentrations throughout the culture period. 
The E2 concentrations in spent media of L-NAME-treated cells at 24 (Figure 6.4) 
and 48 h (Figure 6.5) were higher than those of time-matched control cells. 
Although no significant differences in E2 concentrations were detected at 72 h 
among the treatment groups, L-NAME-treated BGC had E2 concentrations 2-, 3- 
and 4-fold greater than control, AG- and SNP-treated cells, respectively (Figure 
6 .6 ). Combined production of P4 (Figure 6.7) and E2 (Figure 6 .8 ) were different
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among treatment groups. The P4 .E2 ratios of control and AG-treated cells were 
significantly greater than ratios of L-NAME or SNP treated cells (Figure 6.9).
Cell viability of BGC before experimental agents were added into culture 
was not different for the three independent experiments (Table 6.1), among 
treatment groups after 72 h of incubation and within a treatment group for the 
three experiments (Table 6.2).
Table 6.1 Bovine granulosa cell viability determined before experimental agents 
for the different treatment groups were applied. No significant differences in cell 





Mean ± SEM 67.7 ± 3.8
Table 6.2 Cell viability of control, L-NAME (NG-nitro-L-arginine methyl ester 
hydrochloride)-, AG (aminoguanidine)- and SNP (sodium nitroprusside)-treated 
bovine granulosa cells after 72 h of incubation for each experiment. No 
significant differences in cell viability were noted among groups or within a group 
at 72 h of incubation for the three independent experiments. (P > 0.10).
Control L-NAME AG SNP
Experiment 1 71 67 67 64
Experiment 2 69 71 65 66
Experiment 3 69 66 68 63
Mean ± SEM 70 ±1.2 68.1 ± 2.8 66.7 ±4.4 64.7 ±2.3
DISCUSSION
The results of the present study suggest that NO modulates the regulation of 
bovine granulosa cell steroidogenesis and point to a participation in the process 
of in vitro luteinization of granulosa cells. This finding is important as it may 
provide a conciliatory explanation for the apparent discrepant scientific evidence 
that implicates NO as a key player in the ovulatory process (Shukovski and 
Tsafriri, 1994) and as an anti-steroidogenic molecule (Van Voorhis et al., 1994). 
Although several studies have found a major participation of NO in the ovulatory
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24 Hours of Incubation
Figure 6.1 Progesterone (P4) concentration (mean ± SEM) in spent media of 
cultured bovine granulosa cells collected at 24 h of incubation. Cells were treated 
with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor 
agent sodium nitroprusside (SNP). Bars with different letters are significantly 
different; P < 0.05.
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48 Hours of Incubation
Figure 6.2 Progesterone (P4) concentration (mean ± SEM) in spent media of 
cultured bovine granulosa cells collected at 48 h of incubation. Cells were treated 
with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor 
agent sodium nitroprusside (SNP). Bars with different letters are significantly 
different; P < 0.05.
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72 Hours of Incubation
Figure 6.3 Progesterone (P4) concentration (mean ± SEM) in spent media of 
cultured bovine granulosa cells collected at 72 h of incubation. Cells were treated 
with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor 
agent sodium nitroprusside (SNP). Bars with different letters are significantly 
different; P < 0.05.
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24 Hours of Incubation
Figure 6.4 Estradiol (E2) concentration (mean 1  SEM) in spent media of cultured 
bovine granulosa cells collected at 24 h of incubation. Cells were treated with the 
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride (L- 
NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium 
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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48 Hours of Incubation
Figure 6.5 Estradiol (E2) concentration (mean ± SEM) in spent media of cultured 
bovine granulosa cells collected at 48 h of incubation. Cells were treated with the 
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride 
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium 
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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72 Hours of Incubation
Figure 6.6 Estradiol (E2) concentration (mean l  SEM) in spent media of cultured 
bovine granulosa cells collected at 72 h of incubation. Cells were treated with the 
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride 
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium 
nitroprusside (SNP). L-NAME-treated cells had E2 concentrations 2-, 2.5- and 
4-fold higher than control, AG- and SNP-treated cells, respectively. (P < 0.05).
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Figure 6.7 Total progesterone (P4) concentration (mean ± SEM) in spent media 
of cultured bovine granulosa cells incubated for 72 h. Cells were treated with the 
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride 
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium 
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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Figure 6.8 Total estradiol (E2) concentration (mean ± SEM) in spent media of 
cultured bovine granulosa cells incubated for 72 h. Cells were treated with the 
nitric oxide synthase inhibitors NG-nitro-L-arginine methyl ester hydrochloride 
(L-NAME) or aminoguanidine (AG), and the nitric oxide donor agent sodium 
nitroprusside (SNP). Bars with different letters are significantly different; P < 0.05.
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Figure 6.9 Progesteroneiestradiol (P4:E2) ratio (mean ± SEM) in spent media of 
cultured bovine granulosa cells calculated at 24, 48 and 72 h of incubation. Cells 
were treated with the nitric oxide synthase inhibitors NG-nitro-L-arginine methyl 
ester hydrochloride (L-NAME) or aminoguanidine (AG), and the nitric oxide donor 
agent sodium nitroprusside (SNP). Bars with different letters are significantly 
different; P < 0.05
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process, the relationship between the apparent anti-steroidogenic activities of NO 
in relation to its role in ovulation remains unexplained.
The phenomenon of luteinization of granulosa cells in vitro is useful as an 
experimental approach for studying biochemical events associated with 
preovulatory follicular luteinization, because LH or hCG administration to cultured 
bovine granulosa cells evokes similar changes in cell function as it does in vivo 
(Channing, 1970). Accordingly, the endogenous surge of LH has also been 
shown to trigger significant increases in bovine follicular P4 concentrations within 
24 h concomitantly with decreased E2 concentrations (Sirois, 1994; Liu et al.,
1997). In comparison, bovine granulosa cells spontaneously luteinized in vitro 
when cultured in serum-supplemented medium (Davis etal., 1988).
Furthermore, administration of hCG to cows in estrus induced the 
expression of cyclooxygenase-2 (COX-2) and prostaglandin E synthase -  10 h 
before ovulation (Liu et al., 1997; Filion et al., 2001). Administration of hCG to 
spontaneously luteinized bovine granulosa cells in vitro induced the expression 
of PGF2a receptor mRNA and COX-2 mRNA via activation of cyclic AMP 
production (Tsai and Wiltbank, 2001). Similarly, hCG administration to cultured 
bovine granulosa cells up-regulated COX-2, PGF2a receptor and PGE receptor 
mRNA (Tsai et al., 1996). Taken together, these studies indicate that in vitro 
tissue culture systems using bovine granulosa cells can serve as experimental 
research models to study regulation of biochemical events evoked by 
gonadotropins and then applied to in vivo conditions.
Studies that demonstrated the NO-induced inhibition of granulosa cell 
steroidogenesis have failed to elucidate what would be the biological significance 
of the anti-steroidogenic activity of NO for the physiological function of the ovary. 
Undoubtedly, the suggestion that a molecule acts to promote ovulation but also 
strongly inhibits steroidogenesis is puzzling, and poses a challenge for 
reproductive biologists.
The steroidogenic capability of ovarian follicles is high during the 
periovulatory period when expression of specific regulatory genes is induced by 
FSH to promote maximum follicular growth and other genes, induced by LH, are
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expressed to promote follicular maturation and ovulation (Richards, 2001). 
Before the LH surge, E2 is the predominant hormone whereas P4 concentrations 
in the follicular fluid increase remarkably after the LH surge. If NO is truly 
necessary for ovulation to occur, then participation of NO in the phenomenon of 
preovulatory follicular luteinization might, at least partially, serve that function. 
Thus, it seemed logical to investigate what role NO would have on in vitro 
luteinization of granulosa cells. Therefore, the ultimate goal of the present study 
was to investigate NO-induced modulation of steroidogenesis (especially in 
relation to luteinization) in cultured bovine granulosa cells to further relate it to 
NO role in ovulation.
Immunohistochemistry studies have identified NOS isoforms in the 
mammalian ovary (Van Voorhis et al., 1994; Chatterjee et al., 1996; Zackrisson 
etal., 1996; Hesla etal., 1997; Basini e ta i, 1998). Researchers still disagree on 
which NOS isoform (or isoforms) is primarily involved during ovulation and the 
initial stages of luteinization. Although some studies point to a preferential 
involvement of eNOS in ovulation and steroidogenesis (Jablonka-Shariff et al., 
1999; Mitsube et al., 1999), others suggest that iNOS is the primary isoform 
involved in the ovulatory process and biochemical events occurring in the 
preovulatory follicle such as the up-regulation of follicular prostaglandins 
(Shukosvi and Tsafriri, 1994; Faletti etal., 1999). Unlike the results of the equine 
granulosa cell study, the administration of AG to bovine granulosa cells in the 
present study did not significantly increase E2 production over hours as L-NAME 
treatment did. Actually, granulosa cells treated with AG displayed a high degree 
of luteinization demonstrated by increased production of P4 and temporally 
related decrease in E2 production by treated cells. Further work will be needed to 
investigate the mechanisms underlying this difference in the expression of NOS 
activity between bovine and equine granulosa cells.
Immunohistochemistry of granulosa cells or follicle walls of equine and 
bovine preovulatory follicles might help to elucidate species-specific differences 
in the expression of ovarian NOS isoforms. Another approach would be to 
pharmacologically design a specific inhibitor for iNOS devoid of secondary
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effects unrelated to iNOS inhibition. In that regard, AG has been known as an 
inhibitor of diamine oxidase before NO was even discovered as a cell-signaling 
molecule (Schuler, 1952) and, thus, before AG was known as a NOS inhibitor. 
Administration of AG into serum-supplemented tissue culture systems has been 
used to inhibit diamine oxidase, a key enzyme in the process of degradation of 
polyamines. Catabolism of polyamines present in serum-supplemented tissue 
culture systems might potentially lead to a build up in the concentration of toxic 
aldehydes that could be deleterious for the cell viability in the culture system. 
Thus, it should be considered that administration of AG in the present study 
could have promoted a beneficial effect on the process of luteinization that 
overrode inhibition of iNOS-derived NO.
Another possibility for the absence of significant differences between 
L-NAME and AG effects is based on the fact that the culture system employed in 
the present study was adequate for luteinization as indicated by marked 
increases in P4 concentrations over time, both in control and NOS inhibitor- 
treated cells. Perhaps attenuation of factors favorable for luteinization used in the 
present study would allow luteinization of control bovine granulosa cells to be 
conducted at a slower rate or less intensively, thus allowing effects of NOS 
inhibitors in preventing luteinization more evident.
The original hypotheses of the present study stated that the P4:E2 ratios in 
cells treated with SNP would be similar to those noted in control cells, indicating 
that NO is permissive to the process of luteinization through its inhibitory effects 
on steroidogenesis, primarily E2 production. This hypothesis was based on 
strong evidence that suggests an important role for NO in the ovulatory process.
Preovulatory luteinization is an important LH-induced biochemical change 
resulting from the intrafollicular shift in steroidogenesis from E2 to P4 as 
previously discussed. Moreover, analysis of follicular fluid of mares before and 
after stimulation with hCG showed that intrafollicular concentrations of NO were 
higher after hCG stimulation, paralleling the temporally related increase in 
intrafollicular P4 concentrations (Chapter 3). Taken together, these results led to
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the hypothesis that addition of a NO donor agent to cultured granulosa cells 
would favor, or be permissive to, in vitro luteinization of granulosa cells.
However, addition of SNP to cultured bovine granulosa cells in the present 
study seemed to have suppressed production of E2 and P4 but without 
significantly affecting cell viability. It is likely that excessive NO generation 
resulted in generalized binding of NO with CYP450 enzymes that are regulatory 
for the steroidogenesis pathway.
Preliminary data analyzing samples from spent media of the present study 
showed that concentrations of NO in spent media of SNP-treated cells were five­
fold greater than that of control cells. Interestingly, the NO concentrations in 
spent media of control cells increased over time, thus paralleling in vitro 
luteinization of bovine granulosa cells in a somewhat analogous fashion noted in 
intrafollicular NO concentrations in hCG-stimulated mares. The bovine granulosa 
cells were treated with a dose of SNP based on previous studies and also on a 
concentration that did not significantly affect cell viability but likely exceeded the 
ability of cultured cells to utilize the NO produced at a physiological rate. 
Retrospectively, the use of lower concentrations of SNP probably would have 
enhanced the chances of detecting a beneficial effect of SNP toward in vitro 
luteinization of granulosa cells.
Initial results from studies investigating the effects of NO on granulosa cell 
steroidogenesis used serum-free culture medium (Basini et al., 1998) or short­
term culture (Van Voorhis et al., 1994). Therefore, NO-induced modulation of 
steroidogenesis during the process of in vitro luteinization could not be 
determined.
The apparent NO-induced anti-steroidogenic activity was in agreement 
with contemporaneous research investigating NO-induced regulation of rat luteal 
function that found production of basal NO was significantly higher than that 
produced by ovarian cells obtained at various stages of follicular development 
(Olson et al., 1996). Thus, it was concluded that the relatively high amount of 
basal production of NO maintained the E2 production by luteal cells at low 
concentrations because addition of AG to the culture luteal cells produced a
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dose-dependent increase in E2 but not in P4 production (Olson et al., 1996). 
Again, the latter study placed emphasis on the fact that inhibition of NO by AG 
resulted in increased E2 production but did not discuss another seemingly 
important finding, which was that control rat luteal cells produced a relatively high 
amount of NO as well as high concentrations of P4 (Olson et al., 1996).
Subsequent studies using human (Frid6n et al., 2000; Vega et al., 2000) 
and rat (Motta etal., 1999) luteal cells began to emphasize NO anti-steroidogenic 
activity as the basis for a potential luteolytic action in the corpus luteum. In 
Holstein heifers at mid-diestrus, intraluteal administration of L-NAME using a 
microdialysis system provoked significant increases in P4 concentrations in the 
perfusate but not in the peripheral blood (Jaroszewski and Hansel, 2000). When 
heifers were perfused at the end of the diestrus period, the luteal activity was 
prolonged as shown by the maintenance of P4 above 3 ng/ml from d 19 through 
25 in three of the four treated heifers. It was concluded that NO had a direct role 
on luteal regression.
However, in many aspects the NO pathway shares similarities with the 
prostaglandin pathway and, therefore, still fails to provide the last word on the 
molecular mechanisms regulating luteal regression. For example, a dichotomy is 
present in the way prostaglandins interact with luteal cells, as is the seemingly 
paradoxical relationship of NO with the luteinization process. Although PGF2a is 
luteolytic in vivo, hCG-stimulated in vitro luteinization of bovine granulosa ceils is 
accompanied by up-regulation of prostaglandin receptor mRNA for PGE and 
PGF2a, as well as up-regulation of COX-2. Furthermore, PGF2a in vitro did not 
inhibit basal P4 production by bovine large luteal cells and, interestingly, 
significantly stimulated P4 production by small luteal cells. Therefore, the 
evidence of the present study suggesting that NO is involved in the process of 
bovine granulosa cell luteinization in light of evidence showing that NO might 
regulate luteal regression should not be alarming if we consider the lessons from 
prostaglandin research. Accordingly, a recent report discussed a potential dual 
effect of NO on P4 production by luteal cells, that is, NO stimulating P4 production 
in the functional mid-cycle corpus luteum and mediating PGF2a-induced luteolysis
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(Motta et al., 2001). In agreement with a possible luteotrophic role of NO are the 
results of studies that showed that addition of NO donor agents to rat ovaries that 
were simply incubated (Dong et al., 1999) or placed in a perfusion chamber 
(Mitsube et al., 1999) increased the concentration of P4 in a dose-dependent 
manner.
In summary, results of the present study showed that addition of a 
nonspecific NOS inhibitor (L-NAME) to bovine granulosa cells cultured in vitro 
decreased the P4:E2 ratios of treated cells over time, thus altering the pattern of 
in vitro luteinization as compared with control cells. Treatment of cells with AG, a 
specific iNOS inhibitor, did not differ from control cells, suggesting lack of 
involvement of iNOS in the process of in vitro luteinization. However, beneficial 
effects of AG, as a diamine oxidase to serum-supplemented tissue culture 
systems should not be overlooked. The findings of the present study provide a 
new conciliatory insight into the matter of NO participation in the ovulatory 
process, in consideration with its anti-steroidogenic activity. It is proposed that 
NO, along with its vascular effects in the preovulatory follicle, has a permissive 
role on the phenomenon of LH-induced preovulatory luteinization, likely mediated 
by inhibition of CYP450 aromatase.
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CHAPTER 7
PHARMACOKINETICS OF Ng-NITRO-L-ARGININE METHYL 
ESTER (L-NAME) AFTER AN INTRAVENOUS BOLUS 
ADMINISTRATION IN CONSCIOUS HORSES
INTRODUCTION
Nitric oxide (NO) has in its diatomic molecule equimolar amounts of two of 
the most abundant gaseous elements known, nitrogen and oxygen (Fukoto, 
1995). Until recently, NO was primarily known as a pollutant present in the 
atmosphere derived from car combustion and even from cigarette smoke 
(Weitzberg and Lundberg, 1998). Thus, it was as surprising as well fascinating 
the information that the endothelial-derived relaxing factor was undistinguishable 
from NO (Ignarro et al., 1987). Later, it was found that endogenous NO was 
synthesized from the amino acid L-arginine in the presence of O2 and NADPH, 
and releasing an equimolar amount of citrulline as a co-product (Moncada et al., 
1991). The reaction was shown to be catalyzed by a family of enzymes known as 
nitric oxide synthases (NOS; Alderton et al., 2001). These initial discoveries 
launched an avalanche of intensive research trying to elucidate molecular 
mechanisms of NO regulation and function.
Nitric oxide was initially discovered as a molecule controlling vasodilator 
tone (Ignarro et al., 1987; Aisaka et al., 1989), but soon after its discovery NO, 
was also found to be involved in several physiological and pathophysiological 
processes such as neurotransmission (Sanders and Ward, 1992), macrophage 
activity (Stuehr and Marietta, 1985; Abu-Soud et al., 1995) and hormonal 
modulation (Adams et al., 1992). Accordingly, researchers began to turn their 
attention to novel uses for old drugs, such as nitroglycerin, which had been used 
for over 100 years to treat angina pectoris. Preterm labor is a serious condition 
that affects women and nitroglycerin has been used to prevent or stop early labor 
(Lees et al., 1994; Buhimschi et al., 1996). Other areas that were believed to 
potentially benefit from treatment with NO donor agents are infectious diseases 
(Burgner et al., 1999), parasitism (Garcia et al., 1999), pain management
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(Moncada et al., 1991) and, more recently, ovarian function (Rosselli et al., 
1998). However, an excess of NO can be as harmful in some instances as the 
lack of adequate NO production. Thus, when it was found that one NOS isoform 
(inducible isoform; iNOS) was expressed primarily in pathological, life-threatening 
conditions (e.g., septicemia, septic shock, infections), researchers soon realized 
that selective inhibition of iNOS during these critical conditions could potentially 
ameliorate vital conditions that were altered by iNOS-derived NO overproduction. 
The design and investigation of agents that inhibited NOS activity received as 
much attention as did the research on NO-generating agents.
It was determined that the nonspecific NOS inhibitor NG-nitro-L-arginine 
methyl ester (L-NAME) was shown to inhibit acetylcholine-stimulated relaxation 
of rat aortic rings (Hutcheson and Griffith, 1991). Because of its high solubility 
L-NAME was preferred as an experimental agent in NO research (Griffith and 
Kilbourn, 1996). Because of its ester form, L-NAME is quickly hydrolyzed to 
L-NNA by abundant cellular esterases (Pfeifer et al., 1996). The free acid L-NNA 
is likely responsible for L-NAME NOS inhibition. This hypothesis was supported 
by studies that showed that physiological effects denoting that NOS inhibition far 
exceeded the short L-NAME half life. It has been suggested that L-NAME rapidly 
enters the cell, is hydrolyzed and then becomes restricted inside the cell where it 
exerts its physiological effects.
Subsequent studies have shown the potential of L-NAME for therapeutic 
use. Administration of L-NAME resulted in reduction of plasma exudation (Perez 
etal., 1997), neuroprotection following cerebral ischemia (Coertetal., 1999), and 
restoration of normal systemic blood pressure following iatrogenic (Bone et al., 
1998) and naturally occurring (Kiehl et al., 1997; Avontuur et al., 1998) 
endotoxemia.
However, no information has been published on characteristics of 
L-NAME pharmacokinetics following systemic administration in domestic 
animals. Because of its solubility, tissue distribution, and effects on NOS 
blockade, L-NAME is a potentially useful drug for experimental or clinical use. 
Knowledge of its pharmacokinetics is crucial to pursuing research investigating
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the role of NO in equine physiologic and physiopathological processes. However, 
dosages of L-NAME administered to horses in previous studies were not based 
on pharmacokinetic studies but rather extrapolated from dosages from other 
species or empirically from pilot studies (Mills et al., 1997; Manohar and Goetz,
1998). Therefore, in the present study plasma L-NAME concentrations and 
kinetics were investigated after bolus intravenous administration of L-NAME 
hydrochloride to conscious horses. The plasma L-NAME and L-NNA (major 
L-NAME metabolite) concentrations were determined using high-performance 
liquid chromatography system (HPLC).
MATERIAL AND METHODS
Experimental Procedures
Six clinically normal adult horses (4 Quarter Horses, 1 Thoroughbred, 1 
Paint) and in good health were acclimatized to stand unrestrained in stocks 
without chemical sedation and were accustomed to handling and the presence of 
personnel and research equipment at close proximity. There were 2 sexually 
intact females and 4 geldings. The horses weighed (mean ± SEM) 518.94 ±
11.58 kg and were 11.0 ± 1.15 years old. Horses were fed a commercial grain 
ration (4 kg/horse) twice daily in addition to ad libitum access to Alicia hay and 
water. All horses were housed in individual stalls for the duration of the 
experiment (Fall 1999 and Spring 2000).
NG-nitro-L-arginine methyl ester (L-NAME) hydrochloride and N°-nitro-L- 
arginine (L-NNA) were purchased from Sigma Chemical Company (St. Louis, 
MO). This study was approved by the Institutional Animal Care and Use 
Committee of Louisiana State University.
Instrumentation
Two 14-gauge, 13.3 cm Teflon catheters were aseptically inserted 
percutaneously into the right and left jugular vein, and were used for the drug 
administration and blood collections. A 10% (w/v) solution was freshly prepared 
immediately before the experiment commenced by dissolving L-NAME into 0.9 % 
(w/v) saline solution. The L-NAME solution (40 mg/kg) was injected in the left 
jugular vein over 2 min. Blood samples (10 ml) were drawn from the right jugular
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vein immediately before and at 1, 2, 5 ,1 0 ,1 5 , 20, 25, 30, 40, 50,60, 75, 90,105  
min and at 6, 12, 24, 30, 36, and 48 h after L-NAME administration. A 30-ml 
syringe was used to draw 20 ml of blood from the catheter and only then a 12-ml 
plastic syringe was used to collect fresh blood that, likely, did not contain heparin 
saline solution (0.9%, w/v), which was used to prevent catheter occlusion. The 
first 20 mi of blood was then infused back to the jugular vein and catheters were 
immediately flushed with heparinized saline solution. Blood samples (10 ml) were 
immediately placed in tubes coated with lithium heparin, placed on ice and 
centrifuged (2,000 x g for 10 min) within 15 min after collection.
Because hyperthermia has been detected (Mills et al., 1997) in horses 
receiving L-NAME (by mechanisms not yet fully elucidated), fans were 
maintained in the stalls for the duration of the study. Plasma samples were 
stored at -7 0  °C until analysis for determination of L-NAME and L-NNA using 
HPLC.
Sample Preparations and HPLC Analyses
Frozen plasma samples were thawed at room temperature (20 to 23 °C). 
Once samples were thawed and vortex mixed for 45 sec, 0.5 ml of sample was 
transferred into 5-ml conical glass tubes containing 3 ml of ethanol, which 
resulted in plasma deproteinization. After vortex mixing the tubes for 45 sec, 1.5 
ml was transferred into microcentrifuge tubes and centrifuged at 16,000 x g for 
10 min. After centrifugation, 100 pi of supernatant was diluted with 400 pi of 
HPLC water, passed through a 0.45 pm nylon filter and loaded into the HPLC 
system for automated injection (50 pi per sample) and analysis.
A standard curve was determined immediately before each run using 
freshly prepared standard solutions. The L-NAME and L-NNA standard solutions 
were made using L-NAME- and L-NNA-free pooled horse plasma at 
concentrations of 100, 50, 25,10, 5, 1, and 0 pg/ml. The use of horse plasma to 
dilute L-NAME and L-NNA was previously validated against standard solutions 
made with HPLC water. A new calibration curve was prepared daily before 
samples were analyzed. A method (made with HPLC water) and horse plasma 
blank (obtained from horses that were not treated with L-NAME) controls
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containing no chemicals were included in each run. Linear calibration curves with 
an t2 value a 0.99 were used for analysis. The limit of quantification for L-NAME 
and L-NNA was 0.05 pg/ml.
Plasma concentrations of L-NAME and L-NNA were determined using an 
ion exchange HPLC system (HP 1090 Agilent Technologies, Wilmington, DE) 
equipped with a nucleosil SA column (length = 250 mm; internal diameter = 4.6 
mm, Machery-Nagel,) and a column guard (length = 7.5 mm; internal diameter =
4.6 mm, Machery-Nagel). The nucleosil SA is a sulfonic acid-based strong cation 
exchanger with an ion exchange capacity of approximately 1 meq/g. The particle 
diameter was 5 pm. The nucleosil SA column was chosen because it is stable 
when exposed to mobile phase of low pH, such as the one used in the present 
study to detect L-NAME and L-NNA.
The mobile phase was composed of 90% of an aqueous phase containing 
NaH2P0 4 /H3Po4 (1:1 ratio; 200 mM; pH *  2.3) and 10% of an organic phase 
containing MeOH run at (1.5 ml/min). A diode-array light detector for the UV 
signal was set at a wavelength of 268 qm. The mobile phase solutions were 
degassed with helium for 20 min before each run. The run time was 19 min (stop 
time = 14 min; post-time = 5 min). A PC computer equipped with software 
designed for HPLC analysis was connected to the HPLC equipment to collect 
data.
Statistical and Pharmacokinetic Analyses
Plasma L-NAME and L-NNA concentrations of six horses were used to 
calculate pharmacokinetic parameters. Experimental data was further analyzed 
using standard methods and equations performed by computer software 
designed to analyze pharmacokinetic data (WinNonlim®, Scientific Consulting 
Inc., Cary, NC).
RESULTS
In general, no signs of discomfort or colic were noticed in horses receiving 
L-NAME. However, It seemed that, overall, all horses were not as alert after the 
beginning of the experimental procedures including L-NAME infusion, whereby a 
submissive demeanor was observed. Five of six horses were eating and drinking
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normally within the first 12 h after L-NAME administration. Only one horse 
developed hyperthermia (104 to 106 °F) and loss of appetite for 48 h following 
L-NAME administration. Blood chemistry and complete blood count analyses 
were within normal limits. At the end of the study (48 h), the horse was still 
depressed and was treated with fluids. Recuperation to normal health and 
behavior was uneventful.
The mean (± SEM) values of plasma L-NAME and L-NNA concentrations 
for each time point were calculated (Table 7.1) and used to estimate 
pharmacokinetic parameters. Experimental data from analyses for detection of 
L-NAME suggested that a two-compartment model (Figure 7.1) was adequate for 
analyses, whereas a one-compartment model (Figure 7.2) was used to derive 
pharmacokinetic parameters from plasma L-NNA concentrations over time. Both 
one- and two-compartment models were used based on intravenous bolus input 
and first-order output.
Determination of L-NAME and L-NNA in the same sample by HPLC was 
reliable because the peaks for each compound were identified at different 
retention times. Retention time for L-NAME was ~ 7 min, whereas, the retention 
time for L-NNA was -  3 min. Plasma concentrations of L-NAME and L-NNA were 
plotted against time (Figure 7.3 and 7.4, respectively) and pharmacokinetic 
parameters were calculated (Tables 7.2 and 7.3).
The overall biologic half life (K10-HL) for L-NAME was 3.7 min, whereas, 
the K10-HL for L-NNA was 19.5 h. The plasma L-NAME concentrations were 
highest after 1 min and declined rapidly over the next 30 min, stabilizing at -  1 
Mg/ml until the last time point (t = 48 h). The plasma L-NNA concentrations never 
peaked and concentrations determined at the first time point (1 min) were the 
beginning of a plateau (30 to 35 ug/ml) that ended 12 h after L-NAME 
administration when the first significantly different L-NNA concentration was 
noted (18.81 ug/mi). Defined as the average amount of time a compound 
remains in the body, the mean residence time (MRT) was 14.4 min and 28.2 h for 
L-NAME and L-NNA, respectively.
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Table 7.1 Plasma concentrations (mean ± SEM) of NG-nitro-L-arginine methyl 
ester (L-NAME) and NG-nitro-L-arginine (L-NNA) after an intravenous bolus 
administration of L-NAME hydrochloride (40 mg/kg).
Time point (h) L-NAME (ug/ml) L-NNA(ug/ml)
0.017 233.94 ± 17.8 35.35 ± 2.8
0.033 151.37 ±12.8 30.87 ± 3.3
0.083 99.07 ± 6.0 33.25 ±1.7
0.167 42.95 ± 2.2 35.45 ±1.1
0.250 22.93 ± 1.8 36.33 ±1.5
0.330 12.76 ± 1.1 33.35 ± 2.3
0.417 9.32 ± 0.9 35.31 ±1.1
0.500 6.15 ± 0.4 35.27 ±1.3
0.667 3.55 ± 0.5 34.66 ±1.0
0.83 2.35 ± 0.5 32.92 ±1.2
1.0 1.62 ± 0.4 32.17 ±0.8
1.3 1.58 ± 0.5 31.51 ±1.3
1.5 1.03 ± 0.3 31.54 ±0.5
1.8 0.60 ± 0.3 31.29 ±0.8
6.0 1.26 ± 0.4 26.38 ± 3.0
12.0 0.87 ± 0.1 18.81 ±1.9
24.0 1.65 ± 0.3 14.21 ±2.1
30.0 1.35 ± 0.3 12.58 ±1.8
36.0 1.38 ± 0.2 10.52 ±2.0
48.0 0.99 ± 0.1 8.40 ± 0.6
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Figure 7.1 Two-compartment model with intravenous bolus input and first order 
of elimination rate used to calculate pharmacokinetic parameters from 
administration of NG-nitro-L-arginine methyl ester hydrochloride (L-NAME; 40 
mg/kg corresponding to 34.6 mg/kg of L-NAME). K10 *  Elimination rate; K12 = 




Figure 7.2 One-compartment model with intravenous bolus input and first order 
of elimination rate used to calculate pharmacokinetic parameters of NG-nitro-L- 
arginine (L-NNA) following administration of NG-nitro-L-arginine methyl ester 
hydrochloride (L-NAME; 40 mg/kg) corresponding to 32.6 mg/kg of L-NNA. K10 = 
Elimination rate.
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Figure 7.3 First-hour plot of plasma concentration versus time of NG-nitro-L- 
arginine methyl ester (L-NAME) and NG-nitro-L-arginine (L-NNA) derived from 
mean values obtained from 6 horses that were administered an intravenous 
bolus injection of L-NAME hydrochloride (40 mg/kg).
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TABLE 7.2 Pharmacokinetics of NG-nitro-L-arginine methyl ester hydrochloride 
(L-NAME) after an intravenous bolus administration (40 mg/kg) to six adult 
horses.
Parameters Units Estimate (± SEM)
AUC pg.h.mr1 27.57 ±1.41
K10-HL h 0.06 ± 0.01
Alpha h'1 25.95 ± 8.41
Beta h‘1 3.20 ± 0.77
Alpha-HL pg.ml'1 0.04 ± 0.01
Beta -H L pg.ml*1 0.26 ± 0.04
A Mg.ml'1 271.86 ±31.51
B pg.ml'1 53.30 ± 58.27
Cmax Mg.ml*1 325.08 ±47.21
CIB ml.kg .h 1.27 ±0.06
Non-compartmental
AUMC Mg.fr.mr 7.08 ±1.67
MRT h 0.20 ±0.01
Vss ml.kg'1 0.25 ± 0.02
Estimate of pharmacokinetic parameters were calculated from mean values of 
plasma L-NAME concentrations from six horses.
Intravenous bolus dose = 40 mg/kg (corresponding to 34.6 mg/kg free L-NAME). 
AUC = Are under the curve.
K10-HL = Overall biologic half life in relation to the elimination rate.
Alpha = Distribution rate constant.
Beta -  Elimination rate constant.
A = Distribution extrapolated zero time concentration.
B = Elimination extrapolated zero time concentration.
Cmax = Maximum plasma concentration.
CIb = Total body clearance.
AUMC = Area under the moment curve.
MRT = Mean residence time.
Vss = Volume of distribution at steady state.
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TABLE 7.3 Pharmacokinetics of NG-nitro-L-arginine (L-NNA) as a product of 
hydrolysis of L-NAME administered intravenously as a bolus injection (40 mg/kg) 
to six adult horses.









Estimate of pharmacokinetic parameters were calculated from mean values of 
plasma L-NNA concentrations from six horses.
L-NAME hydrochloride intravenous bolus dose = 40 mg/kg (corresponding to
34.6 mg/kg free L-NAME).
AUC = Are under the curve.
K10-HL = Overall biologic half life.
Cmax = Maximum plasma concentration.
CIb = Total body clearance.
AUMC s Area under the moment curve.
MRT = Mean residence time.
Vs, = Volume of distribution at steady state.
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DISCUSSION
The estimates of pharmacokinetic parameters determined for L-NAME in 
the present study were in agreement with previous studies in rats (Brouillet et al., 
1995), rabbits (Schwarzacher and Raberger, 1992), dogs (Krejcy et al., 1993) 
and humans (Klein and Dudenhausen, 1996; Avontuur etal., 1998) that reported 
plasma L-NAME concentrations increased shortly after intravenous infusion and 
decreased rapidly as a result of hydrolysis yielding L-NNA. However, different 
half lives for L-NAME have been found for different species: rats = 2 min; rabbits 
= 7.5 min; dogs = 222 min; humans = 19.2 min and horses (present study) = 3.7 
min. NG-nitro-L-arginine methyl ester hydrochloride were added to blood plasma 
of dogs (Krejcy et al., 1993) and humans (Klein and Dudenhausen, 1996), 
whereas, in other studies L-NAME was administered to live rats (Brouillet et al., 
1995) and humans (Avontuur et al., 1998), as it was performed in the present 
study with horses. Therefore, different experimental approaches and species- 
specific differences likely accounted for the different reported half life (3.6 min).
In contrast, the estimates of pharmacokinetic parameters determined for 
L-NNA in the present study were in agreement with the half life and MRT 
estimated values reported for rats (Piotrovskij etal., 1993; Piotrovskij etal., 1994; 
Tabrizi-Fard and Fung, 1994) and humans (Avontuur et al., 1998). In general, 
L-NNA has a relatively long half life of -  20 h (19.5 h in the present study) and a 
long MRT of around 28 h (28.2 h in the present study). The Vss of L-NNA 
suggests that, despite being a low lipophilic compound (Piotrovskij et al., 1994), it 
might be formed intracellularly by the action of cellular esterases breaking down 
L-NAME (Pfeifer etal., 1996). The L-NNA distribution along with its relatively low 
plasma clearance (CIb) accounted for the relatively long half life documented for 
L-NNA in the present study.
The fact that L-NAME administration has been associated with clinical 
effects that exceeded its long half life led to the hypothesis that inhibition of NOS 
activity was probably accomplished by its free acid, L-NNA (Schwarzacher and 
Raberger, 1992; Brouillet ef al., 1995; Avontuur et al., 1998). In addition, L-NAME 
hydrolysis to the free acid L-NNA has been suggested to be a requirement for
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L-NAME-induced inhibition of NOS isoforms (Pfeifer et al., 1996). Accordingly, 
results of the present study suggested that L-NAME is rapidly hydrolyzed to 
L-NNA, which was detected in plasma samples obtained 1 min post-L-NAME 
administration. Brouillet et al. (1995) noted that L-NAME decomposition was 
concomitant with increases in rat plasma L-NNA concentrations. However, a 
more careful analysis of that data and estimates obtained in the present study 
revealed that L-NAME hydrolysis is not correlated with plasma L-NNA 
concentrations. The plasma L-NNA concentrations reached a plateau soon after 
L-NAME administration that was not correlated with continuously declining 
plasma L-NAME concentrations. Similar results were reported for anesthetized 
rabbits treated with L-NAME, but specific estimates for L-NNA pharmacokinetic 
parameters were not given (Schwarzacher and Raberger, 1992).
Pfeifer et al. (1996) reported that when L-NAME was incubated in rat 
plasma or physiological buffer, hydrolysis of L-NAME occurred resulting in a 
proportional formation of L-NNA over time. Surprisingly, when L-NAME was 
added to total rat blood, hydrolysis occurred at a more rapid rate, but no 
correlation was found between L-NAME hydrolysis and formation of the free acid 
L-NNA. It was concluded that L-NAME must have entered the blood cells.
In a preliminary study in our laboratory, equine plasma samples obtained I 
min after the administration of L-NAME were left at room temperature for up to 8 
h and analyzed by HPLC at 3-h intervals. The resulting L-NAME and L-NNA 
concentrations were inversely proportional, thus, contrasting with the pattern of 
hydrolysis noted in plasma samples analyzed by HPLC in the present study. 
Therefore, one might consider that the rapid L-NAME disappearance in equine 
blood plasma noted in the present study may not be solely explained by 
complete hydrolysis of L-NAME into L-NNA, but rather may suggest that L-NAME 
is rapidly transferred to the intracellular compartment where it is subjected to 
hydrolysis by intracellular esterases. Hence, some researchers have suggested 
that studies using in vivo experimental approaches should not use L-NAME 
(Schwarzacher and Raberger, 1992), however, this may deprive studies from 
benefiting from L-NAME’s solubility and its rapid distribution to target cells.
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Brouillet et al. (1995) raised another concern related to the potential 
therapeutic use of L-NAME in that methanol is formed as a by-product of 
L.-NAME hydrolysis. They noted that radioactive labeled [11C] L-NAME as 
detected by positron emission tomography entered the brain of nonhuman 
primates in less than 30 sec. Because an injection of unlabelled L-NAME was 
unable to displace L-NAME in a previous study (Roeda et al., 1995), it was 
hypothesized that methanol was a candidate for L-NAME hydrolysis by-product. 
Because methanol was found to be one important metabolite of L-NAME 
biodegradation in addition to L-NNA, the authors of that study elected not to 
perform pharmacokinetic studies in primates and dogs as initially planned 
(Brouillet et al., 1995). Furthermore, it was advised to use caution if L-NAME is to 
be used in a clinical situation involving humans or domestic animals. The 
apparent half life of cerebral methanol was 17.6 h. Methanol is not toxic per se, 
but under the catabolic activity of alcohol dehydrogenase, methanol is converted 
to formaldehyde and formic acid, which exert neurotoxicity (Wexler, 1998).
However, in the present study no signs of neurotoxicity were noted in 
horses following L-NAME administration. Furthermore, the amount of injected 
L-NAME (148 pmol/kg) would have yielded only 2.5 g of methanol in a horse 
weighing 500 kg. It is noteworthy to mention that the LD50 for methanol observed 
in rats, rabbits and monkeys is approximately 5 g/kg, 14.4 g/kg and 7 g/kg, 
respectively (Wexler, 1998). Although plasma concentrations of methanol 
associated with toxicity are not well established for horses, the potential amount 
of methanol resulting from L-NAME administration in the present study likely 
would have been insufficient to cause neurotoxicity
In summary, the results of the present study provide for the first time 
information on the pharmacokinetics of L-NAME and L-NNA following an 
intravenous bolus administration to conscious horses suggested the following: 
1) L-NAME has a short half life (3.6 min); 2) L-NNA is rapidly detectable in 
equine plasma following L-NAME administration with a half life of 19.5 h; and 3) 
hydrolysis of L-NAME does not correlate with plasma L-NNA concentrations. 
Furthermore, horses administered L-NAME did not develop signs of neurotoxicity
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that could have been associated with L-NAME-derived methanol formation. The 
pharmacokinetic profile of L-NAME administration in horses documented in the 
present study will be beneficial to developing pharmacological regimens for 
experimental or therapeutic purposes
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CHAPTER 8
HEMODYNAMIC EFFECTS ASSOCIATED WITH AN 
INTRAVENOUS BOLUS ADMINISTRATION OF NG-NITRO-L- 
ARGININE METHYL ESTER (L-NAME) IN CONSCIOUS HORSES
INTRODUCTION
There have been three major nitric oxide synthase (NOS) isoforms 
identified presently that catalyze the formation of nitric oxide (NO) from i-arginine 
(Palmer et al., 1988; Bredt et al., 1991; Alderton et al., 2001). The endothelial 
(eNOS) and the neuronal (nNOS) NOS isoforms are constitutively expressed, 
whereas, a third NOS isoform (iNOS) has its catalytic activity induced in 
response to cytokines and lipolysaccharides (Moncada etal., 1991). It has been 
shown that nitric oxide (NO) derived from eNOS activity exerts control over basal 
vascular tone to maintain normal blood pressure and organ blood flow. 
Conversely, increased production of NO produced by iNOS activity during sepsis 
and endotoxemia results in a remarkable vasodilation, which accounts for 
hypotension and organ hypoperfusion during septic or endotoxic shock (Moore 
and Seahorn, 1997; Mirza et al., 1999). The iNOS-derived NO produced in these 
life-threatening conditions also contributes to extensive tissue damage observed 
in diabetes mellitus, rheumatoid arthritis, and other inflammatory disorders via 
production of reactive oxygen species such as peroxynitrite (a powerful oxidant; 
Beckman and Crow, 1993). Administration of NOS inhibitors may cause 
neurotoxicity as seen in focal cerebral ischemia caused by middle cerebral artery 
occlusion (Coert etal., 1999)
One approach to study the multifaceted aspects of the action of NO in 
pathophysiological mechanisms is to use drugs that block the production of NO 
or the expression of nitric oxide synthase. Analogues of L-arginine, including NG- 
nitro-L-arginine (L-NNA) and its methyl ester, NG-nitro-L-arginine methyl ester 
(L-NAME) can inhibit the production of NO (Moncada et al., 1991). Accordingly, 
L-NAME enantiomerically induces competitive reversible inhibition of NOS in vitro 
and in vivo (Griffith and Kilboum, 1996). Although inhibition of NOS by L-NAME
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has not yet been fully characterized, L-NAME has been extensively used as a 
pharmacological tool to study NOS blockade in tissue homogenates, intact cells, 
animals, and humans (Southan and Szabo, 1996). However, studies have 
disregarded the investigation of its biodistribution and metabolism kinetics.
It has been reported that L-NAME has less affinity for NOS than L-NNA, 
being comparatively a less potent NOS inhibitor than L-NNA (Griffith and 
Kilbourn, 1996). However, L-NAME is quickly hydrolyzed to L-NNA in the 
presence of intracellular esterases. It has been shown that L-NAME is far more 
soluble than L-NNA allowing better intracellular distribution where it undergoes 
intensive hydrolysis to form L-NNA (Griffith and Kilboum, 1996). Estimated half 
life of L-NAME in vivo has been documented in rabbits (7.5 min; Schwarzacher 
and Raberger, 1992), humans (19.2 min; Avontuur et al., 1998), rats (2 min; 
Brouillet et al., 1995), and in vitro in dogs (222 min; Krejcy et al., 1993) and 
sheep (250 min; Whiting et al., 1994). The half life of the metabolite L-NNA has 
been reported to be several hours (3 to 24 h; Piotrovskij et al., 1994; Brouillet et 
al., 1995). Because L-NNA has far greater affinity for NOS than L-NAME, 
inhibition of NOS activity following L-NAME administration is apparently L-NNA- 
mediated (Pfeifer et al., 1996). These few studies addressing the kinetics of 
L-NAME have contributed to a more rational design of therapeutic regimens and 
experimental investigations in these species.
As with humans, dogs, and laboratory animals (Durakbasa et al., 1998), 
NO may play a role in the pathophysiology of diseases of horses involving the 
gastrointestinal (Moore and Seahorn, 1997; Mirza et al., 1999) and respiratory 
systems (Costa et al., 2001). Thus, a potential therapeutic use for L-NAME would 
be to counteract the overproduction of NO in cases of acute or chronic 
inflammation of the gastrointestinal tract, including ischemic and inflammatory 
intestinal diseases (Moore etal., 1994), and inflammatory lung disease (Seahorn 
et al., 1997; Costa et al., 2001). It has also been demonstrated that loss of 
endothelial cell integrity of equine digital palmar vessels may impair NO 
production after carbohydrate overload (Schneider et al., 1999). The resulting
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decrease in digital blood flow contributes to the pathophysiology of laminitis 
(Allen etal., 1990; Schneider etal., 1999).
Results of studies investigating effects of L-NAME administration to 
horses demonstrated that NO regulates pulmonary blood pressure and body 
temperature during exercise in horses following intravenous L-NAME injection 
(Mills et al., 1997). Thus, NO may play a role in pulmonary hypertension and heat 
intolerance during exercise. The presence of the NO pathway in the development 
of pulmonary hypertension has been suggested (Adnot etal., 1991) after NO was 
identified as being the endothelium-derived relaxing factor (EDRF; Ignarro et al., 
1987).
Pulmonary hypertension is directly a result of increased vascular 
resistance and decreased compliance owing primarily to severe injury to 
endothelium of pulmonary vessels followed by extensive remodeling 
(mesenchymal proliferation). Expression of NOS activity is elevated in the 
pulmonary vasculature of animals used in experimental models of pulmonary 
hypertension. The consequent NOS-stimulated production of NO has been found 
to be protective to the lung at initial stages of the disease. However, sustained 
NO production may amplify pulmonary vascular endothelial injury in more chronic 
forms of pulmonary hypertension (Hampl and Herget, 2000). Thus, with selective 
reduction of pulmonary vascular tone by inhaled NO has been shown as a 
therapeutic alternative to treat pulmonary hypertension in newborn humans 
(Weinberger et al., 1999) and foals (Lester et al., 1999), the inhibition of
pulmonary NO and NO-related production of oxygen radicals may be more
advantageous in some forms of chronic pulmonary hypertension (Hampl and 
Herget, 2000). It is probable that modulation of NO concentration by NOS
inhibitors such as L-NAME may be beneficial to treat a number of diseases
especially to overcome detrimental iNOS-derived overproduction of NO.
Because of its solubility, tissue distribution, and effects on NOS blockade, 
L-NAME is a potentially useful drug for experimental or clinical use. Knowledge 
of its pharmacokinetics is crucial to pursue research investigating the role of NO 
in equine physiological and pathophysiological processes. Therefore, the aims of
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the present study were to examine the effects of an intravenous bolus 
administration of L-NAME on hemodynamic variables including systemic arterial 
blood pressure, pulmonary arterial blood pressure, right atrial pressure, heart 
rate and rhythm, and clinical signs. I hypothesized that the administration of 
L-NAME (40 mg/kg) would cause an increase in systemic and pulmonary arterial 
blood pressure while maintaining unaltered clinical signs. I also hypothesized that 




Six clinically normal adult horses (4 Quarter Horses, 1 Thoroughbred, 1 
Paint) and in good health were acclimatized to stand unrestrained in stocks 
without chemical sedation and were accustomed to handling and the presence of 
personnel and research equipment at close proximity. There were 2 sexually 
intact females and 4 geldings. The horses weighed (mean ± SEM) 518.94 ±
11.58 kg and were on average 11.0 ± 1.15 years old. Horses were fed a 
commercial grain ration (4 kg/horse) twice daily in addition to ad libitum access to 
Alicia hay and water. All horses were housed in individual stalls for the duration 
of the experiment.
N°-nitro-L-arginine methyl ester (L-NAME) hydrochloride was purchased 
from Sigma Chemical Company (St. Louis, MO). This study was approved by the 
Institutional Animal Care and Use Committee of Louisiana State University. 
Instrumentation
Instrumentation of animals was performed on average 3 h before L-NAME 
administration. Horses were sedated with xylazine (0.25 mg/kg of body weight, 
iv). Subcutaneous infiltration of mepivicaine hydrochloride (0.5 to 1.0 ml) was 
used to desensitize the skin prior to the insertion of intravascular catheters. Two 
14-gauge, 13.3 cm Teflon catheters were used for the drug administration and 
blood collections. The polyethylene tubing was inserted into a catheter in the 
jugular vein and was positioned into the main pulmonary artery to measure mean 
pulmonary artery pressure. Another polyethylene tubing was positioned into the
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right atrium for measurement of mean right atrial pressure. The position of the 
catheters was verified by characteristic pressure waves. To measure arterial 
blood pressure a 20-gauge, 5.1 cm Teflon catheter was placed into the facial 
artery. The hair was clipped from the paralumbar fossa and an electronic 
stethoscope (Escope, Card ionics, Houston, TX) was secured using tape.
Right atrial, pulmonary artery, and facial artery catheters were interfaced 
with pressure transducers (Ohmeda Medical Devices, Madison, W l) and an 
amplifier and recorder (Grass, AstraMed, Warwick, RT) pressure transducers 
were placed at the height of the point of the shoulders. Intestinal sounds detected 
by the electronic stethoscope were interfaced with the driver amplifier of the 
Grass recorder.
Hemodynamics and Clinical Signs
A bolus dose of L-NAME (40 mg/kg, iv, 10%, w/v, dissolved in saline 
solution) was infused into the left jugular vein over 2 min. Arterial, right atrial and 
pulmonary arterial pressures, heart rate and rhythm, clinical signs, and intestinal 
sounds were monitored continuously 20 min before and for 3 h after the 
intravenous injection of L-NAME. During these initial 3 h animals were kept in 
stocks and thereafter moved into a stall in the bam. Blood samples (10 ml) were 
drawn from the right jugular vein immediately before and at 1, 3, 6, 24 and 48 h 
after L-NAME administration. Blood samples (10 ml) were immediately placed in 
tubes coated with lithium heparin, placed on ice and centrifuged (2,000 x g for 10 
min) within 15 min after collection.
Rectal temperature, respiratory rate, capillary refill time and skin tent were 
monitored every hour for the duration of the experiment (48 h). Because 
hyperthermia has been reported (Mills et al., 1997) in horses receiving L-NAME 
intravenously (by mechanisms not yet fully elucidated), fans were maintained in 
the stalls for the duration of the study. We did not administer L-arginine to reverse 
L-NAME action because clinical examination of horses did not indicate that such 
intervention was necessary.
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Statistical Analyses
All data were expressed as mean ± SEM. The data were analyzed by one­
way repeated measures analysis of variance using a general linear model 
(SigmaStat 2.0, Jandel Corp., San Rafael, CA). All data were evaluated for 
normality using Kolmogorov-Smimov test (with Lilliefors' correction) and 
transformed when appropriate. When statistical differences were detected using 
a P < 0.05, post hoc comparisons were made using Tukey’s test.
RESULTS
Intravenous administration of L-NAME to six conscious horses resulted in 
an immediate increase in systemic arterial pressure that returned to normal 
baseline values at 6 h post-L-NAME administration. Mean right atrial pressure 
was increased significantly between 20 and 30 min, whereas, mean pulmonary 
arterial pressure was not significantly affected by L-NAME administration (Table 
8.1). Mean values for heart rates were not significantly different from the baseline 
values (Table 8.1). No significant differences were detected for rectal 
temperature, heart rate, respiratory rate, capillary refill time and skin tent among 
the 6 horses throughout the experiment (data not shown).
In general, no signs of discomfort or colic were noticed in horses receiving 
L-NAME. However, it seemed that all horses were not as alert after L-NAME 
infusion compared to prior to administration; a submissive demeanor was 
observed as early as early as 15 min post-L-NAME administration. Five of six 
horses were eating and drinking normally within the first 12 h after L-NAME 
administration. Only one horse (gelding) experienced hyperthermia and loss of 
appetite for 48 h following L-NAME administration. Blood chemistry and complete 
blood count analyses were within normal limits. At the end of the study (48 h), 
this horse remained depressed and was treated with fluids administered 
intravenously. Recuperation to normal health and behavior was uneventful.
DISCUSSION
An intravenous bolus administration of L-NAME hydrochloride (40 mg/kg) 
to conscious horses quietly standing in stocks significantly increased mean SAP
155
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Table 8.1 Mean (± SEM) values of systemic arterial blood (SAP), pulmonary 
artery (PAP) and right atrial (RAP) pressures, and heart rates (HR) of conscious 
horses at rest following an intravenous bolus administration of NG-nitro-L-arginine 
methyl ester (L-NAME) hydrochloride (40 mg/kg).
Time (h)a SAP (mm Hg) PAP (mm Hg) RAP (mm Hg) HR (beats/min)
0 (baseline) 156.3 ±6.16 32.0 ± 2.0 11.4 ±1.2 39.0 ±1.3
0.017 186.4 ±19.1 39.9 ± 5.8 19 4 ±3.0 33.0 ± 0.9
0.033 203.7 ± 22.8 * 42.0 ±6.7 20.5 ± 3.9 33.0 ±0.9
0.083 224.7 ± 19.2* 46.3 ± 6.9 23.1 ±2.8 33.0 ± 0.9
0.167 225.7 ± 16.0 * 42.4 ± 6.7 23.9 ±3.1 36.5 ± 2.4
0.25 242.2 ± 17.4 * 45.7 ± 7.7 24.9 ± 6.1 37.5 ± 3.9
0.33 243.5 ±19 .4 * 44.4 ±9.1 27.3 ± 5.9 * 36.8 ± 3.9
0.41 242.4 ± 23.2 * 41.8 ±8.5 27.2 ± 5.3 * 36.8 ±4.8
0.50 240.7 ± 16.6 * 42.1 ± 9.0 26.3 ± 4.9 * 37.2 ±6.0
0.67 240.1 ± 1 5 .8 * 39.4 ±6.7 22.8 ± 5.9 37.2 ±4.9
0.83 241.8 ± 15.3* 39.4 ± 6.7 21.4 ±5.1 38.1 ±4.7
1 244.2 ± 11.7* 38.0 ± 5.8 23.8 ± 6.6 37.3 ±4.8
1.25 239.7 ±1 0 .9 * 39.1 ±5.0 20.1 ±6.2 37.3 ±4.8
1.5 239.2 ± 12.4 * 42.1 ±7.8 21.7 ±4.8 37.8 ± 3.5
1.75 238.2 ± 7.7* 39.4 ± 6.6 22.3 ± 5.4 39.2 ± 4.3
2 231.9 ± 9.5* 37.2 ± 5.7 17.9 ±4.8 38.2 ±4.5
2.5 223.7 ±1 0 .4 * 41.3 ±7.0 18.5 ±5.4 38.5 ±4.6
3 219.1 ± 1 3 .6 * 38.4 ±4.8 12.9 ± 3.9 37.2 ± 3.5
6 154.5 ± 5.3 33.2 ± 2.6 12.0 ±2.2 36.7 ± 2.7
* Time in relation to L-NAME administration.
’ P < 0.05 as compared with baseline values.
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Figure 8.1 Systemic arterial (SAP), pulmonary artery (PAP) and right atrial 
(RAP) mean (± SEM) pressures obtained from six conscious horses after 
administration of NG-nitro-L-arginine methyl ester (L-NAME; 40 mg/kg). Note that 
mean SAP increased significantly by 2 min and returned to baseline values by 
6 h after L-NAME injection. The mean RAP was significantly increased between 
20 and 30 min post-L-NAME administration, whereas, no significant alterations 
were noted for mean PAP throughout the study. * P < 0.05 as compared with 
baseline values before L-NAME administration, was considered significant.
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as early as 2 min post-L-NAME administration, and returning to normal baseline 
values by 6 h after infusion. No significant differences were noted in mean PAP, 
whereas the mean RAP was significantly increased between 20 and 30 min post- 
L-NAME administration. It is interesting to note that these alterations in 
cardiovascular variables were not related to plasma concentrations of L-NAME or 
its metabolite L-NNA (Chapter 7). The estimates for L-NAME and L-NNA half 
lives were 3.7 min and 19.5 h, respectively. The lack of correlation between 
L-NAME plasma concentrations and effects on systemic blood pressure suggests 
that more information has to be gained on the mechanism of L-NAME 
biochemistry before adequate dosage regimens can be adequately designed for 
L-NAME therapeutic use.
Specifically, the knowledge of intracellular L-NAME metabolism and 
pattern of tissue distribution would likely help to clarify the L-NAME mechanism 
of action. Moreover, the plasma L-NNA concentrations did not show a correlation 
with hypertension in horse in the present study. Overall, results of present study 
suggested that even using relatively higher doses than those used in horses 
before, undesirable side effects, such as hypertension were transient in horses 
but significantly more prolonged than previously reported (Manohar and Goetz, 
1998).
Increased mean SAP noted in the present study is in agreement with 
previous studies that demonstrated induction of acute (Aisaka et al., 1989; 
Fernandez et al., 1993) or chronic (Baylis et al., 1992; Manning et al., 1993) 
hypertension following L-NAME treatment in guinea pigs, rats and dogs, 
respectively. The L-NAME-induced hypertension, once thought to be exclusively 
a result of decreased eNOS-derived NO production (Aisaka et al., 1989), has 
also been shown to involve inhibition of nNOS-derived NO pathway (Sander et 
al., 1995; Kagiyama etal., 1998). The nNOS-derived NO has been hypothesized 
to mediate neurotransmission of the sympathetic vasoconstrictor control of 
arterial blood pressure in the brain stem and L-NAME treatment has been 
reported to augment sympathetic vasoconstriction in rats (Sander et al., 1997; 
Kagiyama etal., 1998) and humans (Sanderetal., 1999). In addition to L-NAME-
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induced inhibition of endothelial-dependent vasodilation and augmented 
sympathetic vasodilation, the hypertension documented in horses in the present 
study could have been, at least in part, attributed to nonspecific effects of 
L-NAME on vasomotor tone. It has been shown that the alkyl ester moiety has 
affinity for muscarinic receptors in vitro suggesting a possible anti-muscarinic 
effect for L-NAME (Buxton et al., 1993). However, no evidence of muscarinic 
receptor antagonism was found following administration of L-NAME in vivo 
(Koss, 1997; Sander et al., 1997), thus, potential hypertension attributed to 
L-NAME treatment remains speculative.
Few studies have investigated the effects of L-NAME administration on 
exercised-induced pulmonary hypertension in horses (Mills etal., 1996; Manohar 
and Goetz, 1998; Kindig etal., 2000) and there have discrepancies in the results. 
Mills et al. (1996) and Kindig et al. (2000) reported that L-NAME induced an 
increase in mean pulmonary arterial pressure when horses were exercised on a 
treadmill, whereas no changes were noted in horses exposed to similar 
conditions in another study (Manohar and Goetz, 1998). These investigators 
used a similar L-NAME dose (20 mg/kg) in their studies; however, Mills et al. 
(1996) infused the drug in the pulmonary artery, whereas others used the 
intravenous route (Manohar and Goetz, 1998; Kindig etal., 2000).
Only one research group (Manohar and Goetz, 1998; Manohar et al., 
2001) has reported the effects of L-NAME (20 mg/kg) on horses at rest, and that 
was a rapid onset of increased mean PAP, RAP and HR noted during the first 10 
min post-L-NAME administration. Cursory evaluation and comparison of the 
results of the present study appear to be in contradiction with those from the 
study of Manohar and Goetz (1998) and Manohar et al. (2001) because we failed 
to detect any statistical difference in mean PAP and mean RAP was only 
increased between 20 and 30 min post-L-NAME administration. Furthermore, we 
did not detect any statistical increase in HR after L-NAME infusion. However, if 
our data were analyzed in the current study only for the first initial 10 min as 
Manohar and Goetz (1998) did, we would have found a statistically significant
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difference between mean SAP, PAP, RAP and HR as compared with baseline 
values.
Although apparently discrepant, conclusions drawn from these studies 
likely differ because different experimental designs were used. Results of the 
present study actually expand the previous information that hemodynamic 
variables were increased during the first 10 min after L-NAME infusion by 
showing that recorded mean SAP and RAP were increased for up to 6 h and 
between 20 and 30 min, respectively, in a 6-h monitoring period. In agreement 
with the results of the present study are the findings that administration of NOS 
inhibitors to conscious cats (DeWitt et al., 1997) and dogs (Nishiwaki et al., 1992) 
did not appear to regulate basal pulmonary vasomotor tone. Absence of L-NAME 
effects on mean PAP were noted in normal rats chronically treated with L-NAME 
(Hampl et al., 1993). In contrast, experimental studies using sheep have 
invariably reported L-NAME-induced pulmonary hypertension (Koizumi et al., 
1994; Bone etal., 1998).
In one study, three of five horses were treated with L-NAME hydrochloride 
(20 mg/kg) and subjected to exercise on a treadmill (Gallatin et al., 1999). Shortly 
after runs were completed, the three fastest horses showed weakness and ataxia 
(Gallatin, 1999). Two horses developed anorexia, which resulted in constant 
weight loss that lasted weeks. Because the other two horses that ran at slower 
speeds did not show any alteration in their health combined with the absence of 
severe side effects noted in the horses in the present study (treated with 40 
mg/kg) suggest that animals being treated with L-NAME, experimentally or 
therapeutically should have restricted exercise. Furthermore, exercise-induced 
sweating in horses has been shown to decrease following L-NAME 
administration (Mills etal., 1997), a phenomenon that could aggravate the health 
condition of horses, including hyperthermia, being treated with L-NAME and 
exposed to intensive exercise. It is noteworthy to mention that 30 horses were 
treated with L-NAME in studies reported in this dissertation and all but one had 
no signs of altered clinical parameters. Perhaps the absence of forced exercise 
in our experiments prevented horses from developing unusual clinical signs
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following L-NAME administration associated with hypertension and altered 
thermoregulation.
In summary, results of the present study suggest that intravenous bolus 
administration of L-NAME hydrochloride (40 mg/kg) induced systemic arterial 
hypertension for up to 6 h following intravenous administration. No significant 
alterations were noted in the pulmonary vascular system or in heart rate or 
cardiac rhythm. Furthermore, no significant altered clinical signs in treated horses 
were noted in association with L-NAME treatment, but a mild change in 
demeanor, depression and temporary anorexia were observed that subsided 
within 12 h after L-NAME treatment.
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CHAPTER 9
SUMMARY AND CONCLUSIONS
Nitric oxide has emerged in the last decade as one of the most versatile 
and ubiquitous cell-signaling molecules. These attributes likely reflect its gaseous 
nature and ability to react with oxygen species. One of the most striking 
biological functions of NO is related to its production by endothelial cells to 
promote vasodilator tone. Although the participation of NO in controlling 
cardiovascular functions are remarkable, other systems have been found to 
utilize the NO pathway. For example, NO participation in the female reproductive 
system has been shown at all levels of the hypothalamic-hypophyseal-gonadal 
axis.
Nitric oxide modulation of ovarian function has been suggested by studies 
reporting an NO-mediated anti-steroidogenic activity in granulosa and luteal cells. 
In general, addition of nitric oxide synthase (NOS) inhibitors to cultured granulosa 
cells invariably resulted in higher estradiol (E2) production than that of untreated 
granulosa cells. A less pronounced effect of NOS inhibition on steroidogenesis 
was noted regarding progesterone (P4) production. Van Voorhis et al. (1994) first 
suggested that NO action on granulosa cell steroidogenesis was primarily 
through inhibition of E2 production via NO-mediated inhibitory effects on CYP450 
aromatase activity, a hypothesis later confirmed by Snyder et al. (1996). 
Moreover, studies using granulosa cell cultures that measured only P4 in 
conditioned media failed to detect a significant effect on P4 production by the 
granulosa cells, thus providing additional evidence to support the hypothesis that 
the inhibitory effect of NO on steroidogenesis is primarily through its effects on E2 
production
Shukovski and Tsafriri (1994) first suggested a role for NO in ovulation 
when it was noted that administration of NOS synthase inhibitors to 
gonadotropin-stimulated rats inhibited ovulation. Administration of NO donor 
agents could reverse the inhibition caused by NOS inhibitors. Moreover, 
administration of NO donor agents induced ovulation in a similar fashion to
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ovulation rates induced by administration of human chorionic gonadotropin 
(hCG). A role for NO in ovulation was further suggested for mice and rabbits. It 
has been demonstrated that NO participation in ovulation involved not only 
vascular effects in follicles approaching ovulation (Powers etal., 1995; Bonello et 
al., 1996), but also direct participation in hCG-induced up-regulation of follicular 
prostaglandins (Falletti etal., 1999).
Another facet of the relationship of NO with prostaglandins and 
steroidogenesis in ovarian function was initially suggested by Olson et al. (1996) 
who noted that NO significantly decreased E2 synthesis of luteinized rat ovarian 
cells suggesting a possible role for NO in functional luteal regression. 
Jaroszewski and Hansel (2000) provided direct evidence for NO participation in 
luteolysis when it was noted that intraluteal administration of L-NAME to corpora 
lutea of cycling Holstein heifers stimulated P4 and oxytocin secretion in the 
microdialysis perfusing medium that prolonged the life span of the corpus luteum.
These initial experiments investigating the relationship between NO and 
ovarian physiology clearly pointed to a role for NO in ovarian function, but failed 
to provide a conciliatory hypothesis for the apparent discrepancy between 
studies reporting a role for NO in ovulation and others suggesting a strong anti- 
steroidogenic activity for NO. One might then ask: “How does the anti- 
steroidogenic activity of NO relate to its role in ovulation?” Another question to 
be answered was whether the character of inhibition of ovulation by NOS 
inhibitors would be permanent, leading to follicular atresia, or temporary, 
resulting in delayed ovulation. One of the primary objectives of the present study 
was to design experiments that would answer these two critical questions to 
inform what would be the physiological role of NO in ovulation and follicular 
steroidogenesis.
Ovarian dynamics of domestic large animals such as mares and cows are 
routinely examined by transrectal ovarian ultrasonography. The administration of 
NOS inhibitors to mares and cows in estrus in the present study demonstrated 
that inhibition of ovulation was temporary (delayed) and anovulation was not 
detected in any of the experimental animals treated with NOS inhibitors.
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Therefore, modulation of NO production with NOS inhibitors offers a potential 
alternative for controlling ovarian dynamics for experimental or therapeutic 
purposes.
In a subsequent study, the concentrations of E2 and P4 in the spent media 
of cultured equine granulosa cells treated with NOS inhibitors and an NO donor 
agent were determined. There was a significantly higher E2 concentration in 
spent media from equine granulosa cells treated with NOS inhibitors than control 
cells or cells treated with an NO donor agent. The overall calculated P4:E2 ratios 
of spent media from cells treated with NOS inhibitors were lower than those from 
control cells. Both NOS inhibitors AG, a specific inhibitor of iNOS, and L-NAME, 
a nonspecific NOS inhibitor, showed similar effects on steroidogenesis, thus 
demonstrating that both iNOS and eNOS isoforms are involved in the modulation 
of granulosa cell steroidogenesis. It was concluded that the lower P4:E2 ratios 
noted in cells treated with NOS inhibitors indicated a permissive role for NO in 
functional luteinization.
This hypothesis was further supported by similar results obtained with 
bovine granulosa cells cultured for 72 h. Bovine granulosa cells spontaneously 
luteinize in vitro, especially when exposed to fetal bovine serum. This time, only 
L-NAME altered the pattern of functional luteinization as evidenced by higher E2 
concentrations over 72 h, whereas, AG-treated cells did not show a significant 
difference from control cells. Potential effects of AG treatment unrelated to NOS 
inhibition, such as the well known inhibitory effect on diamine oxidase may have 
favored functional luteinization of bovine granulosa cells, thus masking effects on 
NOS inhibition.
Because treatment of equine and bovine granulosa cells with NOS 
inhibitors suggested a role for NO in functional luteinization, a subsequent 
experiment investigated the relationship between NO and hCG-induced 
preovulatory follicular luteinization. Accordingly, follicular fluid from mares in 
estrus, treated with NOS inhibitors sampled before hCG administration and 36 h 
after hCG, was analyzed for NO, P4 and E2 concentrations. In control mares, 
there was an increase in follicular NO concentrations after hCG administration
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that paralleled the increase in follicular P4 concentration and decrease in follicular 
E2 concentration. It was concluded that hCG stimulation up-regulates the NO 
pathway along with the hCG-induced steroidogenesis shift, thereby increasing P4 
and decreasing E2 concentrations as ovulation approaches. Treatment with NOS 
inhibitors altered the pattern noted in control mares. In general, follicular 
steroidogenesis as well as follicular growth was depressed in mares treated with 
NOS inhibitors when compared with similar parameters in control mares. 
However, it is important to note that E2 concentrations in follicles of mares treated 
with NOS inhibitors did not decrease after hCG treatment, as they did in control 
mares, suggesting that CYP450 aromatase activity was preserved despite hCG- 
induced functional luteinization.
The pharmacokinetics and hemodynamics associated with an intravenous 
bolus injection of L-NAME were also investigated in the present study. The 
calculated half-lives for L-NAME and L-NNA, its major metabolite, were 3.6 min 
and 19.5 h, respectively. Hypertension induced by L-NAME was not present by 6 
h after administration. It was concluded that in vivo effects of L-NAME 
administration on reproductive parameters investigated in this study are likely not 
a result of altered systemic cardiovascular parameters. Furthermore, the major 
metabolite L-NNA has a relatively long half life and partially accounts for effects 
associated with L-NAME administration.
Results of the present study provide novel information in several aspects 
of the relationship between NO and ovarian physiology: 1) administration of NOS 
inhibitors delayed ovulation in horses and cows; 2) hCG administration to mares 
in estrus not only induced preovulatory luteinization, but also up-regulated the 
NO pathway; 3) NO has a permissive role in functional luteinization of equine and 
bovine granulosa cells. Effects of administration of AG on ovulation, in vivo 
follicular steroidogenesis and in vitro granulosa cell steroidogenesis suggested 
that expression of iNOS in regard to ovarian functions is constitutively expressed. 
In the female reproductive system, the constitutive expression of isoforms that 
are primarily induced in other tissues suits the dynamic and cyclic character of 
pivotal cellular and biochemical changes, a recurrent theme in female
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reproductive physiology. Lastly, this study also established for the first time 
pharmacokinetic parameters for L-NAME in horses and hemodynamics of horses 
at rest treated with L-NAME.
In summary, the knowledge that NO participates in the process of hCG- 
induced functional preovulatory luteinization will contribute to the understanding 
of ovarian dysfunction such as cystic ovarian syndrome and unruptured 
luteinized follicles, conditions that affect both domestic animals and humans. In 
addition, the pharmacokinetics of L-NAME in horses will help to design 
pharmacological therapies of NOS inhibitors for experimental or therapeutic 
purposes.
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